



ACTIVITY-BASED PROTEIN PROFILING (ABPP) 




































ACTIVITY-BASED PROTEIN PROFILING (ABPP) BY 















A THESIS SUBMITTED 
FOR THE DEGREE OF DOCTOR OF PHILOSOPHY 
DEPARTMENT OF CHEMISTRY 








I hereby declare that the thesis is my original work and it has been written by 
me in its entirety. Under the supervision of Prof. Yao Shao Q., (in the 
laboratory S5-03-18), Department of Chemistry, National University of 
Singapore, between Aug 2009 and Jan 2014. 
 
I have duly acknowledged all the sources of information which have been 
used in the thesis. 
 
This thesis has also not been submitted for any degree in any university 
previously. 
 
The content of the thesis has been partly published in: 
 
1) Cheng, X.; Li, L.; Uttamchandani, M.; Yao, S. Q.*, In situ Proteome 
Profiling of C75, a Covalent Bioactive Compound with Potential Anti-cancer 
Activities. Org. Lett. (2014), 16, 1414-1417. 
2) Cheng, X.; Li, L.; Uttamchandani, M.; Yao, S. Q.*, A Tuned Affinity-based 
Staurosporine Probe for in situ Profiling of Protein Kinases. Chem. Commun., 
(2014), 50, 2851–2853. 
 
     Cheng Xiamin                                                                    Feb, 2014 
                                                                                                                          





First of all, I would like to thank my supervisor and mentor - Prof. 
Yao Shao Qin for giving me the opportunity to work in his lab and 
always highly supporting my works. Because of his critical and 
comprehensive thinking, research is taking shape in my mind. He let 
me know the passion and aspiration on discovering things and 
pursuing ideas. His enthusiasm and guidance have led me to my 
accomplishments. And I would like to thank Dr Mahesh help me to 
revise the manuscripts especially. 
I would like to thank all members in Prof. Yao group — both past 
and present, Grace, Lay Pheng, Pengyu, Wu Hao, Kalesh, Liu Kai, 
Candy, Mingyu, Haibin, Jingyan, Liqian, Dr. Li Lin, Dr. Li Zhengqiu, Dr. 
Jiang Bo, Dr. Yu Changmin, Zhenkun, Su Ying, Chongjing, Biwei, Jiaqi, 
Jigang, Sijun, Linghui, ,Peng Bo, Danyang, Farhana, Cindy, Pei Xin, 
Chelsea, Xiaoyuan, Rajesh, Yu Min, Joo Leng, Yuhui, Choon Meng, 
Liang Xian, who made this time so special and enjoyable. I thank 
particularly the following people: Haibin, Pengyu, and Wu Hao who 
taught me biological experiments; Dr Li Lin who help me do the 
bioimaging; Xiaoyuan help me do bioexperiments; Jigang taught me 
how to deal with mass samples.; Zhengqiu, Chongjing and Jingyan 
kindly provide intermediates. Thank all of you for helping and 
accompanying these years, providing me a nice and friendly home - 
Yao lab in Singapore. 
I would like to thank Prof Lu Yixin, Zeng Huaqiang and Wang Jian 
as my oral QE examiners when doing my PhD conversion; Prof Tan 
Choon Hong wrote recommendation letter. Thanks to my collaborators 
for their excellent work including: Prof. Siu Kwan Sze (Nanyang 
Technological University, Singapore) for his support for LC-MS/MS 
experiments; Allan, Licheng and Prof. Zhao Yu. for their patience and 
support. 
I appreciate the support from National University of Singapore for 
providing me research scholarship. Thanks also go to Department of 
iii 
 
Chemistry administrative staffs for their supports, especially Ms 
Suriawati and Ms Chia Siew Ing for their help on all kinds of issues. 
Finally, I would like to thank my parents, my wife and my sister for 
their unconditional understanding, supports and encouragement 
throughout these years. 
Big thanks to all of you! 
iv 
 
Table of Contents 
 
Declaration                                                                                              i 
Acknowledgements                                                                                ii 
Table of Contents                                                                                   iv 
Summary                                                                                              viii 
List of Tables                                                                                           x 
List of Figures                                                                                        xi 
List of Schemes                                                                                   xvi 
List of Symbols                                                                                    xvii 
List of Publications                                                                             xviii 
List of Abbreviations                                                                             xx 
List of 20 Natural Amino acids                                                           xxiv 
Chapter 1. Introduction 1 
1.1 Activity-based Protein Profiling (ABPP) and Affinity-
Based Protein Profiling 
2 
 1.1.1  Introduction  2 
 1.1.2 Bioorthogonal Chemistry in ABPP 7 
 1.1.3  Application of ABPP in Target Identification 
of Natural Product and Drug 
13 
 1.1.4  Application of ABPP in Protein Inhibitor 
Design and Enzyme Activity Detection 
17 
1.2 Development of Kinase Inhibitor Drugs 19 
 1.2.1  Kinase and its Catalytic Mechanism 20 
 1.2.2  Development of Kinase Inhibitors 21 
v 
 
1.3 Research Objective 27 
Chapter 2. In situ Proteome Profiling of C75, a Covalent 
Bioactive Compound with Potential Anti-cancer 
Activities 
29 
2.1 Summary 30 
2.2 Introduction 30 
2.3 Results and Discussion 33 
 2.3.1 Design and Synthesis of C75-based Probes 33 
 2.3.2 Design and Synthesis of Tri-functional Tag 35 
 2.3.3 Cell Anit-proliferation Assay and Proteome 
Profiling of HepG2 Cancer Cell with C75-
based Probes 
38 
 2.3.4 Target Identification and Validation 40 
 2.3.5 Target Localization by Cell Fluorescent 
Imaging 
43 
2.4 Conclusion 44 
Chapter 3. Staurosporine-directed Labeling of Kinase and 
Specific Labeling of PDI in Live Cancer Cell 
with Chemically Tuned Electrophiles 
46 
3.1 Summary 47 
3.2 Introduction 47 
3.3 Results and Discussion 51 
 3.3.1 Design and Synthesis of the Probes 51 
 3.3.2 Preliminary Biological Activities Screening 




 3.3.3 STS-C1 Targeting Kinases In Vitro and in 
Live Cell 
55 
 3.3.4 Unexpected STS-T1 Targeting PDI in Live 
Cell 
64 
3.4 Conclusion 69 
Chapter 4. Protein Target Profiling of Lymphostin and 
Ammosamide B by Activity-Based Protein 
Profilings (ABPPs) in Live Cell 
71 
4.1 Summary 72 
4.2 Introduction 72 
4.3 Results and Discussion 74 
 4.3.1 AfBPs based on Ammosamide analogues 74 
 4.3.2 ABPs based on Lymphostin 79 
 4.3.3 Preliminary biological test 83 
4.4 Conclusion 88 
Chapter 5. Cancer Cell Targeted Drug Delivery of Protein 
Kinase Inhibitors by Cell Penetrating Peptide 
(CPP) 
90 
5.1 Summary 91 
5.2 Introduction 91 
5.3 Results and Discussion 95 
5.4 Conclusion 97 
Chapter 6. Cancer Cell Targeted Delivery of Regenerable 
Wortmannin by Folic Acid and Protein Target 




6.1 Summary 99 
6.2 Introduction 99 
6.3 Results and Discussion 104 
6.4 Conclusion 102 
Chapter 7. Experimental Section 107 
Chapter 8. References 171 






Natural products are becoming an important source of drug 
discovery with the advances in the natural product identification and 
organic synthesis. The identification of unknown potential targets of the 
bioactive compounds remains an urgent challenge. However, there is a 
lack of strategy which is capable of large-scale investigation of small 
molecule-protein interaction comprehensively under its native cellular 
environments. The interactions, including on and off, are very important 
at the early stage of drug discovery because they are closely relevant 
to predict the true biological activities of the drug candidates. 
There’s about 2% of human gene encoding a large family of protein 
kinase (500+), which reversibly phosphorylated about 30% of all 
human proteins, including biomolecules that regulate every complex 
cellular processes and pathway. Dysregulation and mutation of kinase 
(more than 180) is a very important pathogeny in human disease such 
as cancer, diabetes, hypertension and other disease, therefore, kinase 
is becoming the interesting targets in the therapy. However, it is difficult 
to design a kinase inhibitor to recognize a kinase from the huge family 
(500+) which possesses the highly conserved sequence and structure 
of the ATP-binding pocket. And in the native cellular environment, the 
interaction between the small molecule and kinase was also interfered 
by other bioactive molecules (such as ATP/ADP/AMP and etc.) 
distributing ubiquitously and other functional proteins containing the 
similar nucleotide-binding site, which are much more than kinases. 
In this thesis, firstly, we describe a click-based in situ profiling 
approach to identify the targets of natural product derivative—C75. 
(Chapter 2) Secondly, a new approach to develop covalent irreversible 
inhibitors of kinase from a natural product —staurosporine, as a 
reversible general binding core, is introduced. (Chapter 3) By this 
strategy, the probe-like inhibitor could also be tested and evaluated by 
a comprehensive proteome profiling. The native cellular targets of the 
probe were identified and localized with the probe by subsequent 
biological experiment in the live cancer cell. The following few projects 
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were unfinished works. Thirdly, this click-based in situ profiling 
approach was applied to Lymphostin (covalent inhibitor) and 
Ammosamide analogues (affinity inhibitor) (Chapter 4). Fourthly, a 
novel approach about cancer cell targeting cell-specific drug delivery of 
protein kinase inhibitors by cell penetrating peptide (CPP) is described 
(Chapter 5). Finally, this project is about cancer cell targeting delivery 
of regenerated wortmannin by Folic acid and protein target profiling of 
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1.1 Activity-based Protein Profiling (ABPP) and Affinity-based 
Protein Profiling 




1.1 Activity-based Protein Profiling (ABPP) and 
Affinity-Based Protein Profiling 
1.1.1 Introduction 
Proteins are the main components of physiological metabolites of 
cells and execute almost all of the cell’s function.1 Genome sequencing 
projects provide a platform to identify the protein encoded by the 
genomes in prokaryotic and eukaryotic organisms.2 However, in the 
subsequent study of biological systems, assigning the functions for the 
entire set of proteins (proteome) contained in a living organism remains 
an ongoing challenge in the post-genomic era. Proteomics (the study of 
proteome) is more complicated than genomics (the study of genome) 
because an organism’s genome is relatively constant, whereas the 
regulation of proteome is dynamic, which may not be directly encoded 
in the genome. Proteome is not only regulated by translation, but also a 
complex array of post-translational modifications and protein-protein 
interactions. 
Proteomics is able to dissect the behaviour of the living system at 
the molecular level by many methods to analyze the presence of the 
proteins and their quantities. Conventional proteomics methods provide 
informations about expression patterns, interactions, and in vitro 
functions of proteins, including liquid chromatography–mass 
spectroscopy (LC-MS) analysis,3 yeast two-hybrid assays4 and protein 
microarrays5. However, these methods are limited because they do not 
reflect the activity of proteins in their native environments. As an 
important sub-filed of proteomics, a chemical proteomics dubbed as 
“activity-based protein profiling” (ABPP) has been systematically 
explored and has become a standard approach for the identification 
and functional characterization of proteins in the native complex 
proteomes.6 
According to the ABPP strategy, a typical activity–based probe 
(ABP)6a normally possesses three elements: 1) a binding group with a 
reactive warhead, which directs ABP to its targets and simulate 
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structure and function of natural substrate or ligand. The warhead very 
close to the affinity binding group therefore is ready to react in the 
active site to form a covalent bonding between ABP and protein; 2) a 
proper spacer, linked the binding group with warhead to tags and avoid 
other parts to disturb the interactions formed; 3) a tag, which allows 
visualization and/ or purification of bound target protein. The tags 
normally could be fluorescent dyes, radioactive tags for visualization 
and/or biotin for affinity purification. Normally, the approach is 
cooperated with Liquid chromatography coupled to tandem mass 
spectrometry (LC–MS/MS) for protein identification. (Figure. 1.1)  
A number of analytical platforms have been developed to 
specifically visualize and identify the labeled protein targets by ABPP 
probe in complex proteomic mixtures. According to the informations 
intended to obtain, the platform is chosen in consideration of its 
advantages and disadvantages in throughput, sensitivity, target 
identification, and sample amount required. As a most mature standard 
high-throughput technique, gel-based analysis is simple and fast to 
visualize the proteins by either in-gel fluorescence scanning or avidin 
blotting, for fluorescent and biotinylated ABPP probes, respectively.7 
However, it does not provide enough informations (only molecular 
weights indicated by 1D electrophoresis and isoelectric points indicated 
by 2D electrophoresis) to reveal the identity of the labeled target 
enzymes. To further identify the probe pulled down proteomes, multiple 
LC-MS strategies8 with high resolution and sensitivity have been 
developed normally after the sample preparation including biotin–
(strept)avidin enrichment and trypsin digest. Subsequent computer-
based database match searching of peptide informations reveals the 
identity of the protein labelled. Microarrays is applied in ABPP by 
combination of the isolation, detection, and identification of probe-




Figure 1.1 (A) The typical stucture of an activity-based probe (ABP); (B) the strategy 
of activity-based protein profiling (ABPP), consisting of a labeling step in complex 
proteomes and an analytical step to visualize and characterize activity-dependent 
labeled proteins. 
 
Using chemically-modified probe, ABPP as a powerful and mature 
functional proteomic technology has been successfully used to study 
the mechanistically-related classes of enzymes including serine 
hydrolase,10 cysteine protease,11 tyrosine phosphatase12 and kinase13. 
In the ABPP strategy, after the ABP is used in the target labeling, the 
tagged protein could be visulized by flurorescent detection with 
fluorscent tags and/or identification by LC-MS/MS with biotin tag. First 
of all, the warhead based-on the enzymatic mechanism is the key of 
specificity. A variety of electrophiles is introduced as warheads. For 
example, fluorophosphonate (FP) served as mechanism-based 
reactive groups is successfully used to speifically profile the serine 
hydrolases family,10 which shows selective reactivity to the enzymes in 
active form and minimal cross-reactivity with other classes of 
hydrolases based on distinct mechanism.14 Other warheads are also 
introduced including epoxide,11 Michael acceptor, haloacetamide,15 
acyl phosphate16, α-bromophosphate,12 vinyl sulfone,17 quinone 




Figure 1.2 Typical instances of activity-base probes (ABPs). 
 
As a complementery for ABP, affinity-based probe (AfBP) is used in 
the target proteome profiling of the affinity-based inhibitor. Unlike the 
mechanism of the suicide-based inhibitor which forms a stable covalent 
bond, the inhibition between the affintiy-based inhibitor and its targets 
is based on the strong affinity. The inhibition of the latter is probably not 
tolerate in the cellular exposure and subsequent affinity-based protein 
profiling process including harsh washing, denauration and so on. For 
example, the beads-immobilized inhibitors is used in the proteome 
profiling of the inhibitors intended. However, the method is limited to in 
vitro assay including recominbant protein and lysates with the problems 
of target missing and false targets, and thereby can’t reflect the the true 
relationship between the inhititors and its celluar targets.19 To 
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overcome the shortcomings, in this approach, a photo-labile group was 
typically incorporated into AfBP. After AfBP binds its targets reversibley 
including noncovalent interactions or reversible covalent bonds, the 
colvalent binding between the probe and targeted protein, upon 
activation of light, is formed. (Figure. 1.3) 
 
 
Figure 1.3 (A) The stucture of a typical affinity-based probe (AfBP); (B) the strategy 
of affinity-based protein profiling. 
 
In the strategy of affinity-based protein profiling, the most important 
difference between AfBP and ABP is the additional reactive groups, 
which established the irreversible covalent binding to form a stable 
protein-probe complex. In order to use an AfBP for labeling of (active) 
enzymes in biological environments, the photo-crossing groups should 
fulfil some requirements. The groups should be inert to the 
environments and activated under a bio-safe light in a specific 
wavelength. The generated species should have a short lifetime to fix 
the enzyme-probe complex with less nonspecific labeling. The size of 
the groups should be small to avoid influences on the interactions 
between the target and probe.20 Upon activation with appropriate light, 
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an aryl azide would generate active species which could react with C–
H bonds and nucleophiles nearby in the ligand binding pocket of 
proteins to form a stable covalent protein-ligand complex. Photolysis of 
diazirine generates active carbenes which react with C–H bonds, C–N 
bonds and hydroxyl groups nearby to covalent adducts. Photolysis of 
benzophenone gives triplet diradical which subsequently reacts with C–
H bonds available in all amino acids.6d The representing examples of 
affinity-based probes (AfBPs) using the photoreactive groups including 
aryl azide,21 benzophenone22 and diazirine23 are introduced in Figure 
1.4. 
 
Figure 1.4 The representing examples of affinity-based probes (AfBPs) 
 
1.1.2  Bioorthogonal Chemistry in ABPP 
In the application of ABP, some typical drawbacks were 
encountered. For example, tag-conjugated modification makes the 
probe too bulky, which probably affects its uptake by the live cell, in 
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terms of cell penetration, drug distribution and disturbance of the 
reactivity by the reporter. To resolve the problems, a new trend of the 
ABP design is developed by separation of the probe from the reporter. 
The advantages of the minimum-modified design include maintaining 
the original reactivity, less bulky and flexible option of reporters. To 
complete the ABPP strategy, the warhead tethered with the target 
proteins should be linked to the reporter for visualization or affinity 
purification, by bioorthogonal chemistry. Typically, a reaction as 
bioorthogonal chemistry which neither interacts with nor interferer with 
a biological system, should fulfill the requirements: 1) the two groups 
used to form a stable linkage should be bioinert and ideally nontoxic; 2) 
the reaction should occurs between each other of the two functional 
groups specifically; 3) have fast kinetics at low concentration under 
physiological conditions such as pH, temperature and biological media; 
and 4) the groups should be small as well.24  
So far, only a few types of reactions fulfilled the requisite qualities of 
biocompatibility and selective reactivity to function as bioorthogonal 
chemical groups in living cells. The Staudinger ligation can be used to 
covalently attach probes to azide-bearing biomolecules.25 The reaction 
proceeds at pH 7 with no apparent toxic effects and the size of azide is 
small, but suffers from low kinetics and the side reaction of the slow 
oxidation of phosphine.24 The typical click chemistry between the 
terminal alkyne and azide group was used widely in ABPP.26 The 
reaction is fast and the reaction groups are small, but the Cu (I) as a 
necessary catalyst is cytotoxic. To overcome this shortcoming, the 
stained-promoted copper-free click chemistry between azide and 
cyclooctyne was developed.27 In the reaction, azide group is small and 
kinetics is faster than unmodified alkyne, but the cyclooctyne part is 
difficult to synthesize and the rate is relatively low. To pursue 
nontoxicity and high kinetics, tetrazine cycloadditions was developed. 
Comparably, the starting material is easy to synthesize and the 
reaction is extremely fast without catalyst. But tetrazine is much larger 
than azide and the reaction is not region/stereoselectivity.28 A 
tetracysteine motif (CCXXCC) chemical reporter can be fused to target 
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proteins at the genetic level and covalently labeled in living cells with 
membrane-permeable dyes (FlAsH and ReAsH).29 The modification is 
small comparing to GFP, but is not tolerated to biosynthetic enzyme.24 
Ketones and aldehydes as bioorthogonal chemical reporters could 
react with hydrazide and aminoxyl groups to form stable Schiff base 




Figure 1.5 Reaction types of bioorthogonal chemistry 
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With the development of the high efficient and biocompatible 
bioorthogonal chemistry, ABP and AfBP in tag-conjugated manner are 
evolved to tag-free manner. Therefore, the probe gets smaller with less 
influence on the drug activity and better cell permeability. The activity-
based protein profiling (ABPP) was broken into two steps and then 
joined together with bioorthogonal chemistry (typically as click 
chemistry). (Figure 1.6) The tag-free design was applied to ABP to 
facilitate the in situ target identification efficiently. (Figure 1.7) The 
“clickable” version of epoxide compound (MJE3) could specifically label 
the glycolytic enzyme phosphoglycerate mutase B (PGAM1) in situ.31 
“Clickable” SAM analogs are used for labeling protein 
methyltransferase substrates which are linked to various human 
diseases.32 A library of β-lactones also is used to screen the bacterial 
proteome.33 Sieber et al. adopted a library of β-lactam probes (CephN, 
Azt and AmpN) derived from natural or synthetic sources for 
comparative in situ profiling experiments in non-resistant and resistant 
strains of S. aureus (SA and MRSA) and identified uncharacterised 
MRSA enzymes which hydrolyse β-lactam antibiotics.34 The traceless 
labeling of glycoprotein with BA-tosyl was reported latest.35 
 
 





Figure 1.7 The representing examples of tag-free activity-based probes (ABPs) 
 
For the tag-free manner of AfBP, there’re many interesting 
instances to achieve the investigation. Similarly to tag-free ABP, a 
ligation handle was introduced to AfBP in the place of tags to make the 
probe smaller. (Figure 1.8) Recently, tag-free AfBP was used in the on 
and off-target identification of Dasatinib,36 Staurosporine and other 
kinase inhibitors by in situ proteome profiling. 36b, 37 The clickable 
handle and photo-labile group are introduced to the suitable positions 





Figure 1.8 Traditional AfBP and new type of affinity-based protein profiling assisted 
with bioorthogonal chemistry 
 
 
Figure 1.9 The representing examples of tag-free affinity-based probes (AfBPs) 
 
1.1.3  Application of ABPP in target identification of bioactive 
molecules including natural product and drug 
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A large number of bioactive molecules including natural product, 
drug and etc. emerge in the sight of scientist. Natural products are 
becoming one of the most important sources of modern drug discovery 
because the privileged structure and biological function of natural 
product must bind to some enzymes to fulfill the inherent purpose of 
their biosynthesis and origin in the organisms.38 Fast development in 
techniques of the modern isolation, purification and identification, 
provides more and more natural product candidates from fungi, 
metabolite, plants, marine source and etc.38a However, the current 
innovation is deficient in the identification of compounds with the 
desired activity.39 In other words, there’re limitations of techniques in 
drug targets identification of natural products. Furthermore, even for 
those FDA-approved drugs, the side-targets remain unknown, which 
result the safety issue and the drug withdrawn from the market.40 
There’re few approaches developed to fulfill the purpose. Firstly, 
identification of an active natural product from the traditional medicine 
against certain disease is a shortcut to establish the relationship 
between natural product and proteins which results the disease in the 
known mechanistic hypotheses. However it does not provide the 
comprehensive information about drug effect. Secondly, high-
throughput screening techniques allow the fast screening over a large 
library of compounds in protein or cell-based assay. Thirdly, comparing 
the phenotype caused by the compound with by gene knockout, RNA 
interference or other chemicals, provide the protein target of the 
compound. Then, the affinity capture by the immobilized natural 
product incorporated with 2D SDS-PAGE and LC-MS/MS analysis is 
applied to identify its targets. It is limited in in vitro assay. Finally, ABPP 
as a powerful tool is applied to target identification of the bioactive 
molecules (e.g. natural product) by establishing a covalent linkage with 
the probe derived from the bioactive molecules and its targets in the 
native state.6d, 10, 41 The probe could be in tag-conjugated or tag-free 
manner.6c, 38b, 42 Based on the nature of interactions between the 
bioactive molecules (e.g. natural product) and targets, the drug-like 
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designs of the probes could be classified into ABP for covalent 
molecule and AfBP for non-covalent molecule. 
For those bioactive molecules containing a reactive group served 
as warhead to recognize and then bind the protein targets covalently, 
their corresponding ABPs are designed with a terminal alkyne group 
(or other tags) at a suitable position. The stable protein-probe complex 
is tolerable to the subsequent enrichment and identification process. 
The representative examples include AX757443 and wortmannin13 in 
tag-conjuated manner. Compared to the probe tagged with TMR and 
Biotin that are only capable to labeling targets in vitro, the probe tagged 
with smaller-size BODIPY shows the improved ability of proteome 
profiling in vivo. Therefore, design of ABP further evolves into the tag-
free manner because of many advantages.(described in section 1.1.1) 
The drug-like probe derived from Showdomycin as a potent nucleoside 
antibiotic is modified minmally with a 5-hexynoic acid tag and shows 
identical MIC value with the parent drug.44 It is applied in the proteome 
profiling and identify 13 potential targets including MurA1 and MurA2, 
which are important enzymes in bacterial cell wall biosynthesis. THL 
(an FDA-approved anti-obesity drug) derived probes (THL-L, THL-R, 
THL-T and other analogues) have identified the cellular off-targets and 
side effects except the the known target fatty acid synthase (FASN) by 
in situ proteome profiling.45 The “clickable” probes (VS-1, diazomethyl 
ketone and azanitrile probe) derived from anti-parasitic compound 





Figure 1.10 ABPs based-on natural products and drugs with warhead 
However, most bioactive compounds bind to their protein targets 
non-covalently and therefore the transient protein–small molecule 
complex may not survive the following enrichment process. The design 
of AfBPs derived from such molecules is applied to identify the cellular 
targets by the proteome profiling. The key is the formation of stable 
protein-probe complex in situ by incorporation of additional photo-labile 
group. Yao group has reported a series of “clickable” probes derived 
from kinase inhibitors incorperating with photo-labile groups, which are 
incapable of in situ target identification. (Structures of partial probes 
listed in Figure 1.9) Trimodular probes are developed to label type I 
methionine aminopeptidase (MetAP) in E. coli cell lysate. Apparently, 
the probe in tag-free manner is much more selective than the biotin-
conjugated probe in this case.47 Probe 1-1 and 1-2 derived from type-II 
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kinase inhibitors allow to label protein kinases in the DFG-out inactive 
conformation by a trifluoromethylphenyl diazarine group.48 Dasatinib 
probe 1-3 could be used to rapid and quantitative profiling of kinase 
active sites in both lysates and live cells.49 In this probe, benzopheone 
is used for photo-linking with targets and hexylchloride tag is served for 
ligation with protein Halo tag. Recently, a clickable cell-permeable 
DzNep probe is developed from a global histone methylation inhibitor 
(3-Deazaneplanocin A) to identify its in situ cellular targets.50 (Figure 
1.11) 
 
Figure 1.11 AfBPs based-on natural products and drugs via affinity interactions 
 
1.1.4  Application of ABPP in Protein Inhibitor Design and 
Enzyme Activity Detection 
Enzyme activity inside cells is regulated by many factors including 
posttranslational modification, small molecules, or cofactor binding. 
Molecular imaging is one of method to monitor the dynamics of 
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distributions of enzyme and bioorganic molecules. Unlike GFP-fusion 
protein, ABPP have the advantages of smaller size and convenience to 
real-time monitor the enzyme function and activity in living cell or 
organism. Several challenges still remain for researchers interested in 
using ABPP to investigate biological processes.6a For example, the 
common ABP conjugated a fluorescent tag served for imaging, have 
the limitation that the permanent fluorescent signal is obtained 
regardless whether the probe is bound to targets or free in the cell. As 
a new concept, a fluorescently quenched Activity-based probe(qABP) 
(GB117) was developed by Bogyo and colleagues for the visualization 
of cathepsin activities in living cells.51 In the probe, BODIPY 
fluorophore was OFF by the interaction with the quencher. Based on its 
mechanism, once the quencher was replaced by cathepsin, the 
fluorophore was turned ON with the strong fluorescence and thereby 
ready for real-time imaging of cathepsin activity in live cell. Hu et al. 
reported a new class of qABPs (P1, P6) which were based on quinine 
methide chemistry and conjugated with 1-photo and 2-photo 




Figure 1.12 qABPs in the activity detection and imaging 
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1.2 Development of Kinase Inhibitor Drugs 
2% of human gene encodes a large family of protein kinases 
(500+), which reversibly phosphorylated about 30% of all human 
proteins, including biomolecules that regulate every complex cellular 
processes and pathway, such as growth, differentiation, proliferation, 
apoptosis and cellular signal transduction.53 
 
1.2.1  Kinase and Its Catalytic Mechanism 
The Nobel Prize in Physiology or Medicine for 1992 was awarded 
jointly to Edmond H. Fischer and Edwin G. Krebs for their discoveries 
concerning "reversible protein phosphorylation as a biological 
regulatory mechanism".54 Phosphorylation and dephosphorylation of 
protein are a pair of reversible contrary processes which plays a very 
important role in regulation of the transformation, charge, activity, 
cellular location of protein and interaction with other cooperating 
protein in living organisms.53 Kinase is a type of protein which could 
modify its specific substrate including small molecule and protein, by 
transferring the terminal phosphate group from the high energy 
molecule—ATP. The process is defined as phosphorylation. 
Simultaneously, the conformation and function of the substrate was 
changed. Contrariwise, phosphatase removes the phosphate group 
from the phosphorylated target and releases an inorganic species—
phosphate ion. Accordingly, the process is defined as 
dephosphorylation. Consequently, in the process, the conformation and 
function of the substrate is recovered to the starting point in the 
phosphorylation process. (Figure 1.13)  
Apart from the kinase named after the small molecular as the 
substrate, protein kinase named after the protein as the substrate, 
could be also classified by types of the residue as acceptor in substrate 
proteins, as serine/threonine-specific kinase and tyrosine-specific 
kinase. From the structure point of view, all of kinases share a catalytic 
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domain including ATP-binding pocket, substrate-bind pocket and 
catalytic loop. ATP-binding pocket serves to coordinate and orient the 
ATP. Substrate pocket is the capacity for substrate pocket. Catalytic 
loop nearby was involved to anchor the substrate and phosphate 
transferring.55 (Figure 1.14A) 
 
 
Figure 1.13 Phosphorylation by kinase and dephosphorylation by phosphatase 
 
1.2.2  Development of Kinase Inhibitors 
In normal state, kinase as part of the larger family of 
phosphotransferase would cooperate nicely with phosphatase to 
regulate the enzymes to complete the cellular process in the complex 
living system. However, in disease state, dysregulation and mutation of 
kinase (more than 180) is a very important pathogeny in human 
disease such as cancer, diabetes, hypertension and other disease. 
Therefore, kinase is becoming the interesting targets in the therapy.56 
Most of FDA (the U.S. Food and Drug Administration)-approved kinase 
inhibitor drugs are especially targeting different types of cancer. 
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There’re several typical ways to inhibit the activity of kinase 
targeting ATP-binding pocket, substrate-binding pocket, allosteric sites 
and other upstream regulation with small molecules and antibodies.57 
Until now, most small molecule kinase inhibitors are ATP competitive, 
which form few hydrogen bonds with ATP pocket and prevent the 
phosphate donor ATP from binding to kinase in order to terminate the 
subsequent phosphorylation. The X-ray diagram of PKA with 
Staurosporine as an ATP competitive inhibitor represents the inhibition 
model in Figure 1.13B. Staurosporine occupies ATP pocket and 
prevents the subsequent phosphorylation of the peptide substrate  
 
 
Figure 1.14 Ribbon representation of PKA c-α in complex with (A) ATP, and a peptide 
inhibitor (PDB ID: 1ATP); and (B) Staurosporine (STS) and a peptide inhibitor (PDB 
ID: 1STC). 
 
In the past decade, a great progress in the development of small 
molecule kinase inhibitors has been achieved. Many of them are used 
in clinical trials with different types of cancer and some are successfully 
approved in clinic protein kinase inhibitors.56b, 58 (Table 1.1) However, 
comparing to the large family (500+) of kinase and their complicated 
interaction network involved in the therapy, an urgent need occurs to 
develop efficient and specific inhibitors. The strategy is normally a 
combination of methods including analogue synthesis, structure-
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informed design and fragment-based assembly strategies.58a To date, 
by the nature of binding, inhibition model is typically classified to 
reversible and irreversible inhibition. The reversible inhibitor is the 
majority as the ATP competitive inhibitor. This type of inhibitor typically 
occupies the pocket of ATP bonding region including “type I” and “type 
II” binding modes. The binding comes from the nature of interactions 
between kinase and inhibitor, including hydrogen bond and 
hydrophobic interaction. The typical instances include staurosporine 
(Figure 1.14B), Imatinib, Dasatinib and so on. (Figure 1.15) This type of 
inhibitor has the advantage in terms of safety as the binding to the off-
targets could be released.  
 
Figure 1.15. Structures of representative reversible kinase inhibitors 
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Agent Target kinases 
US FDA-approved 
indication 
1 1999 Rapamycin FKBP12/mTOR Immunosuppression 
2 2001 Imatinib ABL, PDGFR, KIT CML, GIST 
3 2003 Gefitinib EGFR NSCLC 
4 2005 Erlotinib EGFR NSCLC, PC 
5 2005 Sorafenib 
VEGFR2, PDGFR, RAF, 
etc. 
RCC, HC 
6 2006 Dasatinib ABL, SRC CML, ALL 
7 2006 Sunitinib VEGFR2, PDGFR, KIT RCC, GIST 
8 2007 Nilotinib ABL CML 
9 2007 Lapatinib EGFR, ERBB2 (HER2) Breast cancer 
10 2007 Temsirolimus FKBP12/mTOR RCC 
11 2009 Everolimus FKBP12/mTOR 
Immunosuppression, 
RCC, etc. 
12 2009 Pazopanib VEGFR2, PDGFR, KIT RCC, STS 
13 2011 Crizotinib ALK, MET NSCLC 
14 2011 Vemurafenib BRAF Melanoma 
15 2011 Ruxolitinib JAK1/2 Myelofibrosis 
16 2011 Vandetanib VEGFR2, EGFR, RET MTC 
17 2012 Bosutinib ABL CML 
18 2012 Ponatinib ABL, SRC CML, ALL 
19 2012 Tofacitinib JAK3 RA 
20 2012 Axitinib VEGFR1/2/3, PDGFR, KIT RCC 
21 2012 Cabozantinib VEGFR2, RET, MET MTC 
22 2012 Regorafenib VEGFR2, TIE2, etc 
Colorectal cancer, 
GIST 
23 2013 Dabrafenib BRAF 
Melanoma with 
BRAF(V600E) 
24 2013 Trametinib MEK 
Melanoma with 
BRAF(V600E/V600K) 
25 2013 Afatinib EGFR 
NSCLC with EGFR 
(exon 19 deletion and 
L858R) 
 
ALL (acute lymphoblastic leukemia) MTC (medullary thyroid cancer) 
AMD (Age-related macular degeneration) NSCLC (non-small cell lung cancer) 
CML (chronic myelogenous leukemia) PC (pancreatic cancer) 
DME (diabetic macular edema) RCC (renal cell carcinoma) 
GIST (gastrointestinal stromal tumors) RA (rheumatoid arthritis) 
HC (hepatocellular carcinoma) STS (advanced soft tissue sarcoma 




However, it becomes difficult to design a kinase inhibitor to 
recognize a kinase from the huge family which possesses the highly 
conserved sequence and structure of the ATP-binding pocket. 
Additionally, many cellular biological important molecules like ATP, 
ADP, AMP and etc., may ubiquitously distribute considerable 
interactions to compete with the inhibitor. On the other hand, a sum of 
the functional proteins which is much larger than of kinases, containing 
the similar nucleotide-binding site, makes the screening much more 
complicated.2, 59 Therefore, there’s the opportunity for the irreversible 
covalent inhibitor as another important type. The interactions between 
the irreversible covalent inhibitor and kinase include affinity binding and 
subsequent covalent binding. The potency for toxicity of covalent 
inhibitor is the unredeemable binding to unanticipated targets. Although 
the disadvantages including toxicity come of the irreversible covalent 
kinase inhibitors, many valuable advantages are owing to them, 
including high potency, high specificity, prolonged pharmacodynamics, 
identification of the active site, flexibility of introduction of warhead and 
other fragment. On the other hand, because of the nature of 
irreversibility and high potency, durable target suppression without the 
necessity of keeping high continuous drug exposure like reversible 
drug is the advantage of safety. 
 Balancing the promising benefits and the potential risk, the 
irreversible covalent inhibitor becomes an increasing type in the last 
decade.58d Typically, an electrophile as the warhead targeting the 
unique nucleophilic residue in the ATP pocket is incorporated to a 
scaffold, which is already an affinity-based inhibitor with the decent 
potency and specify. The higher selectivity comes from the cumulation 
of the non-covalent and covalent binding. From the structure point of 
view, the majority type of the nucleophilic residues targeted by the 
inhibitors is cysteine in the ATP pocket. According to the relative 
positions, Zhang et al. gave a pioneering system that classified 
cysteines into four groups in the ATP pocket, and additional two groups 
in the gateway or the activation loop near the ATP pocket.58a The 
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representing crystal structures illustrate how the inhibitors target the 
cysteine in the different locations. (Figure 1.16) 
 
 
Figure 1.16 The representing modes of irreversible inhibition targeting the cysteine in 
the ATP pocket. (A) EGFR with HKI-272 (PDB ID: 2JIV) at Cys 797 in Group 3; (B) 
ERK with hypothemycin (PDB ID: 3W55) at Cys 166 in Group 4. 
 
A number of electrophiles as ‘‘warheads’’ that can react with 
nucleophiles such as cysteine, lysine, or tyrosine within the active sites 
have been investigated in the design of irreversible kinase inhibitors. 
Michael addition reaction is widely utilized to achieve irreversible 
binding, which involves the typical functional groups: vinyl ketone 
(E6201),60 vinyl sulfonates,61 acrylamides (PCI-32765,62 BIBW-2992,63 
EKB-569,64 JNK-IN-8,65 FIIN-1,66 PF-0029980467 and PD16839368), 
alkynyl amides (JH295)69 and quinones70. There are also other 
functional groups which take place nucleophilic displacement or 
addition, including α-haloketones (1-4,71 FMK,72 1-573), thiocyanates,74 
alkynes,75 epoxides76 and sulfonyl fluoride77. The representative 





Figure 1.17 Structures of representative irreversible kinase inhibitors 
 
In conclusion, although a dramatic development has been 
accomplished in the last decade, there’re still some challenges 
including the inhibition mechanism of target and off-target, drug 
metabolic mechanism, drug-resistant of tumour and efficient biomarker 
for tumour. 
1.3 Research Objective 
Assigning the cellular targets of bioactive small molecules is still a 
big challenge in the drug discovery, including the unknown side effects 
of drugs. It is the aim of this thesis to develop a convenient chemical 
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proteomic method to unravel the global target spectrum for the 
bioactive small molecules, using a click-based in situ profiling approach. 
This method should enable the repertoire of drug-target interactions to 
be probed within living systems.  
On the other hand, to study the interactions of kinase inhibitor with 
protein targets in the cancer cell, we also intend to develop a specific 
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This chapter describes a library of C75-based ABPs for investigate 
the cellular targets of C75 in cancer cell. C75, a covalent bioactive 
compound, has been particularly promising as a weight-loss and anti-
cancer agent through its ability to modulate fatty acid oxidation. Various 
pathways have been found to be modulated by C75, including inhibition 
of fatty acid synthase (FASN) and activation of carnitine O-
palmitoyltransferase-1 (CPT1). In the current study, we set out to 
identify unknown cellular targets (on and off) of C75 at its early stages 
of development as a potential therapeutic agent. A small library of eight 
activity-based probes (ABPs) was first designed from the C75 scaffold. 
One probe called 2-9g, was shown to be active in live cancer cells, 
capable of covalent targeting of both known C75 targets including 
FASN and CPT-1A, as well as previously unknown targets including 
PDIA3, TFRC and GAPDH. Further studies could elucidate the 
mechanism of C75 binding against these newly identified targets. 
2.2 Introduction 
Despite recent success with the use of covalent drugs, for example, 
Orlistat (weight-loss), Clopidogrel (anti-platelet) and Esomeprazole 
(peptic ulcer), there remain significant safety concerns over the large-
scale development of covalent-based therapeutics.78 Besides the fear 
that in modifying proteins, such drugs could trigger an idiosyncratic 
immune response. Such concerns are in part attributed to the difficulty 
in establishing the spectrum of 'off-target' binding events which can 
cause many undesirable side-effects.42b 
To address this problem, we have recently developed a convenient 
chemical proteomic method to unravel the global target spectrum for 
any given covalent drug, using a click-based in situ profiling 
approach.6a, 45 This method enables the repertoire of drug-target 
interactions to be probed within living systems. By introducing a very 
conservative modification onto the lead molecule (namely, an alkyne 
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tag), at solvent accessible sites (to retain pharmacodynamic 
properties), observations can be reliably made to determine molecular 
behaviour and interactions within complex and dynamic cellular 
environments (Figure. 2.1).42b 
Figure 2.1 Flow chart of in situ proteome profiling. In the approach, after in situ 
labeling with “clickable” probe, the labeled proteins were clicked with reporters to 




We had previously applied this strategy to successfully profile the 
on- and off- targets of Orlistat,45 as well as those of various kinase 
inhibitors.26, 36a Here we extend the strategy by building a library of a 
covalent bioactive compound, C75, which has been particularly 
promising as a weight-loss and anti-cancer agent through its ability to 
modulate fatty acid oxidation.79 C75 is a more stable synthetic mimic of 
cerulenin (a fungal metabolite), and belongs to a class of α-methylene-
-butyrolactones.79a, b (Figure 2.2) Various pathways have been found 
to be modulated by C75, including inhibition of fatty acid synthase 
(FASN) and activation of carnitine O-palmitoyltransferase-1 (CPT1).79c, 
d The compound is also known to alter the level of neuropeptide Y and 
AMP-activated protein kinase (AMPK) activity in the hypothalamus, 
reducing food intake.79d Many common human cancers, including 
breast, ovarian, prostate and colon, express high levels of FASN. So 
decreased fatty acid production through FASN inhibition is seen as a 
viable anti-cancer strategy.79a, b Prior work using isotopic labeling and 
immunoprecipitation validated FASN as the cellular target of C75.79b In 
a separate study, a very similar butyrolactone scaffold was shown to 
bind histone acetyltransferase GCN5, with a weak IC50 of 
approximately 100 μM, highlighting that other proteins may have affinity 
to C75 as well.80 
 
Figure 2.2 Structures of Cerulenin and C75 
To identify unknown cellular targets (on and off) of C75 at its early 
stages of development as a potential therapeutic agent, a small library 
of eight activity-based probes (ABPs) was first designed from the C75 
scaffold. The 5-member-ring (4-methylene-2-octyl-5-oxo-tetrahydro-
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furan-3-carboxylic acid) nucleophilic acceptor was retained as the 
pharmacophore, for binding to its respective targets. The linker lengths 
were varied between 2 and 10 carbon chains. The terminal alkyne as a 
ligation handle was introduced to the linker side chain. Compared to 
the tag-conjugated manner, the minimized modification was to avoid 
altering the drug activity and available for the in situ proteome profiling. 
(Figure 2.3) 
 
Figure 2.3 Synthetic plan of C75-based probes 
 
2.3 Results and Discussion 
2.3.1 Synthesis of C75-based Probes 
To perform the following biological evaluation, the “clickable” probes 
based on C75 were established first. The synthesis of important 
fragment of alkynal 3 was outlined in Scheme 2.1. Bromocarboxylic 
acid 2-1d (or 2-1e, 2-1g) was treated with lithium acetylide, which was 
prepared from trimethylsiliylacetylene with n-butyllithlium, to give the 
intermediate 2-2d (or 2-2e, 2-2g). After deprotection of trimethylsiliyl 
group and subsequent reduction, alkynol 2-4d (or 2-4e, 2-4g) was 
obtained. . 6-Bromohexanoic acid was treated with ethylide lithium to 
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give 2-6c. Then 2-6b (or 2-6c, 2-6f) was reduced with lithium 
aluminumhydride to give 2-4b (or 2-4c, 2-4f). The final oxidation of 
alkynols 2-4a-g in presence of PCC and sodium acetate proceeded 
smoothly to provide the smelly alkynals 2-5a-g. Due to the high 




Scheme 2.1 Synthesis of alkynal 2-5a-g 
With alkynals 2-5a-g in hand, we pushed forward to the synthesis of 
C75-based probes 2-9a-g as shown in Scheme 2.2. Itaconic anhydride 
reacted with 4-methoxybenzyl alcohol (PMB-OH) to give intermediate 
2-7. The cyclization of compound 2-7 with alkynals 2-5a-g in presence 
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of LDA and subsequent acidification provided compounds 2-8a-g, 
which were unstable in air at room temperature. The final deprotection 
of compounds 2-8a-g with phenol at 60 oC provided the desired probes 
2-9a-g. (Scheme 2.2) 
 
Scheme 2.2 Synthesis of 2-9a-g 
 
2.3.2 Design and Synthesis of Tri-functional Tag 
Rhodamine B and Biotin are common tags which are widely used to 
label protein in azide-conjugated manner. (Figure 2.4) Azide group is 
partner of alkyne in Cu(I)-catalyzed Huisgen 1,3-dipolar cycloaddition 
reaction (Click chemistry). PEG is incorporated as a hydrophilic linker, 
which is compatible to physiological conditions. Rhodamine B as a 
fluorescent dye could be detected easily and inexpensively with 
instruments. Biotin binds to avidin (also streptavidin and neutravidin) 




Figure 2.4 Structures of Rh-PEG-N3, Biotin-PEG-N3 and trifunctional tag Rh-Biotin-N3 
Although the two tags are used widely, it’s not convenient to 
compare the results from fluorescent detection and pull-down 
experiment. Herein, we reported a trifunctional tag (Rh-Biotin-N3), 
which could be used both for fluorescent detection and avidin affinity-
based capture. Two tags Rhodamine and Biotin would be incorporated 
to azide group with proper linkers. The design would facilitate the 
sample preparation for fluorescent detection and affinity-based capture 
by biotin-avidin interaction. (Figure 2.4) 
The synthetic route of trifunctional tag Rh-Biotin-N3 was shown in 
Scheme 2.3. The PEG linker 2-14 was synthesized from 2-10 by four 
steps.81 Biotin 2-15 was activated by NHS and then the resulted 
product 2-16 Biotin-NHS was coupled with deBoc version of Fmoc-
Lys(Boc)-OH 2-17 to give lysine-biotin 2-18.82 Lysine-biotin 2-18 was 
coupled with mono-Boc protected 3-propanediamine 2-1952 to give 
compound 2-20. Deprotection of compound 2-20 with 20 % piperidine 
and subsequent coupling with Rh-acid 2-21,83 provided product 2-22. 
After Boc deprotection of compound 2-22, the final amide coupling with 





Scheme 2.3 The synthesis of trifunctional tag Rh-Biotin-N3 
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2.3.3 Cell Anti-proliferation Assay and Proteome 
Profiling of HepG2 Cancer Cell with C75-based Probes 
After the library of eight probes was established, anti-proliferation 
and proteome profiling were performed. Firstly, anti-proliferation assay 
was used to evaluate activities of C75 analogues at a concentration 
range of 0-100 μM against C75 (positive control) by XTT assay on 
HepG2 cell line (a human hepatocellular liver carcinoma cell line). 
(Figure 2.5) Compared to the parent drug C75, 2-9g produced the best 
anti-proliferation activity amongst the various C75 analogs. The longer 
hydrophobic side chain in 2-9g might have afforded better cell 
permeability of this compound, giving rise to its improved cellular 
activities. The stereoisomers of trans-2-9f and cis-2-9f did not show 
significant activity differences. Subsequently, 2-9g was used for further 
biological studies. 
 
Figure 2.5 Dose dependent inhibition of HepG2 proliferation by C75 and its 
analogues 2-9a-g (0, 20, 50, 100 µM) by XTT assay. 
Next, in vitro and in situ labelling experiments were performed to 
test the proteome reactivity profiles of all probes (2-9a-g) by using 
mammalian cell lysates and live cells, respectively. To in vitro labeling 
experiment, the probes were first incubated at a concentration range of 
5-20 μM with HepG2 cells lysates and clicked with the fluorescent 
reporter Rh-PEG-N3. Then the tag-conjugated proteins were separated 
by SDS-PAGE gel, and analyzed by in-gel fluorescence scanning. 
Results from the in-gel fluorescence scanning showed that even 5 µM 
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of the probes were able to produce numerous significant fluorescent 
bands, in a dose-dependent manner. The labeled bands could be 
competed away by pre-treatment of C75, indicating that the 




Figure 2.6 in vitro labeling of HepG2 proteomes with C75 based probes. The lysate 
was treated with 2-9a-g (5, 10, 20 µM, here abbreviated as a-g) in presence or 
absence of C75 (25 µM). 
Further the library was tested in situ at a higher 20 µM 
concentration with each of the 2-9a-g analogs. The probes were first 
incubated with live HepG2 cancer cells, where its targets were labeled 
in situ covalently. After lysis, the labeled proteins were then clicked with 
and clicked with Rh-PEG-N3. Then labeled proteins were subjected to 
subsequent analysis similar to previous in vitro proteome labeling. This 
provided a compartmentalized living system in which to test the binding 
activities of these scaffolds. The in-gel fluorescence scanning showed 
that probe 2-9g remained the compound with the most intense 





Figure 2.7 In situ labeling of HepG2 proteomes with C75 based probes. The lysate 
was treated with 2-9a-g (20 µM, here abbreviated as a-g) with pretreatment in 
presence or absence of C75 (25 µM) 
 
2.3.4 Target Identification and Validation 
To positively identify some of the putative protein targets visualized 
on the gels, a large-scale pull-down experiment was performed. Live 
HepG2 cancer cells were incubated with the representative probe 2-9g, 
where its targets were labeled in situ covalently. After lysis, the labeled 
proteins were then clicked with Rh-Biotin-N3 under the same conditions 
as previous labeling experiment. Then the biotinylated proteins were 
captured by Avidin-immobilized agarose beads via affinity interaction, 
subsequently washed and eluted, the pulled-down samples were 
separated by SDS-PAGE. The separated proteins were transferred to 
PVDF membrane and analysed with Western Blotting by corresponding 
antibodies. The results unambiguously confirmed the existence of 
FASN and CPT1A, which were previously identified as targets of 
C75.79 (Figure 2.8B) There results indicated that our newly develop 
“clickable” C75 analogues, e.g. 2-9g, were indeed suitable small 
molecule probes for large scale, cell-based proteome profiling of 




Figure 2.8 (A) In situ pull-down experiment treated with 20 µM of 2-9g, clicked with 
Rh-Biotin-N3 or Biotin-N3. Silver stain (left), fluorescent scanning (right); (B) Validation 
of known targets of C75 by in situ pull-down experiment over HepG2 treated with 
DMSO (negative control) and 2-9g. 
After confirmation of the existence of interactions between C75 and 
know targets in live HepG2 cancer cell, we proceeded with pull-
down/LCMS experiments to identify the putative cellular targets of C75. 
The same pulled-down samples were separated by SDS-PAGE and 
visualized with fluorescent scanning and silver stain. (Figure 2.8A) The 
entire gel lane for the pull-down sample was then cut into small 
particles and processed for in-gel trypsin digestion as standard 
procedure. As negative control, a large-scale proteomic experiment 
was also carried out with cells treated by DMSO instead of 2-9g. The 
fragmented peptides were extracted from gel particles and subjected to 
LC-MS/MS analysis. Fragmentation analysis and database match 
searching was performed for protein identification against human 
protein database using an in-house MASCOT server. By the aid of the 
high-throughput technology (LC-MS/MS), the global information of the 
potential targets could be uncovered. A list of the hits, which was 
potential targets of C75, was generated. (Chapter 9 Appendix, Table 
S1)  
We focused our attention on those candidates which possess 
known nucleophilic residues and play important roles in cancer cells 
(Figure 2.9A). FASN and CPT1A again emerged as top candidates on 
this list, as should be expected.79a-c, 84 A number of lipid- and/or fatty-
acid-metabolism-related proteins were also identified, including acyl-
CoA dehydrogenase (ACADVL) and sterol O-acyltransferase (SOAT1). 
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Proteins possessing a cysteine active-site residue, including protein 
disulfide-isomerase A3 (PDIA3), glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), transferrin receptor protein 1 (TFRC), 
asparagine synthetase (ASNS), cytoskeleton-associated protein 4 
(CKAP4), protein disulfide-isomerase (P4HB), thioredoxin reductase 1 
(TXNRD1) and double-stranded RNA-specific adenosine deaminase 
(ADAR), were identified as potential C75 targets. Other proteins, 
including fructose-bisphosphatealdolase A (ALDOA), heat shock 
protein 90 β(HSP90AB2P), L-lactate dehydrogenase A chain (LDHA) 
and methyl crotonoyl-CoA carboxylase (MCCC1), were also identified 
as potential targets and they all contained an active-site lysine residue. 
Based on antibody availability, we validated several of these hits, 
including PDIA3, TFRC and GAPDH, by 2-9g labelling/pull-down/ 
western blotting; all three proteins were positively labelled by 2-9g and 
successfully pulled-down, indicating they are likely true cellular targets 







Localization Protein function* 




Carnitine O-palmitoyltransferase activity 
PDIA3 ER 
Catalyzing the rearrangement of -S-S bonds in 
proteins 





glyceraldehyde-3-phosphate dehydrogenase and 
nitrosylase 
ASNS Cytosol Asparagine biosynthesis 
HSP90AB2P Cytoplasm Molecular chaperone. 
ALDOA Cytosol Glycolysis 
LDHA Cytoplasm Glycolysis 
CKAP4 Membrane Receptor for Surfactant protein-A 
MCCC1 Mitochondrion 






TXNRD1 ER membrane Formation of cell membrane protrusions 
SOAT1 Nucleus 





Catalyzing the formation, breakage and 
rearrangement of disulfide bond 
ADAR Cytoplasm 






Figure 2.9 (A) Proteins identified by pull-down and subsequent mass spectrometry; B) 
Western Blotting validation of pull-down experiment with DMSO (DMSO-treated cell 
proteome as negative control, left) and 2-9g (20 µM, right). 
 
2.3.5 Target Localization by Cell Fluorescent Imaging 
Finally, our probes could also be used as small molecular imaging 
probe to assess the cellular uptake of C75 and detect its cellular 
localization. To do this, the probe 2-9g was selected as a 
representative example. Live HepG2 cancer cell was incubated with 2-
9g for 2 h, fixed with 3.7% formaldehyde, permeabilized with Triton X-
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100 and then clicked with Rh-PEG-N3 in situ. The fluorescent imaging 
experiment was performed to visualize the distribution of targets of the 
probe in the cell. Compared with the nucleus visualized by the blue 
fluorescence (Hoechst as a commercial available nucleus tracker), the 
red fluorescence (Rhodamine B) showed most of the targets of 2-9g 
were located in cytosol, indicating this is where most of C75’s cellular 





Figure 2.10 Fluorescence imaging of HepG2 cell probed with probe 2-9g (20 µM). 
HepG2 cell was incubated with probe for 2 h and click with Rh-PEG-N3 (Rodamine B 
channel, colored in red); the cell was stained with Nucleus tracker (Hoechst, colored 
in blue). Bright filed images (DIC) of the corresponding cells were shown. Overlay of 
probe and nucleus channels were shown Merged. Scale bar = 20 µm. 
 
2.4 Conclusion 
In conclusion, we have successfully designed and synthesized a 
library of C75 analogues with linker lengths varied between 2 and 10 
carbon chains. As ABPs derived from C75, 5-member-ring (4-
methylene-2-octyl-5-oxo-tetrahydro-furan-3-carboxylic acid) 
nucleophilic acceptor was retained as the pharmacophore, for binding 
to its respective targets and the terminal alkyne as a ligation handle 
was introduced to the linker side chain. The probes are suitable for the 
in situ proteome profiling for the minimal modification design. The 
known targets including FASN, CPT-1A were validated and other new 
potential targets including PDIA3, TFRC and GAPDH were identified by 
ABPPs approach including proteome profiling, labeled protein 
enrichment, LC-MS/MS analysis and validation. The cell-peneatrating 
probe 2-9g as a representative sample has been explored in the 
1)                              2)                              3)    Hoechst                          trans-2-9g                       Merged 
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fluorescent imaging experiment to monitor the activity and localization 
of the cellular drug targets in situ. Therefore, the structure-effect 
relationship of C75 over cancer cell could give useful implications to 
design more efficient anti-tumor agent. Further study will enable 
extensive study of drug discovery based on the proteome results by in 
situ living cell profile, such as potential pharmacological effect, 
pharmacokinetic effects including absorption, distribution, even 
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In this chapter, we describe a new approach to design irreversible 
inhibitors of protein kinase from a general inhibitor—Staurosporine 
(STS). Three “clickable” probes based on STS have been successfully 
synthesized by introducing different electrophiles (chloroacetamide, 
sulfonate ester and acrylamide). This new STS-tagging configuration 
has minimized non-specific labeling, by preferentially gearing selectivity 
towards a range of kinases (or the so-called kinase cysteinome), which 
possess potentially targetable cysteine residues near the ATP-binding 
pocket of the enzyme. In the biological test, it was found that the 
inhibitor could irreversibly label protein kinases c-Src in vitro. By the 
ABPP approach, large scaled in situ and in vitro pull-down in cancer 
cell and subsequent LC-MS/MS analysis showed STS-C1 could label 
31 kinases in vitro (cell lysate) and 8 kinases in live cancer cell. 
Imaging experiment showed the probe was cell-permeable and 
predominantly cytosolic in HepG2 cells. On the other hand, by in situ 
proteome profiling and pull-down/WB validation, human PDI was 
identified as the major cellular target of STS-T1 in the live cancer cell 
MCF-7. 
3.2.  Introduction 
The brief introduction of kinase and kinase inhibitors was 
summarized in Chapter 1. Although small molecule inhibitor is rising as 
a hotspot to regulate the activity of kinase, it is still a big challenge in 
the drug discovery today.58a Only 25 small molecules were approved as 
kinase inhibitors by FDA (Food and Drug Administration, USA) until 
mid-2013.58e Compared the large number of disease-associated 
kinases with the limited successful instances, discovery of more 
specific kinase inhibitor drugs to the according kinases is becoming 
urgent now.  
Most small molecule kinase inhibitors suffer from broad reactivities. 
For example, it was reported that the reversible drug—Dasitinib may 
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have many off-targets including dozen of kinases.37 The highly 
conserved sequence of ATP-binding pocket and large number of 
kinases (500+) made it difficult to screen out kinase inhibitors, 
especially for reversible manner. Additionally, the interactions between 
the inhibitor and kinase were interfered by many nucleotide analogs 
such as ATP/ADP/AMP and etc, and a great number of nucleotide-
pocket-holding proteins distributed ubiquitously in the cell.2, 59 
Therefore, it remains a challenge to design therapeutics that are able 
to specifically target the disease-causing kinase, and thus minimize 
toxicity and undesirable side effects. One proven strategy to enhance 
the selectivity of kinases inhibitors is through the development of novel 
kinase-targeting small molecule probes capable of interrogating 
endogenous kinase-drug interactions in an in vivo setting.72 
 
Figure 3.1 Structure of Staurosporine (STS) 
Staurosporine (STS) is a natural product alkaloid isolated from 
Streptomyces staurosporeus, and is the most potent broad spectrum 
kinase inhibitor known.19c, 85 (Figure 3.1) It has been applied as a tool 
to study the binding and inhibition spectrums of various kinases. Of the 
approximately 518 kinases in humans, a sizeable number (at least 253) 
are inhibited by staurosporine.19c, 85 We and others have sought to 
modify and develop probes from STS, to better profile and understand 
its binding spectrum of kinases in vivo.37, 86 In previous examples, other 
groups have developed biotin tagged STS,86 which is too bulky and not 
cell permeable. We have separately designed cell-permeable diazirine-
containing STS probes capable of large-scale kinase profiling 
experiments in live mammalian cells.26, 37 Due to need to introduce a 
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photo-reactive diazirine moiety into such probes, they have intrinsically 
strong background labeling toward high-abundance endogenous 
proteins. 
 
Figure 3.2 Proposed “clickable” STS-based probes 
Herein, we report a method to convert STS into an irreversible 
covalent kinase probe by incorporation of electrophilic warheads 
(chloroacetamide, acrylamide and sulfonate ester) into STS (Figure 
3.2). The modification commenced at the secondary amine of STS (a 
position previously shown to be highly tolerant to structural changes87) 
with a small handle containing the warhead and a terminal alkyne. The 
subtle modification was aimed to retain its biological function and 
activity in live cells. The design of the probe would enable in vitro and 
in situ proteome profiling for the convenience of investigation of the 
interactions between the probe and its targets.(Figure 3.3) We 
hypothesized that this new STS-tagging configuration may minimize 
non-specific labeling observed in previously developed STS probes,26, 
37, 86 by preferentially gearing selectivity towards a range of kinases (or 
the so-called kinase cysteinome56b), which possess potentially 
targetable cysteine residues near the ATP-binding pocket of the 
enzyme. In so doing, such a strategy could prove useful in lead 
development, and tune potencies of kinase inhibitors (i.e. enhance on- 




Figure 3.3 The flow chart of in situ proteome profiling strategy with Staurosporine 
derived probes. After the probe was incubated with live cell, the labelled protein was 
clicked with azide-conjugated tags and purified by Avidin-biotin binding. The pulled-




3.3.  Results and Discussion 
3.3.1. The Synthesis of STS-derived Probes 
Three STS derived probes have been synthesized successfully by 
introduction of different electrophiles together with terminal alkyne to 
STS, which would be described in details subsequently. 
 




The synthesis of probe STS-C1 was outlined in Scheme 3.1. Fmoc-
O-tert-Butyl-L-serine was coupled with propargylamine to give 
compound 3-2. After deprotection of Fmoc group, the resulted 
compound 3-3 was reacted with 2-chloroacetyl chloride to give 
compound 3-4. The intermediate 3-4 was treated with TFA for 
deprotection of t-butyl group to give compound 3-5. STS was treated 
with succinic anhydride to provide the key intermediate 3-6, which was 
subjected to coupling with compound 3-5 to afford the desired probe 
STS-C1. In the solution phase synthesis of chloroacetamide-containing 
probe, the functional group shows highly reactivity to the free amine. 
So the scaffold was changed from lysine to serine. 
 
Scheme 3.2 Synthesis of STS-T1 
The synthesis of probe STS-T1 was outlined in Scheme 3.2. 
Benzoyl chloride 3-7 was reacted with N-Boc-ethylenediamine 3-8 to 
give sulfonyl chloride 3-9, which was reacted with but-3-yn-1-ol to 
afford sulfonate ester 3-10. After Boc-deproteciton with TFA, the 
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resulted amine 3-11 was coupled with intermediate 3-6 to give the 
desired product STS-T1. 
 
 
Scheme 3.3 Synthesis of STS-A1 
The synthesis of probe STS-A1 was outlined in Scheme 3.3. Fmoc-
D-Lys (Boc)-OH 3-12 was coupled with propargyl amine to give 
compound 3-13. Then deprotection of Boc of compound 3-13 with TFA 
to obtain compound 3-14, which was coupled with acyl acid to give 
compound 3-14. After removal of Fmoc with piperidine, compound 3-14 
was coupled with compound 3-6 to give product STS-A1. 
 




It was hypothesized that the newly synthesized STS-derived probes 
targeted the ATP-pocket-holding proteins (especially kinases). In order 
to evaluate reactivity of the probes, we carried out screening in live 
cancer cells including HepG2, MCF-7, MDA-MB-231 and T47D by the 
well-established proteome profiling approach. (Figure 3.4)  In in situ 
labelling experiment, it was found that several representatives 
possessed interesting in situ proteome reactivity profiles. STS-C1 
showed distinct and strong labeling signals over four cancer cell lines. 
STS-T1 showed strong and unique band over T47D, MDA-MB-231 and 
MCF-7, which potentially indicated the major target of STS-T1 in the 
live cancer lines.  
 
Figure 3.4 In situ proteome reactivity profiles of various electrophilic probes in live 
cancer cells (5 µM: T1, A1; 1 µM: C1) for 2 h. Then Cancer cells were lysed and 
clicked with Rh-PEG-N3, separated by SDS-PAGE gels followed by in-gel 
fluorescence scanning (FL) 
 
Many protein kinases, including c-Src, have potentially reactive 
cysteine residues near their ATP-binding pockets.88 In the current study, 
we chose c-Src as one of our intended targets due to its obvious 
biological importance. In addition, few irreversible inhibitors of c-Src are 
known. One very recent report, however, has already indicated that it is 
possible to irreversibly target Cys277 (a residue near the ATP pocket 
of c-Src) by using an aminopyrazole based kinase inhibitor decorated 
with a suitable electrophilic moiety.61 To test the labeling of STS 
derived probes against desired targets — protein kinases in vitro, five 
recombinant kinases including c-Src were selected. (Figure 3.5) The 
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proteins were incubated with the probes, followed by the formation of 
covalent bond. The stable probe-protein complex was ready for click 
reaction with Rh-Biotin-N3 and then detected by in-gel fluorescence 
scanning. The labeling test showed STS-C1 and STS-A1 strongly 
labeled c-Src compared to other kinases. The results directed the 
following investigation. 
 
Figure 3.5 In vitro labeling of recombinant protein kinases (CSK, PKA, Abl, Erk2, Src) 
and BSA (as a negative control) with STS-C1 STS-A1 and STS-T1 (1 µM). The 
intensity of Src was reduced. PMT of others was normal (600). 
 
3.3.3. STS-C1 targeting kinases in vitro and in live cell 
Based on the preliminary screening results, STS-C1 showed the 
possibility to target the kinase cysteinome including c-Src. Following 
experiments would be performed to evaluate the selectivity of the 
probe and in-vivo labeling reactivity. By the proteome profiling 
approach, the cellular targets of STS-C1 could be identified 
comprehensively. 
Molecule modeling and IC50 assay against c-Src 
We performed docking experiments to guide the design of linker 
size and configuration in STS-C1. The binding mode of STS-C1 with c-
Src was simulated by molecular docking with AutoDock Vina (Figure 
3.6).89 After the probe STS-C1 was docked into the ATP pocket of c-
Src (PDB code: 3F6X),61 Cys277 in c-Src was found to be located ~5.2 
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Å from the chloroacetamide moiety of STS-C1. In addition, the alkyne 
handle of STS-C1 in the docked complex was shown to project toward 
the protein surface, thus making it accessible for subsequent click 
conjugation. The result showed the importance of the affinity-driven 
induction by STS core.  
  
Figure 3.6 Docking of STS-C1 into the ATP pocket of c-Src (PDB code: 3F6X), Cys 
277 near to the warhead of the probe 
 
IC50 assay against c-Src 
To establish inhibition profiles of STS-C1 against kinases, enzyme 
activity assays were tested. Compared to STS, the IC50 of STS-C1 
against recombinant c-Src in an in vitro kinase inhibition assay was 
approximately 2-fold lower. Interestingly, a 4-fold increase in IC50 value 
was observed for STS-C1 against PKA (also a known target of STS). 
This suggests that while introduction of linker moiety in STS in general 
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negates the kinase/inhibitor interaction,26 suitable positioning of the 
electrophilic moiety near Cys277 in c-Src actually promote such 
interactions, presumably via the formation of an irreversible covalent 
complex. (Figure 3.7) 
 
Figure 3.7 IC50 value of STS-C1 against recombinant PKA and c-Src. 
 
In vitro labeling of purified kinases 
We next tested the covalent labeling of STS-C1 against 
recombinantly purified proteins including BSA (not a kinase) and 
several kinases (ERK2, CSK, Abl, PKA and c-Src). As shown in Figure. 
3.8, only c-Src was prominently labeled. Interestingly, even PKA was 
not positively labeled by STS-C1 despite a relative potent inhibition (e.g. 
IC50 = 267.9 + 2.1 nM). This clearly showed that in order for the probe 
to covalently label the target protein, a proximal reactive cysteine 
residue, e.g. Cys277 in c-Src, is essential. We also compared the 
labeling profile of STS-C1 with that of our previous developed photo-
reactive probe STS-2.26 The results further confirmed that these 




Figure 3.8 In vitro labeling of recombinant protein kinases and BSA with (A) STS-C1 
(200 nM) and STS-2 (1 µM). 
 
In vitro labeling of Bacterial proteome overexpressed c-Src 
We next performed labeling of c-Src in a more complex 
environment by using bacterial lysates that overexpress c-Src (Figure 
3.9); with different amounts of STS-C1 (0 to 200 nM) being used to 
label 20 μg (each lane) of the lysates, it was observed that selective c-
Src labeling could be readily detected with as little as 10 nM of the 
probe. (Figure 3.9A) In a separate experiment with 200 nM of STS-C1, 
c-Src labeling was clearly detected in as little as 1 μg of the bacterial 
lysate, indicating a good detection sensitivity of the probe. (Figure 
3.9B) Competitive labeling experiment was also carried to confirm the 
covalent labeling of c-Src by STS-C1 was activity-based (Figure.3.9C); 
the presence of excessive STS (2 μM; 10x of STS-C1) was able to 





Figure 3.9 (A) in vitro labeling of bacterial lysate expressing c-Src (20 µg) with STS-
C1; (B) Dose-depending labeling of bacterial lysate expressing c-Src with STS-C1 
(0.2 µM); (C) The labeling of bacterial lysate expressing c-Src  with STS-C1 (0.2 µM) 




Anti-proliferation and  
After a series of experiments show STS-C1 could specifically 
label c-Src in bacterial proteome, we further evaluated the anti-
proliferative effects of STS and STS-C1 on HepG2 cell lines (a human 
liver cancer cell line). The anti-proliferation by XTT assay showed the 
cell toxicity of STS-C1 comparing with the parent drug-staurosporine 
(STS). (Figure 3.10) The profiles demonstrated very similar toxicity 
profiles, and indicated retention of STS function in STS-C1.  
 
Figure 3.10 Anti-proliferation result by STS-C1 and STS as determined by the XTT 
assay. 
Cancer cell proteome profiling 
Encouraged by these results, we went on to test the labeling of 
STS-C1 in endogenous mammalian proteomes. HepG2 liver cancer 
cells were used and the labeling reactions were carried out both in vitro 
(cell lysates) and in situ (live cells) (Figure. 3.11); results from the in-gel 
fluorescence scanning of the labeled proteomes showed multiple 
fluorescent bands, highlighting the presence of many potential cellular 




Figure 3.11 Labeling of HepG2 proteome with STS-C1 in vitro and in situ. 
 
Pull-down experiment of HepG2 proteome and LC-MS/MS 
analysis 
In order to confirm that endogenous c-Src present in the HepG2 
proteomes was indeed one of the labeled targets, these labeled 
proteomes were clicked with Rh-Biotin-N3, pulled down with avidin 
beads followed by Western blotting analysis with anti-c-Src antibody; 
labeled c-Src was successfully detected in probe-treated proteomes, 
but not in negative controls (e.g. DMSO-treated proteomes), under 
both in vitro and in situ settings. (Figure 3.12) 
 
Figure 3.12 Target Identified of STS-C1 by Western Blotting (anti-Src) 
 
We further subjected the labeled proteomes to pull-down/LC-
MS/MS analysis for large-scale identification of putative labeled protein 
targets and the results are summarized, with selected candidate 
proteins listed. As should be expected, kinases formed the bulk of the 
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most highly ranked hits. In total 35 kinases were identified from the in 
vitro pull-down and 11 kinases from the in situ pull-down, with 7 
kinases that overlapped across both experimental sets (Fig. 3.13B). 
Full list of kinases identified from these experiments are provided in 
Chapter 9 Appendix Table S3. Compared to proteins identified from 
earlier-generation probes (e.g. diazirine-containing STS probes26, 37), 
STS-C1 provided a different range of targets. In Figure 3.13A, by 
focusing our analysis on the 11 kinases identified from the in situ pull-
down experiments we found some interesting hits. For example, both 
CDK1 and CDK2 were previously predicted to possess targetable 
cysteine near their ATP binding pockets,56b and they were positively 
puled-down/identified from our experiments. These findings further 
indicate that our newly developed probe might be a suitable chemical 
for future identification of unknown proteins in kinase cysteinome. 
 
A)                                                                                B) 
 
ID Gene Name Score 
Peptides 
Matched 
H3BTN5 PKM 127 6 
P60891  PRPS1 46 2 
 E5RIU6 CDK1 40 2 
 E7EUY0 PRKDC 52 5 
 B2R5T5 PRKAR1A 34 1 
 G3V5T9 CDK2 29 2 
Q5R3A8 FYN 25 2 
Q05655 PRKCD 39 1 
Q8IWB6 TEX14 36 1 
 H7C175 AATK 32 1 
Q4LE51 PIK3CA variant protein 16 1 
 
Figure. 3.13 (A) Kinases identified from in situ pull-down/LC-MS/MS; (B) Venn 







Target validation of STS-C1 by Western Blotting  
The target identified by LC-MS/MS could be validated by Western 
Blotting. (Figure 3.14) 
 
Figure 3.14 Western Blotting (anti-CDK1) validation of large scale pull-down samples 
(in vitro and in situ) with STS-C1 (1 µM). 
 
Localization of Targets STS-C1 in HepG2 by fluorescent 
imaging experiment  
The probe could also be used as small molecular probe to detect 
the distribution of target and enzymatic activity. The cells seeded on 
glass-bottom dish were treated with DMSO and three gradually 
increasing concentration (DMSO, 200 nM, 500 nM and 1 µM). After 
fixation, permeabilization and clicked with Rh-PEG-N3, the confocal 
fluorescence imaging showed the real signal of targets start to appear. 
(Figure 3.15) Results showed the probe was cell-permeable and 




Figure 3.15 Fluorescence imaging of HepG2 cell probed with and different 
concentration of probe STS-C1 (DMSO, 200, 500, 1000 nM). HepG2 cell was 
incubated with probe for 2 h and click with Rh-PEG-N3 (Rodamine B channel, colored 
in red, Column 2); the cell was stained with Nucleus tracker (Hoechst, colored in blue, 
Column 3). Bright filed images (DIC) of the corresponding cells were shown in column 
1. Overlay of probe and nucleus channels were shown in column 4. 
 
3.3.4. Unexpected STS-T1 targeting PDI in live cancer cell 
Protein disulfide isomerase (PDI) as a chaperone protein plays very 
important roles in cell life, which catalyses disulfide bond breakage 
(reduction), formation (oxidation) and rearrangement (isomerization) in 
endoplasmic reticulum (ER).90 The covalent bonding to form disulfide 
bridge between two cysteine residues is involved in the protein folding, 
which is the key process to assume the functional shape or 
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conformation of protein. PDIA1 (normally abbreviated as PDI, encoded 
by the P4HB gene)91, is the well-known member of the PDIs family (at 
least 21 PDI family members known in human). The 57-kDa protein 
locating mostly in the ER, contains four thioredoxin-like domains (a, b, 
b’ and a’), two of which have a canonical CGHC motif with two active 
sites within the catalytic domains (a and a’). The other two non-catalytic 
domains (b and b’) are essential for docking the incompletely folded 
protein substrates by the non-covalent binding.92 In recent years, PDI 
has been found to be involved in the apoptosis of cells in several 
neurological disorders including Huntington’s disease, Alzhiemer’s 
diseases and Parkinson’s disease;93 elevated PDI expression levels in 
a variety of human cancers;92, 94 regulation of HIV infection of 
lymphocytes and monocytes.92  
Traditional drug candidate screening requests a huge library 
synthesized by huge manpower consumed works such as peptide solid 
phase synthesis and therefore it is always a time and cost consumed 
program in the drug discovery. Staurosporine (STS) is a well-known 
general protein kinases inhibitor targeting ATP pocket of protein 
kinases. The irreversible inhibitor by introducing an electrophile on the 
pharmacophore may help to find the ATP-chaperone relationship in the 
live cell. It may even give the possibility to design a specific inhibitor to 
some ATP-pocket-holding enzyme by proper modification. The design 
may help to recognize the target under the slightly different 
environment in the pocket, from which possess particular nucleophilic 
residue specifically reacting with chemically tuned electrophiles of the 
probe.  
It is reported that ATP has high affinity to PDI (Kd = 9.66 µM) and 
PDI has the ability of an ATP-dependent auto-phosphorylation.95 In this 
section, we report a specific inhibitor STS-T1 against human PDI in live 
cancer cell developed by proteome profiling approach, which allowed 
us to study the active targets in the complex cell environment. 
In situ Cancer cell proteome profiling 
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Cravett et al reported phenyl sulfonate ester probes tageting PDI 
(~57 kD) together with ECH-2, GST, VLCAD and other proteins.96 In 
section 3.3.2, preliminary results showed there’re a unique strong band 
(~57 kD) resulted by STS-T1 used sulfonate ester as warhead in the in 
situ labeling experiment over MCF-7 and T47D. These results 
suggested that the protein labeled may be the major cellular target of 
STS-T1. The concentration- and time-dependent labeling experiments 
were performed to confirm the band as the putative cellular target of 
STS-T1. (Figure 3.16)  In the concentration-dependent labeling 
experiment, signal of the target (~57 kD) increased obviously with the 
increasing concentration of STS-T1 from 0 to 10 µM. In the time-
dependent labeling experiment, longer incubation time gave stronger 
and more distinct signal at ~57 kD. The band could be competed by 
STS (the parent drug) and 16F16 (a known PDI inhibitor97). Results 
showed the protein indicated by the fluorescent band was true cellular 
target of STS-T1. 
 
 
Figure 3.16 In-gel fluorescence protein profiling of concentration- (0, 1, 5, 10 µM for 2 
h) and time-dependent (10 µM: 0.5, 1, 2, 4, 8 h) in situ labelling of MCF-7 cells 
treated with STS-T1. 
 
Pull-down experiment of MCF-7 proteome and Target 
validation of STS-T1 by Western Blotting  
To identify the cellular targets of STS-T1, large-scale pull-down 
experiment was performed in Figure. 3.17. The live cell MCF-7 was 
incubated with the probe, lysed and clicked with Rh-Biotin-N3. After the 
biotinylated proteins were purified by affinity capture with Avidin beads. 
The protein detected as unique band (~57 kDa) by in-gel fluorescent 
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scanning was identified as human PDI by Western Blotting (anti-PDI). 
The results of Western Blotting against anti-biotin also supported PDI 
as the major target of STS-T1 in live MCF-7 cell. Compared with the 
phenyl sulfonate ester probes mentioned previously,96 STS-T1 showed 
more specificity. The reason probably resided in the additional affinity 






Figure 3.17 Validation of targets of STS-T1 by Western Blotting. In situ labeling of 
MCF-7 cells by STS-T1, followed by click chemistry with Rh-Biotin-N3, pulled-down 
(PD) by avidin agarose beads, then gel-separated before in-gel fluorescence 
scanning (FL) and Western blotting (WB) with (A) anti-PDI and (B) anti-biotin. 
 
Pure enzyme labeling with STS-T1 
Since the major target of STS-T1 in live cancer cell MCF-7 was 
confirmed as PDI by Western Blotting, the subsequent pure enzyme 
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labeling was performed to evaluate the inhibition of STS-T1 over PDI. 
In the experiment, recombinant bovine PDI, which shares > 95% 
sequence homology with human PDI, was used. Dose- and 
concentration-dependent labeling experiment showed the labeling 
efficiency of STS-T1 is quite low. The possible reason is not clear. 
Compared to reported inhibitor P1, 100 ng of dose amount is higher 








Figure 3.18 Concentration-dependent and dose-dependent labeling of recombinant 
bovine PDI by STS-T1. 
 
Localization of Targets STS-T1 in MCF-7 by fluorescent 
imaging experiment  
Although our probe STS-T1 did not show good labeling activity to 
the recombinant bovine in vitro for some unknown reason, it could be 
used to visualize the localization of endogenous human PDI in 
mammalian cells. Live MCF-7 was treated with STS-T1, then clicked by 
Rh-PEG-N3 and imaged. The same cells were subsequently treated 
with anti-PDI antibodies following standard immunofluorescence (IF) 
protocols, and imaged again. Merged channels indicated nearly 
complete co-localization of the fluorescence signals to the expected 
endoplasmic reticulum (ER). It showed a strong evidence to prove the 




Figure 3.19. Cellular imaging of live MCF-7 cells was probed with STS-T1 (5 µM; 2-h 
treatment, then clicked with Rh-PEG-N3 (543 nm Channel, colored in red). Bright filed 
images (DIC) of the corresponding cells were shown in the first column. Co-
localization experiments were performed with ER and Nucleus tracker. (A) co-
localization with ER Tracker (colored in green), Overlay of probe, ER and nucleus 
channels were shown in last column. (Top) (B) Immunofluorescence (IF) was 
performed with anti-PDI (colored in green). Overlay of probe, IF and nucleus 
channels were shown in last column. (Bottom) 
 
3.4. Conclusion 
Three “clickable” probes have been successfully synthesized by 
introducing different electrophiles (chloroacetamide, sulfonate ester 
and acrylamide). Among of them, STS was successfully converted into 
an irreversible covalent probe, STS-C1, in an effort to minimize non-
specific labeling from earlier-generation photoaffinity-based probes. We 
found STS-C1 was able to preferentially target the protein kinase 
cysteinome both in vitro and in situ, by using c-Src as a representative 
example. Through the course of our study, we have tentatively 
identified previously unknown proteins in the kinase cysteinome, and 
they will be further validated in due course. The probe STS-C1 also 
could be used as small molecular probe to detect the distribution of 
target and enzymatic activity in situ by fluorescent imaging experiment. 
On the other hand, human PDI was identified as the major cellular 
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target of STS-T1 in the breast cancer cell MCF-7 by in situ proteome 
profiling. The reactive group sulfonate ester on the probe was served 
as a warhead which shows high reactivity to PDI.96 However, in our 
design, the probe was incorporated with STS as the affinity binding to 
the ATP pocket and therefore a better specificity was achieved. The 
probe could be potentially applied to indicate the enzyme activity and 
cellular localization to facilitate the diagnoses and therapy of the PDI 
related diseases. There’re also some questions need to be further 
investigated. The inhibition mechanism is essential to be clarified 
including active site. Side-target identification as another issue related 
its specificity in situ is needed to further address by LC-MS/MS and 
validation. Totally, the approach provides a new way to design the 
inhibitor of PDI. The approach about the probe design and has more 
flexibility for other general affinity scaffolds. It may give us efficient way 
to design a series of whole inhibition picture of protein kinases or other 
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In this chapter, we try to develop the activity-based probes (ABPs) 
based on Lymphostin and affinity-based probes (AfBPs) based on 
Ammosamide scaffold to identify their cellular targets. 
 
4.2. Introduction 
Marine natural products with a variety of unique structural classes 
are now very important sources for the candidate of synthesis and 
medicine.39, 99 As one of marine natural product, Lymphostin could be 
used as an immunosuppressant which shows potential inhibitory 
activity against lymphocyte kinase (LCK) and phosphoinositide 3-
kinase (PI3K).100 Additionally, Ammosamide A and B were isolated from 
Streptomyces strain CNR-698 by cytotoxicity-guided (HCT-116) 
fractionation.101 (Figure 4.1A) Because their novel mechanism of action 
impinged on a crucial biological cascade, the interactions between the 
natural products with protein targets have drawn the attention of 
medicinal scientists. Many approaches were developed to identify the 
cellular targets of natural products, including target-based screening of 
molecules library, cell-based phenotypic, affinity-based proteome 
profiling/LC-MS and so on.6d At a further stage, a promising in situ 
method emerged, which could reflect the small molecule–protein 




Figure 4.1 (A) Structure of Lymphostin and analogues of Ammosamide; and (B) The 
immunoaffinity fluorescence probe (IAF) of Ammosamide B; C) sites of chemical 
modification denoted by arrow. 
 
By the affinity proteome profiling approach, Myosin was claimed the 
as the main target of Ammosamide A and B with an immunoaffinity 
fluorescence probe (IAF).102 (Figure 4.1B) However the limitation of IAF 
is obvious. Firstly, the tag-conjugated manner makes the probe too big 
to maintain the original activity of parent drug. For example, the 
experiment indicated that cytotoxicity of IAF (IC50 = 17 µM) is much 
lower than of Ammosamide A and B (IC50 = 320 nM) for HCT-116 cells. 
Secondly, the interaction between IAF probe and protein is reversible 
as IAF is an affinity based probe. The targets could be lost in the 
process. Finally, the most possible reason is that Myosin as a high 
abundant protein has saturated the channel for other potential targets 
with low-expressed level. Therefore, this reversible tag-conjugated 
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approach using IAF probably has lost other interesting protein targets 
while at low expressed level. 
To overcome the shortcomings of tag-conjugated and reversible 
probe design, the “clickable” probes based on Lymphostin and 
Ammosamide analogues was proposed. In our design, the typical 
modification sites and installed functional group were shown in Figure 
4.1C. The nature of binding between ammosamide analogues and their 
targets is non-covalent. The transient protein–small molecule complex 
may not survive the in vitro affinity-based target enrichment process. 
Based on our successful design of affinity-based probes (AfBPs),26, 36a, 
37 the affinity scaffold incorporated with photo-labile linker (diazirine) 
could be facilitated to perform in situ proteome-based profiling of 
marine natural products, combined with downstream LCMS-based 
target identification. Diazirine as a photo-labile group, which could 
produce highly reactive species upon UV irradiation, could react with 
the molecules nearby. Of course, the size of the linker is as small as 
possible to avoid the additional influence over drug activity. Terminal 
alkyne as click handle was introduced with minimized modification. A 
variety of potentially bioactive functional groups would be included, 
such as chlorine, sulfur and carbonyl groups appeared in the 
ammosamide analogues. On the other hand, Lymphostin as covalent 
inhibitor would be converted to activity-based probes (ABPs) directly 
incorporated with a terminal alkyne group at suitable positions. While 
covalently bound with the “clickable” probes (AfBPs and ABPs) derived 
from the natural products, cellular targets would be investigated 
comprehensively by in situ proteome profiling/pull-down/target-
identification to facilitate the drug discovery. 
4.3. Results and discussion 
4.3.1. AfBP based on Ammosamide analogues 
Since our AfBPs are based on the scaffold of Ammosamide, the first 
step is to establish Ammosamide B as the pharmacophore template. In 
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the first synthetic route of Ammoamide B, intermediate 4-3 was made 
from 2-Oxoglutaric Acid 4-1 through esterification, bromination and 
elimination reactions subsequently.103 Following the literature,104 
compound 4-11 was made from 1,3-dichlorobenzene 4-4 by seven 
steps of reactions. However, Boc deprotection of compound 4-11 did 
not proceed well to give the desired product 4-12 with the starting 
compound 4-11 decomposed. (Scheme 4.1) Compound 4-10 and 4-11 
have poor solubility in common organic solvents. 
 
Scheme 4.1 The first synthetic route of Ammosamide B 
So the alternative route was considered as shown in Scheme 
4.2.105 The synthesis was pushed forward to Ammosamide B through 
seven steps from 1,3-dichlorobenzene 4-4 and intermediate 4-3. The 
cyclization reaction to compound 4-14 led to low yield as the product is 
unstable in the process of reaction and column purification. The longer 
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time in the purification, the more side-product appeared which was very 
close to the desired product 4-14. The chlorination of compound 4-16 
gave low yield as the starting material 4-16 decomposed under the 
condition and the reaction gets lousy and difficult to purify. The 
intermediates from compound 4-15 to Ammosamide B have poor 
solubility in common organic solvents. 
 
 
Scheme 4.2 The second synthetic route of Ammosamide A and B 
 
In Scheme 4.3, to extend the library of the analogues, two probes 4-
17 and 4-19 were obtained by coupling with photo-labile linker.26 
However, the desired product 4-20 was not obtained from 
Ammosamide B under the same condition. The reactivity of amine on 
Ammosamide B was deactivated by chlorine atom as electron-





Scheme 4.3 The synthesis of the AfBPs 
 
In order to get enough Ammoamide B, we have to continue 
optimizing synthetic route. Comparing with second route in Scheme 
4.2, the reactions in the first route (Scheme 4.1) proceeded smoothly 
except the Boc-deprotection of compound 4-11. So the Boc-
deprotection of model compound 4-10 was optimized further by using 
thermolysis. Different solvents and temperature under microwave 
irradiation had been optimized. It was found that solvent system played 
key role in thermolysis reaction. No product was obtained by only 
DMSO as solvent. Only one Boc group was removed by DMF as 
solvent at 185 oC. The mixture of DMF-H2O (1:1 by v/v) solvent system 
was found to be most efficient. Then the optimized condition was 
applied into the Boc-deprotection of compound 4-11. This reaction 




Scheme 4.4 Thermolysis of Boc group 
 
With compound 4-12 in hand, we pushed forward the synthesis of 
Ammosamide B by the first synthetic route. The methylation of 
compound 4-12 did not work well. Then the third synthetic route was 
proposed as shown in Scheme 4.5. The methylation led to a mixture of 
starting material 4-11 and desired product 4-22. The reaction was not 
complete even with longer time and high temperature. The two 
compound 4-11 and 4-22 were very difficult to be separated because of 
the same Rf value on TLC and same retention time on HPLC analysis. 
Then we forwarded the mixture to thermolysis of Boc-group. The Boc-
deprotection proceeded well and the ratio of compound 4-13 to 4-12 
was found to be 2:1. Due to the poor solubility, the two compound 4-13 
and 4-12 were also difficult to be separated and then used as a mixture 





Scheme 4.5 Methylation and thermolysis of Boc group 
 
Since the coupling reaction of Ammosamide B with photo-labile 
linker did not work (Scheme 4.3), the reactivity of compound 4-13 with 
photo-labile linker was tested. It was found that no product 4-23 was 
observed, once the adjacent amide was methylated. However pure 
compound 4-24 was isolated after purification from the same pot of 
reaction. The stereohindrance of N-methyl group may be the possible 
reason to prevent the reaction from proceeding. (Scheme 4.6) 
 
Scheme 4.6 Coupling reaction with photo-labile linker (diazirine) 
 
4.3.2. ABP based on Lymphostin 
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Another mission is to synthesize ABPs based on Lymphostin. Three 
ABPs based on Lymphostin was proposed with the modification at 
different sites with “clickable” handle. 
 
Figure 4.2 Chemical modification sites on Lymphostin 
 
Since the total synthesis of Lymphostin in literature is complicated 
with up to 21 steps of linear multistep reactions, 106 we reconsidered 
the synthetic plan of ABP based on Lymphostin as shown in Scheme 
4.7. With valuable experience on the synthesis of Ammosamide B 
(section 4.3.1), the key intermediate 4-10 would be employed as 
starting point to pursue the efficient synthesis of Lymphostin scaffold 
for further modifications to ABPs. Three key steps would be involved in 
this synthetic plan. First is the formation of cyclic imine 4-25. And 
second is introduction of Michael accepter in compound 4-27 and 4-28. 
The third is the selective formation of propiolamide 4-29 and 4-30. 





Scheme 4.7 Synthetic plan of ABPs based on Lymphostin 
 
In the synthesis of cyclic imine starting from intermediate 4-10, 
several conditions were employed.107 The transformation of amide to 
triflate 4-31 proceeded well, followed by elimination. However, no 
desired product 4-32 was obtained but starting material 4-10 was 
recovered. Schwartz reagent and DIBAL-H were also employed. It was 
found that the desired product 4-32 was successfully synthesized by 
both reduction methods. The following synthesis of Weinreb amide 4-






Scheme 4.8 Preparation of cyclic imine and Weinreb amide 
 
Since the intermediate with cyclic imine was difficult to handle, the 
amide 4-10 was used as starting material to explore the second key 
step to introduce α, β-unsaturated alkyne. The synthesis of Weinreb 
amide 4-24 had been optimized by using aminolysis with Weinreb 
amine hydrochloride. No product was observed even using Grignard 
reagent or high temperature. The combination of hydrolysis with LiOH 
and amide coupling successfully provided Weinreb amide 4-34 in good 
yield. The following alkynlation encountered problem. Grignard reagent 
or Butyl lithium condition failed to give the desired product. The 
synthetic route would be modified by converting methyl ester to 
aldehyde, which would be subjected to Grignard reaction followed by 





Scheme 4.9, Synthesis of Weinreb amide and subsequent alkynlation 
 
4.3.3. Preliminary biological test  
Two AfBPs (Am-1 and Am-2) are ready in hand as shown in Figure 
4.3. Some preliminary experiments were explored, including pure 
enzyme labeling over kinases, bacterial lysate labeling, mammalian 
lysate labeling and Jurkat cell lysate pull-down. 
 
Figure 4.3 Structure of two AfBPs and control 
To evaluate the potential activity with protein kinases, in vitro labeling 
of pure recombinant kinases was performed. Am-1 and Am-2 showed 
weak labeling with c-Src and Abl and no labeling with PKA and Lck. 
(Figure 4.4) while, in the labeling of bacterial lysates overexpressing 
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kinases, no obvious labeling by Am-1 and Am-2 was obtained 
comparing to the positive control (Figure 4.5), and even in the dose-
dependent labeling (STS-2). (Figure 4.6) 
 
Figure 4.4 in vitro labeling of pure recombinant kinases. Recombinant kinases were 
incubated with STS-2, Am-1 and Am-2 (20 μM) at rt for 30 min and irradiate for 20 
min (UV). 
 
Figure 4.5, Bacterial lysate labeling. Cell lysates were incubated with STS-2, Am-1 




Figure 4.6 Bacterial lysate over-expressing c-Src was incubated with STS-2, Am-1 
and Am-2 at rt for 30min and irradiate for 20 min (UV). DMSO was used as negative 
control. 
Then, the next experiment is in vitro mammalian cell lysate labeling. 
Among of the three cell lines, jurkat cell shows distinctive bands with 
other two cell line (Figure 4.7). So the in vitro concentration-dependent 
labeling was studied in Figure 4.8. The results showed the labeling 
increased with the progressive concentration of Am-2 from 1 to 10 µM. 
To identify the putative cellular targets of Am-2, the large scale pull-
down experiment was performed as shown in Figure 9. The distinctive 
band circled by red rectangle was cut and submitted to MS analysis. 
Those non-specific binding proteins were deducted, which also 
appeared in negative control (treated with NP). After other operations 
of filtration, a list of the potential protein targets was obtained. (Chapter 
9 Appendix, Table S3) We focused our attention on those candidates 
which play important roles in cancer cells including Myosin, PKM2, 
GAPDH, LDHB, HNRNPA2B1 and ECH1. GAPDH was a therapeutic 
target in deregulation of glycolysis in cancer.108 (Table 4.1) Myosin 
appeared in the list without surprise, which was also identified by the 
tag-conjugated probe (IAF).102 PKM2 was involved in the proliferation 
86 
 
of cancer cell.109 LDHB was used as tumor marker.110 HNRNPA2B1 
was related to cell proliferation and carcinogenesis.111 ECH1 was 
involved in the lymphatic metastasis of tumors.112 
 
Figure 4.7 In vitro labeling of mammalian cell lysate. 20 μg of cell lysate was 






Figure 4.8 Concentration dependent mammalian cell lysate labeling. 20 μg of cell 
lysate was incubated with STS-2, Am-2 (1, 5 and 10 μM) and NP (10 μM) as the 
negative control at rt for 30 min and irradiate for 20 min (UV). 
 
Figure 4.9 Pull-down experiment over Jurkat cell lysate. Cell lysate was incubated 








Table 4.1 The list of the potential protein targets of Am-2 
Gene code Description MS score 
Peptides 
matched 
PKM2 Pyruvate kinase isozymes M1/M2 30929 34 7 




36201 189 19 
LDHB L-lactate dehydrogenase B chain 36900 118 10 
HNRNPA2B1 
Isoform A2 of Heterogeneous nuclear 
ribonucleoproteins A2/B1 
36041 91 7 
ECH1 
Delta(3,5)-Delta(2,4)-dienoyl-CoA 
isomerase, mitochondrial OS=Homo 
sapiens 
36136 30 7 
 
4.4. Conclusion 
In the project, we have tried to develop a library of ABPs and AfBPs 
based on nature marine product-Lymphostin and Ammosamide 
analogues. Three AfBPs based on the bioactive scaffold of 
Ammosamide B have been successfully synthesized and the library of 
probes would be expanded with other bioactive elements. The efforts to 
construct ABPs based on Lymphostin have afforded some progress 
including methodologies in three key steps including the formation of 
cyclic imine 4-25, introduction of Michael accepter in compound 4-27 
and 4-28 and the selective formation of propiolamide 4-29 and 4-30. 
Continuing with the investigationes, the synthesis would put forward in 
the further study. With the probes (Am-1 & Am-2) in hand, some 
progress in proteome profiling of bacterial and mammalian cell lysate 
has given some interesting preliminary results. By the ABPP approach, 
Myosin was validated as a reported target of Ammoamide A and B, and 
other unknown targets were newly identified including PKM2, GAPDH, 
LDHB, HNRNPA2B1 and ECH1, which play important roles in cancer 
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cells. The preliminary results promote us to do comprehensive study 
further with more ABPs and AfBPs probes derived from Lymphostin 
and Ammosamides. Further study will enable extensive study of the 
library of the marine products by in situ living cell profile, such as 
potential pharmacological effect, pharmacokinetic effects including 
absorption, distribution, even metabolism and excretion especially in 
the cancer cell. The approach would further expand the sight over the 
cellular targets of the natural products by the novel systematic 
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We described a drug delivery of protein kinase inhibitors into the 
cancer cell by the aid of biomarker and cell penetrating peptide (CPP). 




Protein kinases (500+) play very important roles in cell life including 
cell signalling regulating the cellular pathway and are regulated as 
therapeutic targets by kinase inhibitors in many diseases especially for 
cancer.53, 58 However, in the development of new therapeutic kinase 
inhibitors as anticancer drugs, the low biocompatibility of hydrophilic 
substances and the nonspecific toxicity toward healthy tissues are 
major obstacles. Firstly, in the regulation of the import and export of 
substances, cell membrane is selectively permeable to ions and 
organic molecules including peptides, proteins, DNA oligonucleotides 
and etc.113 Secondly, drug-safety-related issues have been a major 
contributing factor to embarrass the development of new kinase 
inhibitor drug. At the early stage of drug discovery, there’s a big 
challenge in the drug-target interactions optimization. Most small 
molecule kinase inhibitors suffer from broad reactivities because ATP 
pockets as their targets are high conserved, even across distantly 
related kinases. At the later stage, the lack of tumor-specific treatments 
limits the clinical applications of chemotherapy. Traditional 
chemotherapy relies on the cytotoxic agents to kill the rapidly 
proliferating cancer cells, however, cytotoxic agents have very little or 
no specificity and result systemic toxicity to healthy tissues, causing 
undesirable severe side effects, such as hair loss and damage to other 
tissues including liver, kidney, and bone marrow.114 Therefore, there is 




Although pharmacologists have paid a lot of efforts to develop the 
kinase inhibitor drugs which could specifically inhibit their targets as 
nosogenesis, limited outcome of the drug discovery and the difficulty 
inside push them to extend the scope to other fields. A rapidly growing 
tumor overexpress many tumor-specific receptors to get various 
nutrients and vitamins, which could be used as cancer biomarkers for 
cancer diagnosis, prognosis, epidemiology and treatment.115 Those 
receptor proteins on the surface of cancer cell could be used as targets 
to deliver cytotoxic agents into tumors.116 For example, monoclonal 
antibodies,117 polyunsaturated fatty acids,118 folic acid,119 aptamers,120 
oligopeptides121 and hyaluronic acid122 has been applied to conjugate 
cytotoxic agents toward tumor-specific delivery. Unlike the endocytosis 
by the aid of specific receptors, cell-penetrating peptides (CPPs) have 
been developed to achieve the internalization of large therapeutic 
molecules, which is capable of crossing the membrane barrier.123 In 
addition, the conjugated cytotoxic drug in prodrug manner could be 
released under control by different mechanisms.124 
Herein, we try to develop an efficient approach which could 
specifically deliver cytotoxic kinase inhibitors into cancer cells to 
improve therapeutical effect. Many cancer cell lines overexpress matrix 
metalloproteinases (MMPs).125 It is the key that triggers the cancer cell-
specific recognition, where.the specific peptide as MMP substrate 
between CPP and its mask could be cleaved enzymatically to give the 
active CPP in drug conjugated manner (Figure 5.1) The enzymatic 
reaction takes place on surface of the cancer cell and therefore CPP is 
attached on the cell membrane and absorbed into the internalization of 
the cancer cells. The masked peptide by cation-anion pair (structure 
seen in Figure 5.2) is inactive for cell absorption and therefore the 
conjugated drug outside is safe for the normal cell. After absorption, 
the conjugated drug would be released by UV cleavage126 or thiol 
cleavage by intracellular Glutathione (GSH)127. Then the life of cancer 
cells would be interrupted and even induced to apoptosis as the 






Figure 5.1 Concept study of drug delivery. A polycationic CPP peptide (in blue) fused 
to a polyanionic masking peptide (in red) through a linker cleavable by matrix 











Figure 5.3 Strategy of cell specific delivery study 
 
To control the release of the cytotoxic kinase inhibitor from a 
conjugated, the cleavable linkers would be introduced. The synthetic 
plan of lead probes is shown in Scheme 5.1. STS would be 
incorporated with CPP through different linkers such as photo-
cleavable and disulfur inker, by which the controlled release of drugs 
could be triggered by different mechanism. Stable alkyl linker is used 
as control. TER would be used as a fluorescent tag in the paralleled 
imaging experiment. The clickable kinase inhibitors listed in the Figure 
5.4 are the candidates in the place of STS, which provide a wide-range 





Scheme 5.1. Synthesis of the probes for the concept study of drug delivery 
 
 
Figure 5.4 Candidates of kinase inhibitors 
 
5.3. Results and discussion 
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The linkers were synthesized as shown in Scheme 5.2. In the 
synthesis of alkyl linker, 4-azidobutanoic acid 5-6 was synthesized from 
4-bromobutanoic acid 5-5 by 3 steps of reactions. The di-sulfur linker 5-
4 was synthesized from cystamine dihydrochloride 5-1 by mono-
protection with Boc group, azidation and extension with succinic acid. 
In the synthesis of photo-cleavable linker, protection of compound 
5-7 with Bn group was proceed well to afford compound 5-8, which was 
subjected to nitration to give compound 5-9 in good yield. After 
deprotection of Bn group with TFA, phenol 5-10 was obtained, which 
was subjected to the reaction with methyl 4-bromobutanoate to give 
compound 5-11. Reaction with sodium borohydride and activation with 
carbonyl imidazole provided compound 5-13 in good yield, which was 
stable to be stored in -20 oC. Compound 5-13 was refluxed with amine 






Scheme 5.2 The synthesis of linkers 
In the synthesis of coupling of CPP with di-sulfur 5-4 and photo-
cleavable linker 5-15, no product was detected by LC-MS as shown in 
Scheme 5.1. Compound 5-15 is unstable in the LC-MS probably as the 
photo-cleavable group is very sensitive in the UV detector. Mild 




This chapter has described an approach to design a probe by specific 
delivering the cell toxic kinase inhibitors into the cancer cell by CPP. 
The ion pair of CPP would be cleaved by MMPs overexpressed on 
some cancer cell surface through the specific substrate recognition. 
Then the inhibitors were supposed to be released after transported into 
the cell specifically by the trigger action with UV irradiation or cellular 
Glutathione (GSH). Therefore, it was hypothesized that kinases in 
targeted cancer cell would be regulated. In the efforts to synthesize the 
CPP probes, some progress has been obtained. Uncleavable alkyl 
linker 5-6, di-sulfur linker 5-4 cleaved by GSH and photo-cleavable 
linker 5-15 were successfully synthesized. The synthesis of the probes 










Cancer Cell Targeted Delivery of 
Regenerable Wortmannin by Folic Acid 














A novel approach was introduced to deliver specifically 
Wortmannin-based probes into target cancer cell by molecular 
transporter and then regenerate Wortmannin in active form inside. And 





Wortmannin has been studied for many years as an irreversible 
inhibitor of phosphoinositide 3-kinase (PI3K),128 which is involved in 
many types of cancer.129 Wortmannin is also a potential inhibitor for 
PLK1, which plays critical roles throughout mitosis.130 Unlike those 
kinase inhibitors targeting the cysteinome, as a special example, the 
active furan ring on Wortmannin targets the unique K833 as the active 
site in PI3K ATP pocket to form a covalent binding.131 (Figure 6.1) To 
evaluate the interactions between Wortmannin and its cellular targets, 
Cimprich et al developed tag-conjugated probes of Wortmannin, in 
which the activities of the tag-conjugated probe were affected obviously 
by its modification mode.13 At same time, similar work has been done 
by Liu et al130, 132 and Lee et al133. However, the comprehensive 
identification of the cellular targets under the native environment is not 
performed, which could potentially reveal the pharmacodynamic events 






Figure 6.1 Interactions between Wormannin and the PI3K active site. (PDB ID: 
1E7U)
131b
 K833 as a nucleophile reacts with Wortmannin on the furan ring. 
 
However the stability and toxicity issue of Wortmannin limited its 
further application in the therapy.134 As an interesting example, PX-866 
derived from Wortmannin with better stability and less toxicity, has 
been involved in a phase 1 clinical trial.135 (Figure 6.2) The mechanism 
that Wortmannin-C20 conjugates could generate Wortmannin was well 
studied.136 (Figure 6.3) Compared to the stable adduct from a primary 
amine with Wortmannin, the reversible adduct from a secondary amine 
with Wortmannin could regenerate Wortmannin through an 
intramolecular attack. This phenomenon provides possibility to design 
safer PI3K inhibitors in slow release form without additional 
consideration of influence of the modification on C20 position between 
inhibitor and PI3K. 
 






Figure 6.3 Possible mechanisms of Wortmannin (WT) C20 Derivatives.
136 For the 
reversible adduct from secondary amine with WT, in route 1, it was hypothesized 
that WT C20 derivatives generate WT and then inhibits PI3K; in route 2, WT C20 
derivatives could also bind to PI3K by replacement of secondary amine by lysine as 
proposed. For the stable adduct from primary amine with WT, no WT is regenerated 
and no substitution of amine occurs. 
 
To further overcome the toxicity issue, receptor-mediated 
endocytosis was also developed to allow selective intracellular delivery 
of therapeutic biomolecules into the cell membrane.137 This drug 
delivery approach helps to achieve a better status about safety issue 
by reducing the drug exposure time and concentration while maintain 
the same drug effect. For example, the folate receptor (FR) for folic 
acid and reduced folic acid derivatives is a well-known tumour-
associated receptor that is overexpressed on ~40% of human cancers, 
including those of the breast, lung, kidney brain and so on,138 whereas 
in normal tissues and organs its distribution is highly limited.139 Folic 
acid (known as vitamin B9), in itself, shows low risk of toxicity and 
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therefore is suitable for the conjugating drug design.140 Folate 
receptors on the cell membrane bind folate or its derivatives specifically 
and subsequently mediate delivery into the interior of cells. Based on 
the natural mechanism of folate uptake by folate receptor protein (FR), 
folate in drug-conjugated manner also binds tightly to the FR and 
trigger cellular uptake via endocytosis.138d, 141 After delivery inside the 
cell, with the use of proper linkers, folate-conjugated drugs can be 
released inside the targeted cells where they can perform their desired 
activity including cytotoxicity. Like folic acid, Biotin was also adopted to 
deliver drug targeting cancer cell.142 
Incorporating the advantages above, we try to design a cell 
permeable, specific and efficient probe, which is capable of the 
proteomic study of cellular Wortmannin targets. The probe targeting the 
cancer cells will be delivered by FR, and regenerate the “clickable” 
Wortmannin probe with minimum modification compared to its parent 
drug—Wortmannin. The typical format of the probe fulfilling the 
requirements is shown in Figure 6.4. C11 modified site is to click with 
reporter and C20 site is for transporter conjugating. Secondary amine 
is needed to form an adduct other than primary amine because the 
former could form a reversible adduct, while the latter could form a 
stable uncleavable adduct.136 The folic acid conjugated probe will be 
delivered into cancer cell by FR, and then Wortmannin part will be 
regenerated through the reversible mechanism at C20. Then the 
regenerated “clickable” probe of Wortmannin will be available for 












Figure 6.5 Specific delivery of Folic acid (FA) conjugated Wortmannin probe into 
cancer cell. In the first step, the probe was delivered into cancer cell specifically. 
Then in the second step, the uptaken probe regenerates “clickable” Wortmannin (WT) 







6.3. Results and discussion 
The synthetic route to the regenerated probe 6-7 was outlined in 
Scheme 6.1. Wortmannin was deacetylated successfully through two 
steps to give compound 6-2.13 The following esterification of compound 
6-2 proceeded well to introduce terminal alkyne group, which is 
clickable with reporter. The modification of folic acid part also worked 
well to form compound 6-6 through two steps without further 
purification as the poor solubility of folate. Since Wortmannin was 




Scheme 6.1 Synthesis of the probe 
 
In the model reaction of Wortmannin 6-1 with cyclic amine 6-6, 
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product of 6-8 was detected by LC-MS analysis. (Scheme 6.2). 
Because of the poor solubility of folic acid moiety even in DMSO or 
DMF (insoluble in other solvents), we tried to isolate the product by 
HPLC. Unfortunately, the product as green fractions was decomposed 
in 30 min. The product 6-7 was too unstable to be handled. The 
stability of the conjugation adduct should be tuned by the different 
types of substituted amine. The uncyclic secondary amine conjugated 
product should be more stable according to the literatures.136 And in 
situ generation of the ring-opening product 6-7 will be a better choice 
since the reaction is very fast to complete in few minutes. 
 
 




This project has described an approach to design a prodrug-like 
probe 6-7 which delivers a cell toxic inhibitor-Wortmannin into the 
cancer cell by receptor-ligand based endocytosis. Based on the 
reversible mechanism of the C-20 conjugated adduct, the probe as a 
prodrug will re-generate a “clickable” Wortmannin probe 6-4 in situ after 
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being transported into cancer cells specifically by aid of folate receptor 
(FR)-triggered cellular uptake via endocytosis. This drug delivery 
approach would help to reduce the drug exposure time and 
concentration to achieve a better status about safety issue by 
“protecting” the drug in a prodrug manner. Combined with the LC-
MS/validation experiment, the approach also would facilitate the 
subsequent protein profiling of the potential cellular targets in situ 
comprehensively. The key intermediate 6-4 which is the true probe 
used in the proteome labeling was successfully synthesized. This work 
is still under investigation to overcome the synthetic problems 
described before. Biotin as a ligand for the tumor-related receptor 



















7.1. General  
All chemicals were purchased from commercial vendors and used 
without further purification, unless indicated otherwise. All reaction 
requiring anhydrous conditions were carried out under argon or 
nitrogen atmosphere using oven-dried glassware. HPLC-grade 
solvents were used for all reactions. Reaction progress was monitored 
by TLC on pre-coated silica plates (Merck 60 F254, 0.25 μm) and spots 
were visualized by UV or iodine stain. Flash column chromatography 
was carried out using Merck 60 F254, 0.040-0.063 μm silica gel. All 
NMR spectra (1H-NMR, 13C-NMR) were recorded on a Bruker NMR 
spectrometer (300 MHz for 1H and 75 MHz for 13C). Chemical shifts 
were reported in parts per million referenced with respect to 
appropriate internal standards or residual solvent peaks (CDCl3 = 7.26 
ppm, CD3OD = 3.31 ppm, DMSO-d6 = 2.50 ppm). The following 
abbreviations were used in reporting spectra, s = singlet, d = doublet, t 
= triplet, q = quartet, m = multiplet, dd = doublet of doublets, br = broad. 
All analytical HPLC were carried out on Shimadzu LCMS (IT-TOF) 
system or Shimadzu LCMS-2010EV system equipped with an auto-
sampler using reverse-phase Phenomenex Luna 5 μm C18(2) 100 Å 
50 × 3.0 mm columns. Water with 0.1% TFA and acetonitrile with 0.1% 
TFA were used as eluents and the flow rate was 0.6 mL/min. For 
enzyme inhibition and IC50 measurements, Tecan microplate reader 
(Multimode Reader, Infinite®200) in luminescence mode with i-
controlTM software was used. Fluorescence scanning of the SDS-
PAGE gels was carried out with Typhoon 9410 fluorescence gel 
scanner (Amersham Biosciences), and where applicable, the bands 
were quantified with ImageQuant 3.3 (Molecular Dynamics) software 
installed on the scanner. Imaging was done with the Leica TCS SP5X 
confocal microscope system equipped with Leica HCX PL APO 
63×/1.20 W CORR CS, 405 nm diode laser, white laser (470−670 nm, 
with 1 nm increments, with eight channels AOTF for simultaneous 
control of eight laser lines, each excitation wavelength provides 1.5 
mV), and a photomultipliertube (PMT) detector ranging from 410 to 700 
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nm for steady state fluorescence. Images were processed with Leica 
Application Suite Advanced Fluorescence (LAS AF). All enzymes used 
were expressed in E. coli strain BL21-DE3 and purified as described 
previously.1 Staurosporine (98%) were purchased from LC Lab. Tris(2-
carboxyethyl) phosphine (TCEP), and the click chemistry ligand, tris[(1-




7.2. Chapter 2 
7.2.1. Procedures for the syntheses of probe C75 
analogues 2-9a-g and trifunctional tag (Rh-Biotin-N3) 
General procedure of the synthesis of alkynoic acid 2-2d, 2-2e, 2-
2g: To a solution of ethynyltrimethylsilane (5.1 mL, 36 mmol) in dry 
THF (45 mL) was added dropwise BuLi (23 mL, 37 mmol) at -78 °C. 
After 15 min of stirring, dry DMPU (28 mL) was added and the reaction 
was stirred for 1 h at -78 °C. The solution of bromoalkanoic acid 2-1 
(14 mmol) in THF (2.0 mL) was added dropwise. The reaction was 
slowly warm to rt and stirred overnight. The reaction was quenched 
with 1 N HCl to pH=1~2 and extracted with ethyl acetate (10 mL × 3). 
The combined organic layers were dried over anhyd sodium sulfate, 




9-(Trimethylsilyl)non-8-ynoic acid (2-2d), as a colorless liquid (52%). 
1H NMR (300 MHz, CDCl3) δ 10.02 (brs, 1H), 2.34 (t, J = 7.5 Hz, 2H), 
2.20 (t, J = 6.9 Hz, 2H), 1.70 – 1.56 (m, 2H), 1.56 – 1.45 (m, 2H), 1.45 
– 1.28 (m, 4H), 0.15 – 0.06 (m, 9H);13C NMR (75 MHz, CDCl3) δ 
180.27, 107.37, 84.44, 33.97, 28.44, 28.29, 24.46, 19.71, 0.12; 13C 
NMR (DEPT 135, up(+), down(-), 75 MHz, CDCl3) δ 33.97(-), 28.44(-), 





10-(Trimethylsilyl)dec-9-ynoic acid (2-2e), as a colorless liquid (50%). 
1H NMR (300 MHz, CDCl3) δ 10.34 (s, 1H), 2.32 (t, J = 7.4 Hz, 2H), 
2.18 (t, J = 6.9 Hz, 2H), 1.60 (dd, J = 13.7, 6.8 Hz, 2H), 1.54 – 1.42 (m, 
2H), 1.42 – 1.17 (m, 6H), 0.12 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 
180.34, 107.49, 84.30, 34.02, 28.82, 28.62, 28.47, 28.44, 24.52, 19.73, 
0.10; 13C NMR (DEPT 135, up(+), down(-), 75 MHz, CDCl3) δ 34.02(-), 
28.82(-), 28.62(-), 28.47(-), 28.44(-), 24.52(-), 19.73(-), 0.10(+). 
 
 
13-(Trimethylsilyl)tridec-12-ynoic acid (2-2g), as a white solid (56%). 
1H NMR (300 MHz, CDCl3) δ 9.98 (s, 1H), 2.33 (t, J = 7.5 Hz, 2H), 2.19 
(t, J = 7.1 Hz, 2H), 1.73 – 1.55 (m, 2H), 1.48 (dd, J = 14.6, 7.2 Hz, 2H), 
1.31 (d, J = 23.3 Hz, 12H), 0.13 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 
180.35, 107.71, 84.22, 34.07, 29.37, 29.31, 29.18, 29.02, 29.00, 28.73, 
28.59, 24.64, 19.81, 0.15. 
 
General procedure for the syntheses of alkynol 2-4d, 2-4e, 2-4g: 
To the suspension of LiAlH4 (1.1 g, 7.4 mmol) in THF (30 mL) was 
added dropwise the solution of alkynoic acid 2-2d (2-2e, 2-2g) in THF 
(2 mL) at 0 °C. The reaction was slowly warm to rt and stirred at r.t for 
3 h. The reaction was quenched with aq NH4Cl and filtered. After the 
precipitated solid was refluxed with THF (30 mL) for 30 min and filtered, 
the combined filtrates were concentrated, dissolved in the solution of 
TBAF (1.0 M, 15 mmol) and stirred at rt for further 3 h. After the 
reaction was complete, the reaction mixture was proportion with aq 
NH4Cl (20 mL) and ethyl acetate (10 mL). The aq layer was extracted 
with ethyl acetate (10 mL × 3). The combined ethyl acetate was 
washed with brine, dried over anhyd sodium sulfate and concentrated 
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in vacuo. The residue was purified by column chromatography to give 
the desired product. 
 
 
Non-8-yn-1-ol (2-4d), (86%). 1H NMR (300 MHz, CDCl3) δ 3.54 (t, J = 
6.6 Hz, 2H), 2.28 (s, 1H), 2.11 (td, J = 6.9, 2.6 Hz, 2H), 1.88 (t, J = 2.6 
Hz, 1H), 1.64 – 1.40 (m, 4H), 1.40 – 1.23 (m, 6H); 13C NMR (75 MHz, 
CDCl3) δ 84.47, 68.03, 62.54, 32.50, 28.74, 28.52, 28.23, 25.48, 18.18. 
 
 
Dec-9-yn-1-ol (2-4e), (86%). 1H NMR (300 MHz, CDCl3) δ 3.58 (t, J = 
6.6 Hz, 2H), 2.14 (td, J = 7.0, 2.6 Hz, 2H), 1.96 (br, 1H), 1.91 (t, J = 2.7 
Hz, 1H), 1.63 – 1.43 (m, 4H), 1.42 – 1.24 (m, 8H); 13C NMR (75 MHz, 




Tridec-12-yn-1-ol (2-4g), (95%). 1H NMR (300 MHz, CDCl3) δ 3.58 (t, 
J = 6.6 Hz, 2H), 2.14 (td, J = 7.0, 2.5 Hz, 2H), 1.97 – 1.84 (m, 1H), 1.60 
– 1.42 (m, 4H), 1.36 – 1.17 (m, 14H); 13C NMR (75 MHz, CDCl3) δ 
84.48, 67.96, 62.43, 32.51, 29.42, 29.36, 29.31, 29.29, 28.92, 28.56, 





The synthesis of oct-7-ynoic acid (2-6c): To the mixture of ethane-
1,2-diamine-ethynyllithium complex (2.0 g, 20 mmol) in THF (25 mL) 
was added 6-bromohexanoic acid 2-1c (2.0 g, 10 mmol) in 1,3-
Dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone (DMPU,13 mL) at 0 °C. 
The reaction was allowed to warm to r. t. and stirred overnight. The 
reaction was quenched with aq NH4Cl, extracted with ethyl acetate (30 
mL × 3). The combined organic layers were dried over anhyd sodium 
sulfate, concentrated to give the residue purified by column 
chromatography to give 2-6c. (73%) 1H NMR (300 MHz, CDCl3) δ 
11.54 (s, 1H), 2.33 (t, J = 7.4 Hz, 2H), 2.15 (td, J = 6.8, 2.6 Hz, 2H), 
1.91 (t, J = 2.6 Hz, 1H), 1.61 (dt, J = 11.4, 7.4 Hz, 2H), 1.56 – 1.34 (m, 
4H); 13C NMR (75 MHz, CDCl3) δ 180.24, 84.09, 68.35, 33.82, 27.96, 
27.92, 24.00, 18.08. 
 
General procedure of the synthesis of alkynol 2-4b, 2-4c, 2-4f: To 
the suspension of LiAlH4 (1.13 g, 7.4 mmol) in THF (30 mL) was added 
dropwise the solution of alkynoic acid 2-6 (7.4 mmol) in THF (2 mL) at 
0 °C. The reaction was slowly warm to rt and stirred at rt for 3 h. The 
reaction was quenched with aq NH4Cl and filtered. After the 
precipitated solid was refluxed with THF for 30 min and filtered, the 
combined filtrates were concentrated to give the residue which was 
purified by column chromatography. 
 
 
Hept-6-yn-1-ol (2-4b), (82%). 1H NMR (300 MHz, CDCl3) δ 3.55 (t, J = 
6.3 Hz, 2H), 2.46 (s, 1H), 2.14 (td, J = 6.7, 2.5 Hz, 2H), 1.90 (t, J = 2.6 
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Hz, 1H), 1.57 – 1.35 (m, 6H); 3C NMR (75 MHz, CDCl3) δ 84.30, 68.20, 
62.32, 31.99, 28.09, 24.78, 18.20. 
 
 
Oct-7-yn-1-ol (2-4c), (96%). 1H NMR (500 MHz, CDCl3) δ 3.56 (t, J = 
6.6 Hz, 2H), 2.33 (s, 1H), 2.15 – 2.12 (m, 2H), 1.90 (s, 1H), 1.53 – 1.39 
(m, 4H), 1.42 – 1.28 (m, 4H); 13C NMR (126 MHz, CDCl3) δ 84.47, 
68.12, 62.50, 32.39, 28.35, 28.25, 25.12, 18.17. 
 
 
Undec-10-yn-1-ol (2-4f), (97%). 1H NMR (300 MHz, CDCl3) δ 3.56 (t, J 
= 6.6 Hz, 2H), 2.16 – 2.01 (m, 1H), 1.90 (t, J = 2.6 Hz, 1H), 1.52 – 1.44 
(m, 1H), 1.40 – 1.05 (m, 5H); 13C NMR (75 MHz, CDCl3) δ 84.61, 68.00, 
62.70, 32.60, 29.32, 29.25, 28.90, 28.59, 28.34, 25.61, 18.25. 
 
General procedure of the synthesis of alkynal 2-5a-g: To the 
mixture of PCC (3.8 g, 18 mmol) and sodium acetate (0.15 g, 1.8 mmol) 
in dry DCM (15 mL) was added alkynol 4 (12 mmol) at 0 °C. After the 
reaction was complete, diethyl ether (15 mL) was added to the reaction. 
The mixture was loaded to silica gel column chromatography eluted 
with diethyl ether. The desired aldehyde was concentrated carefully 
and used in next step because most of the aldehydes are volatiles. 1H 
NMR was used to detect proton of aldehyde (~9.7 ppm) in presence of 
residual solvent if any. (70%~quant.) 
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The representing 1H NMR data for 2-5C, 1H NMR (300 MHz, CDCl3) δ 
9.77 (s, 1H), 2.55 – 2.38 (m, 2H), 2.20 (td, J = 6.8, 2.7 Hz, 2H), 1.94 (t, 
J = 2.6 Hz, 1H), 1.70-1.61 (m, 2H), 1.57 – 1.35 (m, 4H). 
 
 
The synthesis of 4-((4-methoxybenzyl)oxy)-2-methylene-4-oxobu-
tanoic acid (2-7)80 Itaconic anhydride (10 g, 89 mmol) and 4-
methoxybenzyl alcohol (12.30 g, 85 mmol) were suspended in 100 mL 
of a mixture of toluene/n-hexane = 1/1 (v/v) and stirred at 60 °C for 36 
h. After cooling down, the formed precipitate was collected, washed 
with n-hexane and dried in vacuo to give 2-7 (100%) 
 
General procedure for the synthesis of PMB-C75 analogues 2-8a-g: 
LDA (8.2 mL of 1 M solution in THF, 8.2 mmol) was added to a solution 
of 2-7 (1 g, 4 mmol), dissolved in 10 mL of dry THF and cooled to –
78 °C in a dry ice-acetone bath. After 1 h, the aldehyde 2-5g (5.2 mmol) 
was added and the mixture was stirred for additional 4 h at low 
temperature. To the reaction was added cold 6 N H2SO4. After 5 min, 
the reaction mixture was extracted with ethyl acetate. The organic layer 
was separated, dried with anhyd sodium sulfate and concentrated in 
vacuo. The resulted oily residue was purified through column 




hydrofuran-3-carboxylate (2-8a), as a colorless oil (19%). 1H NMR 
(300 MHz, CDCl3) δ 7.27 (d, J = 8.6 Hz, 2H), 6.88 (d, J = 8.5 Hz, 2H), 
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6.35 (d, J = 2.9 Hz, 1H), 5.86 (d, J = 2.6 Hz, 1H), 5.14 (q, J = 11.8 Hz, 
2H), 4.92 (dd, J = 13.2, 5.8 Hz, 1H), 3.79 (s, 3H), 3.65 (dt, J = 5.6, 2.7 
Hz, 1H), 2.37 (t, J = 6.2 Hz, 2H), 1.99 – 1.83 (m, 3H); 13C NMR (75 
MHz, CDCl3) δ 168.59, 167.88, 159.89, 132.41, 130.27, 126.91, 125.52, 




hydrofuran-3-carboxylate (2-8b), as a colorless oil (58%). 1H NMR 
(500 MHz, CDCl3) δ 7.28 (d, J = 8.6 Hz, 2H), 6.89 (d, J = 8.6 Hz, 2H), 
6.34 (d, J = 2.9 Hz, 1H), 5.84 (d, J = 2.7 Hz, 1H), 5.14 (dd, J = 27.6, 
11.8 Hz, 2H), 4.78 (dd, J = 12.6, 6.2 Hz, 1H), 3.80 (s, 3H), 3.59 (dt, J = 
5.8, 2.9 Hz, 1H), 2.17 (td, J = 6.5, 2.6 Hz, 2H), 1.95 (t, J = 2.7 Hz, 1H), 
1.80 – 1.68 (m, 2H), 1.61 – 1.48 (m, 4H); 13C NMR (126 MHz, CDCl3) δ 
168.74, 167.96, 159.75, 132.74, 130.10, 126.87, 124.92, 113.89, 83.66, 




hydrofuran-3-carboxylate (2-8c), as a colorless oil (29%). 1H NMR 
(300 MHz, CDCl3) δ 7.27 (d, J = 8.7 Hz, 2H), 6.89 (d, J = 8.7 Hz, 2H), 
6.34 (d, J = 3.1 Hz, 1H), 5.83 (d, J = 2.7 Hz, 1H), 5.14 (q, J = 11.8 Hz, 
2H), 4.78 (dd, J = 12.8, 6.0 Hz, 1H), 3.81 (s, 3H), 3.55 (dt, J = 5.8, 2.9 
Hz, 1H), 2.19 – 2.12 (m, 2H), 1.93 (t, J = 2.6 Hz, 1H), 1.76 – 1.63 (m, 
2H), 1.54 – 1.39 (m, 6H); 13C NMR (75 MHz, CDCl3) δ 168.97, 168.23, 
159.96, 132.93, 130.31, 127.02, 125.14, 114.09, 84.25, 78.79, 68.38, 






hydrofuran-3-carboxylate (2-8d), as a colorless oil (11%). 1H NMR 
(300 MHz, CDCl3) δ 7.27 (d, J = 8.6 Hz, 2H), 6.89 (d, J = 8.7 Hz, 2H), 
6.34 (d, J = 3.1 Hz, 1H), 5.82 (d, J = 2.7 Hz, 1H), 5.14 (q, J = 11.8 Hz, 
2H), 4.77 (dd, J = 12.9, 5.9 Hz, 1H), 3.80 (s, 3H), 3.55 (dt, J = 5.8, 2.9 
Hz, 1H), 2.22 – 2.08 (m, 2H), 1.93 (t, J = 2.6 Hz, 1H), 1.78 – 1.62 (m, 
2H), 1.57 – 1.44 (m, 2H), 1.38 (m, 6H); 13C NMR (75 MHz, CDCl3) δ 
168.97, 168.19, 159.92, 132.97, 130.26, 127.01, 125.02, 114.04, 84.40, 





hydrofuran-3-carboxylate (2-8e), as a colorless oil (14%). 1H NMR 
(300 MHz, CDCl3) δ 7.27 (d, J = 8.4 Hz, 2H), 6.90 (d, J = 8.6 Hz, 2H), 
6.34 (d, J = 3.0 Hz, 1H), 5.81 (d, J = 2.6 Hz, 1H), 5.15 (q, J = 11.9 Hz, 
2H), 4.76 (dd, J = 12.4, 6.2 Hz, 1H), 3.81 (s, 3H), 3.55 (dt, J = 5.7, 2.8 
Hz, 1H), 2.20 – 2.13 (m, 2H), 1.92 (t, J = 2.6 Hz, 1H), 1.79 – 1.64 (m, 
2H), 1.56 – 1.48 (m, 2H), 1.46 – 1.29 (m, 8H); 13C NMR (75 MHz, 
CDCl3) δ 169.01, 168.25, 159.93, 132.99, 130.29, 127.02, 125.05, 
114.06, 84.56, 78.88, 68.15, 67.53, 55.25, 49.85, 35.60, 28.94, 28.77, 






hydrofuran-3-carboxylate (trans-2-8f), as a colorless oil (26%). 1H 
NMR (500 MHz, CDCl3) δ 7.29 (d, J = 8.6 Hz, 2H), 6.90 (d, J = 8.6 Hz, 
2H), 6.35 (d, J = 3.0 Hz, 1H), 5.83 (d, J = 2.7 Hz, 1H), 5.15 (dd, J = 
30.0, 11.8 Hz, 2H), 4.79 (dt, J = 7.4, 5.7 Hz, 1H), 3.82 (s, 3H), 3.56 (dt, 
J = 5.8, 2.8 Hz, 1H), 2.18 (td, J = 7.1, 2.6 Hz, 2H), 1.94 (t, J = 2.6 Hz, 
1H), 1.76 – 1.64 (m, 2H), 1.56 – 1.47 (m, 2H), 1.47 – 1.22 (m, 12H); 
13C NMR (75 MHz, CDCl3) δ 168.98, 168.20, 159.89, 133.00, 130.22, 
127.01, 124.96, 114.01, 84.58, 78.86 , 68.08, 67.46, 55.19, 49.80, 




hydrofuran-3-carboxylate (cis-2-8f), as a colorless oil (24%). 1H NMR 
(300 MHz, CDCl3) δ 7.27 (d, J = 8.7 Hz, 2H), 6.86 (d, J = 8.7 Hz, 2H), 
6.36 (d, J = 2.4 Hz, 1H), 5.78 (d, J = 2.1 Hz, 1H), 5.17 – 5.02 (m, 2H), 
4.62 – 4.51 (m, 1H), 3.96 (dt, J = 7.7, 2.2 Hz, 1H), 3.79 (d, J = 6.3 Hz, 
3H), 2.16 (td, J = 7.0, 2.6 Hz, 2H), 1.92 (t, J = 2.6 Hz, 1H), 1.55 – 1.43 
(m, 4H), 1.34 (dd, J = 12.2, 3.6 Hz, 2H), 1.29 – 1.14 (m, 8H); 13C NMR 
(75 MHz, CDCl3) δ 168.74, 168.66, 159.85, 133.57, 130.47, 127.02, 
124.88, 113.91, 84.58, 78.26, 68.08, 66.95, 55.16, 48.88, 31.25, 29.04, 






trahydrofuran-3-carboxylate (2-8g), as a colorless oil (22%). 1H NMR 
(300 MHz, CDCl3) δ 7.27 (d, J = 8.7 Hz, 2H), 6.89 (d, J = 8.6 Hz, 2H), 
6.34 (d, J = 3.0 Hz, 1H), 5.82 (d, J = 2.6 Hz, 1H), 5.14 (q, J = 11.8 Hz, 
2H), 4.78 (dd, J = 12.7, 6.0 Hz, 1H), 3.81 (s, 3H), 3.56 (dt, J = 5.7, 2.8 
Hz, 1H), 2.17 (td, J = 7.0, 2.5 Hz, 2H), 1.93 (t, J = 2.6 Hz, 1H), 1.77 – 
1.59 (m, 2H), 1.54 – 1.45 (m, 2H), 1.40 – 1.22 (m, 14H); 13C NMR (75 
MHz, CDCl3) δ 169.04, 168.27, 159.94, 133.05, 130.27, 127.05, 125.01, 
114.07, 84.72, 78.94, 68.03, 67.52, 55.24, 49.87, 35.64, 29.35, 29.29, 
29.10, 29.01, 28.68, 28.43, 24.67, 18.34. 
 
General procedure for the synthesis of C75 analogues 2-9a-g: The 
4-methoxybenzyl protected lactones 2-8a-g were stirred together with 
phenol (7.5 g, 80 mmol) and acetic acid (0.37 mL, 6.5 mmol) for 3 h at 
60 °C. The reaction mixture was loaded to column chromatography 




boxylic acid (2-9a), as a white solid (27%). 1H NMR (300 MHz, CDCl3) 
δ 6.45 (s, 1H), 6.02 (s, 1H), 4.81 (d, J = 5.3 Hz, 1H), 3.62 (s, 1H), 2.21 
(s, 2H), 1.95 (s, 1H), 1.76 (d, J = 5.6 Hz, 2H), 1.58 (s, 4H); 13C NMR 
(75 MHz, CDCl3) δ 173.44, 168.09, 132.01, 126.36, 82.07, 77.50, 
69.84, 49.30, 34.31, 14.59; RMS m/z calcd for C10H10O4 194.1, [M –H]
- 
193.1, found 193.0 (ESI); HRMS m/z calcd for C10H10O4 194.0579, [M –






boxylic acid (2-9b), as a white solid, (32%). 1H NMR (300 MHz, CDCl3) 
δ 6.45 (s, 1H), 6.02 (s, 1H), 4.81 (d, J = 5.3 Hz, 1H), 3.62 (s, 1H), 2.21 
(s, 2H), 1.95 (s, 1H), 1.76 (d, J = 5.6 Hz, 2H), 1.58 (s, 4H); 13C NMR 
(75 MHz, CDCl3) δ 173.97, 168.34, 132.37, 126.03, 83.80, 78.80, 
68.78, 49.54, 35.12, 27.79, 23.85, 18.14;LRMS m/z calcd for C12H14O4 
222.1, [M –H]- 221.1, found 221.0 (ESI); HRMS m/z calcd for C12H14O4 




boxylic acid (2-9c), as a white solid (29%). 1H NMR (300 MHz, CDCl3) 
δ 6.44 (d, J = 2.9 Hz, 1H), 6.01 (d, J = 2.5 Hz, 1H), 4.80 (q, J = 6.2 Hz, 
1H), 3.69 – 3.50 (m, 1H), 2.27 – 2.12 (m, 2H), 1.94 (t, J = 2.6 Hz, 1H), 
1.74 (t, J = 6.7 Hz, 2H), 1.63 – 1.36 (m, 6H); 13C NMR (75 MHz, CDCl3) 
δ 173.89, 168.41, 132.39, 125.99, 84.25, 78.89, 68.44, 49.59, 35.54, 
28.15, 28.08, 24.30, 18.21; LRMS m/z calcd for C13H16O4 236.1, [M –
H]- 235.1, found 234.9 (ESI); HRMS m/z calcd for C13H16O4 236.1049, 




boxylic acid (2-9d), as a white solid (31%). 1H NMR (300 MHz, CDCl3) 
δ 6.43 (d, J = 2.9 Hz, 1H), 6.00 (d, J = 2.5 Hz, 1H), 4.79 (dd, J = 12.3, 
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6.1 Hz, 1H), 3.60 (dt, J = 5.3, 2.5 Hz, 1H), 2.19 – 2.11 (m, 2H), 1.92 (t, 
J = 2.6 Hz, 1H), 1.76 – 1.69 (m, 2H), 1.56 – 1.48 (m, 2H), 1.43 – 1.30 
(m, 6H); 13C NMR (75 MHz, CDCl3) δ 173.93, 168.50, 132.50, 125.88, 
84.42, 79.02, 68.27, 49.57, 35.55, 28.55, 28.33, 28.14, 24.58, 18.23; 
LRMS m/z calcd for C14H18O4 250.1, [M –H]
- 249.1, found 249.0 (ESI); 
HRMS m/z calcd for C14H18O4 250.1205, [M –H]





boxylic acid (2-9e), as a white solid (34%). 1H NMR (300 MHz, CDCl3) 
δ 6.45 (d, J = 2.9 Hz, 1H), 6.01 (d, J = 2.5 Hz, 1H), 4.80 (dd, J = 12.3, 
6.1 Hz, 1H), 3.68 – 3.55 (m, 1H), 2.18 (td, J = 7.0, 2.7 Hz, 2H), 1.93 (t, 
J = 2.6 Hz, 1H), 1.81 – 1.65 (m, 2H), 1.50 (m, J = 7.0 Hz, 2H), 1.44 – 
1.29 (m, 8H); 13C NMR (75 MHz, CDCl3) δ 174.14, 168.35, 132.51, 
125.86, 84.59, 78.95, 68.19, 49.59, 35.66, 28.97, 28.78, 28.47, 28.30, 
24.67, 18.30; LRMS m/z calcd for C15H20O4 264.1, [M –H]
- 263.1, found 






boxylic acid (trans-2-9f), as a white solid (33%). 1H NMR (300 MHz, 
CDCl3) δ 6.43 (d, J = 2.8 Hz, 1H), 6.00 (d, J = 2.5 Hz, 1H), 4.79 (q, J = 
6.1 Hz, 1H), 3.66 – 3.53 (m, 1H), 2.16 (td, J = 7.0, 2.6 Hz, 2H), 1.92 (t, 
J = 2.6 Hz, 1H), 1.78 – 1.65 (m, 2H), 1.49 (dd, J = 14.2, 7.0 Hz, 2H), 
1.44 – 1.19 (m, 10H); 13C NMR (75 MHz, CDCl3) δ 174.23, 168.48, 
122 
 
132.49, 125.85, 84.64, 79.01, 68.10, 49.56, 35.62, 29.14, 29.02, 28.83, 
28.55, 28.32, 24.65, 18.28; LRMS m/z calcd for C15H20O4 278.2, [M –
H]- 277.1, found 277.1 (ESI);HRMS m/z calcd for C15H20O4 278.1518, 




boxylic acid (cis-2-9f), as a white solid (27%). 1H NMR (300 MHz, 
CDCl3) δ 6.41 (d, J = 1.8 Hz, 1H), 5.87 (d, J = 1.5 Hz, 1H), 4.64 (dd, J 
= 13.7, 7.3 Hz, 1H), 4.00 (d, J = 7.5 Hz, 1H), 2.21 – 2.12 (m, 2H), 1.93 
(t, J = 2.6 Hz, 1H), 1.72 – 1.68 (m, 2H), 1.55 – 1.46 (m, 2H), 1.44 – 
1.26 (m, 10H); 13C NMR (75 MHz, CDCl3) δ 173.72, 169.02, 133.51, 
125.45, 84.67, 78.22, 68.13, 48.98, 31.30, 29.20, 29.06, 28.87, 28.58, 
28.35, 25.52, 18.31;LRMS m/z calcd for C16H22O4 278.2, [M –H]
- 277.1, 
found 277.1 (ESI);HRMS m/z calcd for C16H22O4 278.1518, [M –H]
- 




carboxylic acid (2-9g), as a white solid (52%). 1H NMR (300 MHz, 
CDCl3) δ 6.44 (d, J = 2.6 Hz, 1H), 6.00 (d, J = 1.9 Hz, 1H), 4.80 (dd, J 
= 11.9, 6.0 Hz, 1H), 3.61 (s, 1H), 2.18 (td, J = 7.0, 2.6 Hz, 2H), 1.93 (t, 
J = 2.6 Hz, 1H), 1.79 – 1.65 (m, 2H), 1.54 – 1.47 (m, 2H), 1.42 – 1.25 
(m, 14H); 13C NMR (75 MHz, CDCl3) δ 174.37, 168.43, 132.64, 125.78, 
84.77, 79.09, 68.06, 49.60, 35.72, 29.67, 29.39, 29.34, 29.16, 29.03, 




305.2, [2M –H]- 611.4, found 305.2, 611.3 (ESI);HRMS m/z calcd for 
C18H26O4 306.1831, [2M –H]
- 611.3589, found 611.3606 (ESI). 
 
1-Azido-2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethane (4-12)81a To a 
solution of 1,2-Bis(2-hydroxyethoxy)ethane 2-10 (10 g, 52 mmol) and 
triethylamine (44 mL, 319 mmol) in diethyl ether (40 mL) was added 
MsCl (8.9 g, 115 mmol) at 0 oC. The reaction mixture was concentrated 
to give the residue containing compound 4-11 which was dissolve in 
ethanol (60 mL). The ethanolic solution was then refluxed with sodium 
azide (7.2 g, 112 mmol) for 1 d. The reaction mixture was concentrated, 
dissolved in diethyl ether (80 mL) and washed with brine. The oganic 
solution was dried over anhyd sodium sulfate, concentrated to give the 
product 2-12 as a yellowish oil. (10 g, 80%) 1H NMR (300 MHz, CDCl3) 
δ 3.69 – 3.62 (m, 12H), 3.37 (t, J = 5.1 Hz, 4H); 13C NMR (75 MHz, 
CDCl3) δ 70.62, 70.58, 69.94, 50.62. 
 
 
2-(2-(2-(2-Azidoethoxy)ethoxy)ethoxy)ethanamine (2-13)81a To a 
solution of compound 2-12 (4.9 g, 20 mmol) in diethyl ether (70 mL) 
and THF (10 mL) was added aq HCl (1 M, 89 mL). The solution of 
triphenylphosphine (5.3 g, 20 mmol) in diethyl ether (50 mL) was added 
dropwise at rt and the reaction was stirred at rt for 2 h. The aq layer 
was separated, saturated with sodium chloride and basified with NaOH 
(1 N, to pH = 14). Then the solution was extracted with toluene (50 mL 
X 3). The extract was washed with brine and dried over dry potassium 
hydroxide and concentrated to give the product. (3.1 g, 71%) 1H NMR 
(300 MHz, CDCl3) δ 3.70 – 3.49 (m, 10H), 3.48 – 3.37 (m, 2H), 3.37 – 
3.10 (m, 2H), 2.95 – 2.63 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 73.20, 





1-Azido-13-oxo-3,6,9-trioxa-12-azahexadecan-16-oic acid (2-14) 
The solution of compound 12 (0.80 g, 3.7 mmol) and succinic 
anhydride (0.44 g, 4.4 mmol) in THF (100 mL) was stirred overnight at 
rt. The solution was concentrated and the residue was dissolved in 
chloroform (100 mL) followed by washing with 1 N HCl (20 mL) and 
drying over anhyd sodium sulfate. After concentration in vacuo, the 
product was used in next step without further purification. (0.95 g, 81%) 
1H NMR (300 MHz, CDCl3) δ 6.67 (s, 1H), 3.79 – 3.59 (m, 12H), 3.55 – 
3.52 (m, 2H), 3.43 – 3.38 (m, 4H), 2.66 (t, J = 6.5 Hz, 2H), 2.51 (t, J = 
6.5 Hz, 2H); 13C NMR (75 MHz, CDCl3) δ 175.5, 172.4, 70.5, 70.4, 70.1, 
69.9, 69.5, 50.6, 39.4, 30.8, 29.9. 
 
 
Synthesis of compound 2-20 After the solution of Fmoc-Lys(Biotin)-
OH (4.0 g, 6.7 mmol), HBTU (3.0 g, 8.0 mmol) and HOBt (1.1 g, 8.0 
mmol) was stirred at rt for 10 min, N-boc-propyldiamine52 (1.8 g, 10 
mmol) and DIEA (2.4 mL, 14mmol) were added. After the reaction was 
stirred overnight at rt, the product was precipitated with water as 
yellowish solid. (3.5 g, 69%) 1H NMR (300 MHz, DMSO-d6) δ 7.95-7.85 
(m, 3H), 7.74 (s, 3H), 7.44-7.39 (m, 3H), 7.32 (t, J = 7.3 Hz, 2H), 6.76 
(s, 1H), 6.42 (s, 1H), 6.35 (s, 1H), 4.49-4.22 (m, 4H), 4.11-4.09 (m, 1H), 
3.92-3.85 (m, 1H), 3.15 – 2.75 (m, 9H), 2.04 (t, J = 6.8 Hz, 2H), 1.68 – 
1.10 (m, 23H); 13C NMR (75 MHz, DMSO-d6) δ 171.8, 162.7, 155.9, 
155.6, 143.9, 143.8, 140.7, 127.6, 127.0, 125.3, 120.1, 108.4, 77.4, 
65.6, 61.0, 59.2, 55.4, 54.7, 46.7, 38.3, 37.4, 36.2, 35.8, 35.2, 31.6, 




Synthesis of compound 2-22 A solution of compound 2-20 (3.5 g, 4.7 
mmol) in piperidine-DMF (1:4, 15 mL) was stirred at rt for 1 h. After the 
volatiles were removed under reduced pressure, to the solution was 
added water (40 mL) until no more precipitate formed. The precipitate 
was filtered and the filtrate was concentrated under reduced pressure 
to give the product as a yellowish oil which was slowly changed to 
yellowish solid. (2.2 g, 89%)  The product was pure enough to use in 
next step.  
After the solution of TER acid (1.6 g, 2.2 mmol), HBTU (1.0 g, 2.6 
mmol) and HOBt (0.36 g, 2.8 mmol) in DMF (18 mL ) was stirred at rt 
for 10 min, crude product above (1.8 g, 3.4 mmol) and DIEA (0.74 mL) 
were added. After the reaction was stirred at rt overnight, the 
compound 2-22 (IT-TOF 1121.3252) was purified by prepHPLC (ACN-








Synthesis of Rh-Biotin-N3 To a solution compound 2-22 (300 mg, 
0.27 mmol) in DCM (10 mL) was added TFA (0.5 mL) and the reaction 
was stirred at rt for 1 h. The volatiles were removed under reduced 
pressure. The residual TFA was removed by azeotropy with toluene. 
After the solution of the residue above, DIEA (400 µL), HATU (137 mg, 
0.36 mmol) and compound 2-14 (0.11 g, 0.35 mmol) in DMF (10 mL) 
was stirred at rt overnight, the desired product (IT-TOF 661.3368) was 







7.2.2. Cell culture and anti-proliferation  
HepG2 were maintained in DMEM medium supplemented with 10% 
FBS and 1% P/S. The cells (0.2-0.4 × 106 per mL) were plated in 
duplicate in 96-well plates containing three different concentrations (20, 
50 and 100 μM) of the 8 inhibitors and C75. After incubation at 37 °C in 
5% CO2 for 48 h, the effect of the compounds on the cell proliferation 
was determined by the XTT (sodium 3’ – [1- (phenylaminocarbonyl)-3, 
4-tetrazolium]-bis (4-methoxy-6-nitro) benzene sulfonic acid hydrate) 
colorimetric dye reduction method. Briefly, the procedure for the assay 
was as follows. The XTT was dissolved in hot DMEM media (37 °C) at 
a concentration of 1 mg/mL. Immediately before use, the electron 
coupling reagent PMS (N-methyl dibenzopyrazine methyl sulfate) was 
added to the XTT solution giving a PMS concentration of 125 μM (The 
PMS was stored as 100 mM stock solution in saline at 4 °C). 25 μL of 
this XTT/PMS solution was added to each well in the 96-well plate 
containing ~ 100 μL per well culture giving a final concentration of 0.2 
mg/mL XTT and 25 μM PMS. After incubation at 37 °C in 5% CO2 for 6 
h the absorbance of each well was measured at a wavelength of 450 
nm using Tecan microplate reader and effect of the compounds on the 
cell proliferation was determined by comparing with the DMSO (no 
inhibitor) controls. 
 
7.2.3. Preparation of proteomes and proteomes labeling 
(in vitro and in situ) 
HepG2 was grown in DMEM (Invitrogen, Carlsbad, CA) containing 
10% heat-inactivated fetal bovine serum (FBS, Gibco Invitrogen), 100 
U/mL penicillin and 100 μg/mL streptomycin (Thermo Scientific, 
Rockford, IL) and maintained in a humidified 37 °C incubator with 5% 
CO2. To generate protein lysates, cells were washed twice with cold 
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phosphate buffered saline (1 × PBS), and harvested with a cell scraper, 
and collected by centrifugation. Cell pellets were re-suspended in 1 × 
PBS (0.1% SDS) and lysed by sonication (few seconds). Protein 
concentration was determined by the Bradford assay. Cell lysates were 
diluted with PBS to achieve final concentration of ∼1 mg/mL for 
labeling reactions. 
For in vitro proteome labeling, probes were added to cell lysates 
(100 μg) in 100 μL of PBS (0.1% SDS) at a final concentration of 5-20 
μM in the presence or absence of excess C75 (a final concentration of 
50 μM). Unless indicated otherwise, samples were incubated for 2 h 
with varying concentrations of probe at room temperature. After 
incubation, 20 μL of the freshly premixed click chemistry reaction 
cocktail in 1 × PBS [Rhodamine-azide (100 μM, 10 mM stock solution 
in DMSO), tris(2-carboxyethyl)phosphine hydrochloride (TCEP) (1 mM, 
50 mM freshly prepared stock solution in deionized water), tris[(1-
benzyl-1H-1,2,3-triazol-4-yl)methyl] amine (TBTA) (100 μM, 10 mM 
stock solution in DMSO) and CuSO4 (1 mM, 50 mM freshly prepared 
stock solution in deionized water)] was added and vortexed, then 
incubated for 2 h at room temperature with gentle mixing. The 
reactions were terminated by the addition of pre-chilled acetone (0.5 
mL), placed at -20 °C for 30 min and centrifuged at 13000 rpm for 10 
min at 4 °C to precipitate proteins. The supernatant was discarded and 
the pellet washed two times with 200 μL of prechilled methanol. The 
protein pellets were allowed to air-dry for 10 min, re-suspended in 50 
μL 1 × standard reducing SDS-loading buffer and heated for 10 min at 
95 °C; ∼20 μg of protein was loaded per gel lane for separation by 
SDS-PAGE (10%), then visualized by in-gel fluorescence scanning 
using a Typhoon 9410 Variable Mode Imager scanner. 
For in situ labeling, cells were grown to 80-90% confluence in 24-
well plates under the conditions described above. The medium was 
removed, and then cells were washed twice with cold PBS, and treated 
with 0.5 mL of DMEM-containing probe (0, 20 μM) in the presence or 
absence of excess C75. Probes were applied from DMSO stocks 
whereby DMSO never exceeded 1% in the final solution. The same 
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volume of DMSO was used as a negative control. After 24 h of 
incubation at 37 °C/5% CO2, the growth medium was aspirated, and 
cells were washed twice with 1 × PBS to remove the excessive probe, 
trypsined, and pelleted by centrifugation. The cell pellet was re-
suspended in 1 × PBS (50 μL), homogenized by sonication, and diluted 
to ∼1 mg/mL with PBS. Probe targets were detected by click chemistry 
with Rhodamine-azide, SDS-PAGE analysis, and in-gel fluorescence 
scanning. 
 
7.2.4. Proteomes pull-down, LC/MS-MS and Western 
blotting experiments 
In situ pull-down experiment on HepG2 cell line and sample 
preparation for MS analysis was carried out as described below. 
HepG2 cell was incubated with 2-9g (0, 20 µM) in grow medium DMEM 
with 10% FBS and 1% P/S for 12 h at 37 °C, then lysed with 0.1% SDS 
and PMSF (100 µM) in 1 × PBS, and the lysate was adjusted to 5 mg/ 
5 mL with 1 × PBS. Click chemistry was performed over lysate with 
CuSO4 (1 mM), TBTA (100 µM), TCEP (1 mM), Rh-Biotin-N3 or Biotin-
N3 (100 µM) overnight at rt. After cold acetone (20 mL) precipitation at 
–20 °C overnight and washed with cold methanol (1 mL × 3), the 
protein pellet was re-dissolved in 1% SDS-PBS solution. After 
centrifugation, the clear supernatant was incubated with Avidin beads 
(200 µL) with gentle shaking for 1 d at rt After the mixture was 
centrifuged at 1000 rpm for 10 min and the supernatant was removed, 
the beads were washed with 1% SDS-PBS solution (5 mL × 8); To the 
beads were added 1 × SDS loading buffer (100 µL), the protein was 
denatured at 95 °C and released into the buffer; 
After SDS-PAGE, the whole lanes of samples treated with Rh-
Biotin-N3 and DMSO were processed and submitted to LC-MS/MS. The 
digestion process was introduced as following: the collected gel cut into 
small paritcles was washed twice with ~400 µl of 25 mM ammonium 
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bicarbonate/50% acetonitrile and vortex for 10 min; gel pieces was 
then washed with 400 µl of 100 mM ammonium bicarbonate at pH = 8 
for 10 min while vortexing, and dehydrated with ~400 µl of 100% 
acetonitrile. After repeating rehydration and dehydration and Removing 
the solution, gel particles was incubated with 300 µL of 0.05 mg/mL 
trypsin solution for 16 h at 37 ºC; the solution was combined with two 
additional extractions using 2 vol of 5% FA/50% acetonitrile and 
concentrated in vacuo. The peptides were separated and analyzed on 
a Shimadzu UFLC system (Shimadzu, Japan) coupled to an LTQ-FT 
Ultra (Thermo Electron, Germany). Mobile phase A (0.1% formic acid 
in H2O) and mobile phase B (0.1% formic acid in acetonitrile) were 
used to establish the 60 min gradient comprising 45 min of 5−35% B, 8 
min of 35−50% B, and 2 min of 80% B, followed by re-equilibrating at 5% 
B for 5 min. Peptides were then analyzed on LTQ-FT with an Advance 
CaptiveSpray Source (Michrom Bio Resources) at an electrospray 
potential of 1.5 kV. A gas flow of 2 L/min, iontransfer tube temperature 
of 180 °C, and collision gas pressure of 0.85 mTorr were used. The 
LTQ-FT was set to perform data acquisition in the positive-ion mode as 
previously described, except that the m/z range of 350−1600 was used 
in the full MS scan. The raw data were converted to mgf format. The 
database search was performed with an in-house Mascot server 
(version 2.2.07, Matrix Science) with MS tolerance of 10 ppm and 
MS/MS tolerance of 0.8 Da. Two missed cleavage sites of trypsin were 
allowed. Carbamidome-thylation (C) was set as a fixed modification, 
and oxidation (M) and phosphorylation (S, T, and Y) were set as 
variable modifications. The LC-MS/MS data were searched against the 
IPI (International Protein Index) human protein database using an in-
house MASCOT server. All proteins were identified by a minimum 
score of 40 and at least one unique peptides. Based on these criteria, a 
list of the hits, which was potential targets of C75, was generated in 
Table S1. Some “sticky” or contaminated protein such as keratin, actin, 
and tubulin were deleted. “False” hits that appeared in negative control 
pull-down/LCMS experiments were further eliminated. The informations 




For Western blotting analysis, the PVDF membrane was blocked 
with 3% BSA-TBST (Tween-20, 0.1%) at 4 ºC overnight after the 
proteins on gel was transferred. Then PVDF membrane was incubated 
with primary antibody in 3% BSA-TBST (tween-20, 0.1%) at rt for 1 h 
followed by washing with TBST (Tween-20, 0.1%) for 10 min × 4. The 
PVDF membrane was further incubated with corresponding secondary 
antibody at rt for 1 h followed by washing with TBST (tween-20, 0.1%) 
for 10 min × 4.  SuperSignal West Dura Kit (Thermo Scientific) was 
used to develop the blot. 
 
7.2.5. Fluorescent imaging microscopy 
HepG2 grow in DMEM in 12-well dish and incubated in 2-9g (20 µM) 
at 37 °C for 6 h. The cells were washed with cold 1 × PBS (200 µL) and 
fixed with 3.7% formaldehyde in 1 × PBS (200 µL) for 2 h; Then cells 
were penetrated with 0.1% Triton in PBS at rt for 10 min; Click 
chemistry was performed with CuSO4 (1 mM), TBTA (100 µM), TCEP 
(1 mM), TER-azide (10 µM) for 1 h at rt; After washed with PBS (0.5 
mL × 8), the salts were washed with 0.5 mM EDTA-1% tween-20-PBS 
for 1 h twice at rt. The cells were stained with Hochest for 10 min at rt 
and washed with 1 × PBS. 
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7.3. Chapter 3 
7.3.1. The procedure for the synthesis of STS probes  
 
(9H-Fluoren-9-yl)methyl (3-(tert-butoxy)-1-oxo-1-(prop-2-yn-1-yla-
mino)propan-2-yl)carbamate (3-2) To a solution of Fmoc-O-tert-Butyl-
L-serine (3.8 g, 10 mmol), HBTU (5.7 g, 15 mmol) and HOBt (2.7 g, 20 
mmol) in dry DMF (150 mL) was added propargyl amine (0.96 mL, 15 
mmol) and DIEA (3.5 mL, 20 mmol) at room temperature after 10 min 
of stirring. The reaction mixture was stirred at room temperature for 2 h. 
Solvent was removed in vacuo to give the residue which was purified 
by column chromatography to give white solid. (4.0 g, 95%) 1H NMR 
(300 MHz, CDCl3) δ 7.77 (d, J = 7.5 Hz, 1H), 7.60 (d, J = 7.3 Hz, 1H), 
7.41 (t, J = 7.2 Hz, 1H), 7.32 (t, J = 7.4 Hz, 1H), 6.89 (s, 1H), 5.72 (s, 
1H), 4.42 (d, J = 7.0 Hz, 1H), 4.23 (t, J = 6.8 Hz, 1H), 4.05 (dd, J = 5.1, 
2.6 Hz, 1H), 3.81 (s, 1H), 3.37 (t, J = 8.4 Hz, 1H), 2.24 (t, J = 2.5 Hz, 
1H), 1.22 (s, 5H); 13C NMR (75 MHz, CDCl3) δ 170.06, 156.01, 143.72, 
141.32, 127.73, 127.06, 125.07, 120.00, 85.88, 79.13, 74.41, 71.72, 
67.06, 61.65, 54.30, 47.17, 29.22, 27.40. 
 
 
2-Amino-3-(tert-butoxy)-N-(prop-2-yn-1-yl)propanamide (3-3) The 
solution of compound 3-2 (2.0 g, 4.8 mmol) in piperidine-DCM (1:4, 50 
mL) was stirred at room temperature for 30 min. The reaction was 
concentrated in vacuo to give white solid which was purified by column 
chromatography to give compound 3-3 as colorless oil. (0.94 g, 
quantatitive) 1H NMR (300 MHz, CDCl3) δ 7.66 (s, 1H), 4.29 – 3.79 (m, 
2H), 3.66 – 3.20 (m, 3H), 2.21 (t, J = 2.5 Hz, 1H), 1.14 (s, 9H); 13C 
133 
 





amide (3-4) To a solution of 2-chloroacetyl chloride (1.1 g, 10 mmol) 
and DIEA (2.6 mL, 15 mmol) in dry DCM (10 mL) was added a solution 
of compound 3-3 (0.94 g, 5 mmol) in dry DCM (5 mL) at 0 oC. After 30 
min of stirred at 0 oC, then the reaction was allowed to warm to room 
temperature. After the reaction mixture was concentrated in vacuo, the 
residue was re-dissolved in DCM (10 mL), washed with aq sat. sodium 
bicarbonate solution. The organic layer was dried over anhydrous 
sodium sulfate and concentrated to give residue which was purified by 
column chromatography to give compound 3-4 as a white solid. (1.0 g, 
72%) 1H NMR (300 MHz, CDCl3) δ 7.49 (d, J = 6.5 Hz, 1H), 7.12 (s, 
1H), 4.40 (td, J = 7.4, 4.4 Hz, 1H), 4.12 – 3.84 (m, 4H), 3.72 (dd, J = 
8.7, 4.2 Hz, 1H), 3.35 (t, J = 8.3 Hz, 1H), 2.21 (t, J = 2.2 Hz, 1H), 1.14 
(s, 9H); 13C NMR (75 MHz, CDCl3) δ 169.43, 166.24, 78.97, 74.26, 




(3-5) To a solution of compound 3-4 (0.80 g, 2.9 mmol) at room 
temperature was added TFA (15 mL). After 45 min of stirring, the 
reaction was concentrated to remove volatiles. The residue was re-
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dissolved in ethyl acetate (10 mL) and washed with aq sat. sodium 
bicarbonate. The aq layer was extracted with ethyl acetate (10 mL X 3). 
The combined organic layers were dried over anhyd sodium sulfate 
and concentrated to give residue, which was purified by column 
chromatography to give compound 3-5 as a white solid. (0.25 g, 39%) 
1H NMR (500 MHz, MeOD) δ 4.44 (t, J = 5.1 Hz, 1H), 4.24 – 4.08 (m, 
2H), 4.08 – 3.92 (m, 2H), 3.80 (qd, J = 11.2, 5.2 Hz, 2H), 2.58 (t, J = 
2.5 Hz, 1H); 13C NMR (75 MHz, MeOD) δ 171.57, 169.28, 80.29, 72.34, 





oxobutanoic acid (3-6) To a solution of Staurosporine (STS) (5.0 mg, 
10 μmol) in DMSO, succinic anhydride (1.5 mg, 15 μmol) and DMAP 
(61 μg, 20 μmol) were added under dark. After 30 h stirring, the mixture 
was precipitated with 0.1 % TFA in water, and the precipitate was 
triturated twice with 0.1 % TFA in water to afford compound 3-6. (5.6 
mg, 92%). 1H NMR (300 MHz, DMSO-d6) δ 12.06 (s, 1H), 9.29 (d, J = 
7.9 Hz, 1H), 8.59 (s, 1H), 8.05 (d, J = 7.7 Hz, 1H), 7.99 (d, J = 8.5 Hz, 
1H), 7.67 (d, J = 8.2 Hz, 1H), 7.48 (t, J = 7.7 Hz, 2H), 7.35 (t, J = 7.5 
Hz, 1H), 7.29 (t, J = 7.5 Hz, 1H), 7.03 (t, J = 7.5 Hz, 1H), 5.00 (s, 3H), 
4.22 (s, 1H), 2.81 (s, 3H), 2.77 (s, 3H), 2.68 (d, J = 5.6 Hz, 1H), 2.60-
2.56 (m, 2H), 2.33 (s, 3H), 2.28-2.17 (m, 1H). LCMS m/z calcd for 
C32H30N4O6 [M+H]









oxobutanoate (STS-C1) To a solution of STS-acid 3-6 (5.0 mg, 8.8 
μmol) in DMSO (0. 5 mL) was added compound 3-5 (3.9 mg, 17.8 
pmol), EDC (15 mg, 80 μmol) and DMAP (2.4 mg, 20 μmol) at 0 oC. 
Then the reaction was allowed to warm to rt and stirred at rt overnight 
until no more product formed monitored by LC-MS. Product was 
purified by HPLC (10% - 95% ACN/H2O). (0. 50 mg, 7.4%) 
1H NMR 
(300 MHz, DMSO-d6) δ 9.28 (d, J = 8.2 Hz, 1H), 8.67 (t, J = 5.1 Hz, 1H), 
8.60 (s, 1H), 8.55 (d, J = 8.1 Hz, 1H), 8.05 (d, J = 7.9 Hz, 1H), 7.99 (d, 
J = 8.6 Hz, 1H), 7.67 (d, J = 8.5 Hz, 1H), 7.49 (t, J = 7.9 Hz, 2H), 7.41 – 
7.33 (m, 1H), 7.29 (t, J = 7.4 Hz, 1H), 7.03 (t, J = 6.9 Hz, 1H), 5.00 (s, 
3H), 4.64 – 4.57 (m, J = 14.1, 5.9 Hz, 2H), 4.33 – 4.15 (m, 5H), 3.92 (s, 
2H), 2.82 (s, 3H), 2.78 (s, 3H), 2.73 (s, 1H), 2.68 (s, 1H), 2.54 (s, 1H), 
2.33 (s, 3H), 2.21 (m, 1H); LCMS m/z calcd. for C40H40ClN6O8 [M+H]
+ 
767.2596, found 767.244; C40H39ClN6NaO8 [M+Na]
+ 789.2416, found 
789.224 (IT-TOF). 
 
tert-Butyl (2-(3-(chlorosulfonyl)benzamido)ethyl)carbamate (3-9) 
To a solution of 3-(chlorosulfonyl)benzoyl chloride 3-7 (1.9 mL, 12 
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mmol) in dry DCM (7.5 mL) was added dropwise the solution of N-Boc-
ethylenediamine 3-8 (0.96 g, 6 mmol) and DIEA (2.6 mL, 15 mmol) in 
dry DCM (7.5 mL) at 0 oC. The reaction was stirred at r.t overnight. 
Solvent was evaporated under reduced pressure to give the residue 
which was purified by column chromatography. The solid was stored at 
-20 oC. (1.7 g, 40%) 1H NMR (300 MHz, CDCl3) δ 8.49 (s, 1H), 8.23 (d, 
J = 7.8 Hz, 1H), 8.10 – 8.02 (m, 1H), 7.63 (t, J = 7.9 Hz, 1H), 5.49 (s, 
1H), 3.58 – 3.48 (m, 2H), 3.43 – 3.31 (m, 2H), 1.36 (s, 9H); 13C NMR 
(75 MHz, CDCl3) δ 164.96, 144.39, 136.02, 133.81, 129.90, 129.06, 




benzenesulfonate (3-10) To a solution of 3-7 (218 mg, 0.60 mmol) in 
dry DCM (3 mL) was added a solution of but-3-yn-1-ol (54 µL, 0.72 
mmol), DIEA (208 µL, 1.2 mmol) and DMAP (14.5 mg, 0.12 mmol) in 
dry DCM (2 mL) at 0 oC. The reaction was stirred at r.t overnight. 
Solvent was evaporated under reduced pressure to give the residue 
which was purified by column chromatography. (212 mg, 89%) 1H NMR 
(300 MHz, CDCl3) δ 8.35 (s, 1H), 8.12 (d, J = 7.8 Hz, 1H), 7.98 (d, J = 
7.9 Hz, 1H), 7.89 (s, 1H), 7.59 (t, J = 7.8 Hz, 1H), 5.30 (s, 1H), 4.10 (t, 
J = 6.8 Hz, 2H), 3.54 (dd, J = 10.6, 5.1 Hz, 2H), 3.43 – 3.26 (m, 2H), 
2.52 (td, J = 6.8, 2.6 Hz, 2H), 1.95 (t, J = 2.6 Hz, 1H), 1.38 (s, 9H); 13C 
NMR (75 MHz, CDCl3) δ 165.58, 157.63, 136.26, 135.59, 132.52, 






Synthesis of compound STS-T1 To a solution of compound 3-10 (40 
mg) in DCM (3 mL) was added TFA (1 mL) at rt. The reaction mixture 
was allowed to warm to rt and stirred for 6 h. TFA and solvent were 
removed by azeotropy with toluene. The residue was re-dissolved in 
dry DMF (1 mL). To the solution was added compound 3-6 (5.0 mg), 
HOBt (4.8 mg), DIEA (2 µL) and EDC (6.0 mg) at rt and stirred 
overnight. The final product was purified by HPLC. (5.0 mg, 67%) 1H 
NMR (300 MHz, DMSO-d6) δ 9.29 (d, J = 8.3 Hz, 1H), 8.87 (s, 1H), 
8.60 (s, 1H), 8.37 (s, 1H), 8.26 (d, J = 7.5 Hz, 1H), 8.07 (t, J = 6.9 Hz, 
3H), 7.97 (d, J = 8.3 Hz, 1H), 7.81 (t, J = 7.9 Hz, 1H), 7.66 (d, J = 8.4 
Hz, 1H), 7.48 (t, J = 7.7 Hz, 2H), 7.41 – 7.21 (m, 2H), 7.02 (t, J = 7.2 
Hz, 1H), 5.00 (s, 3H), 4.20 (s, 1H), 4.12 (t, J = 6.1 Hz, 2H), 3.38-3.34 
(m, 2H), 3.30-3.26 (s, 2H), 2.85 (t, J = 2.5 Hz, 1H), 2.80(s, 3H), 2.76 (s, 
3H), 2.66 (d, J = 8.3 Hz, 1H), 2.57-2.54 (m, 2H), 2.42-2.38 (m, 2H), 
2.30 (s, 3H), 2.25-2.17 (m, 1H). LCMS m/z calcd for C45H45N6O9S 
[M+H]+ 845.2969, found 845.2415. 
 
(9H-Fluoren-9-yl)methyl tert-butyl (6-oxo-6-(prop-2-yn-1-ylamino) 
hexane-1,5-diyl)dicarbamate (3-13) To a solution of Fmoc-L-
Lys(Boc)-OH (4.7 g, 10 mmol), HBTU (4.6 g, 12 mmol) and HOBt (1.6 
g, 12 mmol) in dry DMF (10 mL), propargyl amine (1 mL, 15 mmol) and 
DIEA (3.5 mL) were added at r.t and the reaction was stirred at rt 
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overnight. After reaction was complete, the reaction mixture was 
poured into cold water. The collected precipitate was re-crystallized in 
ethyl acetate to give compound 3-13 as a white solid. (3.1 g, 61%) 1H 
NMR (300 MHz, MeOD) δ 7.79 (d, J = 7.4 Hz, 2H), 7.65 (d, J = 5.4 Hz, 
2H), 7.35 (dt, J = 23.6, 7.3 Hz, 2H), 6.55 (s, 1H), 4.38 (d, J = 6.8 Hz, 
2H), 4.21 (t, J = 6.4 Hz, 1H), 4.03 (d, J = 5.7 Hz, 1H), 3.95 (s, 2H), 3.03 
(d, J = 5.9 Hz, 2H), 2.58 (s, 1H), 1.83 – 1.57 (m, 2H), 1.56-1.28 (m, 4H), 
1.42 (s, 9H); 13C NMR (75 MHz, MeOD) δ 174.61, 158.63, 158.46, 
145.33, 145.16, 142.60, 128.79, 128.17, 126.21, 120.92, 80.45, 79.88, 
72.28, 67.88, 56.31, 41.18, 41.07, 32.92, 30.52, 29.48, 28.79, 24.12. 
 
 
 (9H-Fluoren-9-yl)methyl (6-amino-1-oxo-1-(prop-2-yn-1-ylamino) 
hexan-2-yl)carbamate (3-14) The solution of compound 3-13 (1.0 g, 2 
mmol) was stirred in TFA-DCM (1:19, 20 mL) at rt overnight. Then the 
reaction mixture was concentrated in vacuo to give oily redidue. Add 
ether until no more precipitate formed, the white solid 3-14 was 
collected by filtration and washed with ether until no more TFA. (0.78 g, 
79%) 1H NMR (300 MHz, CDCl3) δ 11.02 (s, 1H), 7.68 (d, J = 7.4 Hz, 
1H), 7.48 (d, J = 6.8 Hz, 1H), 7.38 – 7.30 (m, 1H), 7.25 (d, J = 7.3 Hz, 
1H), 6.17 (s, 1H), 4.31 (d, J = 4.8 Hz, 1H), 4.11 (d, J = 5.9 Hz, 1H), 
3.89 (s, 1H), 2.97 (s, 1H), 2.12 (s, 1H), 1.87 – 1.46 (m, 1H), 1.30 (dd, J 
= 29.7, 9.2 Hz, 1H); 13C NMR (75 MHz, CDCl3) δ 173.07, 160.99, 
160.47, 156.98, 143.34, 143.22, 141.18, 127.86, 127.09, 124.85, 
120.94, 119.99, 117.10, 113.31, 109.53, 77.97, 72.00, 67.94, 54.52, 






ylamino)hexan-2-yl)carbamate (3-15) To a solution of compound 3-
14 (0.20 g, 0.4 mmol) and DIEA (0.21 mL) in THF (4 mL) was added  
acryloyl chloride (29 µL, 0.48 mmol) dropwise at 0 oC. Then the 
reaction was warm to rt and stirred at rt overnight. The reaction was 
concentrated in vacuo to give residue which was purified by column 
chromatography to give the product 3-15 as a white solid. (0.10 g, 55%) 
1H NMR (300 MHz, CDCl3) δ 7.76 (d, J = 7.5 Hz, 2H), 7.58 (d, J = 6.8 
Hz, 2H), 7.40 (t, J = 7.3 Hz, 2H), 7.30 (t, J = 7.4 Hz, 2H), 6.77 (s, 1H), 
6.28 (d, J = 16.9 Hz, 1H), 6.07 (dd, J = 16.9, 10.2 Hz, 1H), 5.93 (s, 1H), 
5.72-5.58 (m, 2H), 4.41 (d, J = 6.5 Hz, 2H), 4.20 (t, J = 6.7 Hz, 2H), 
4.01 (s, 2H), 3.40 – 3.21 (m, 2H), 2.17 (t, J = 2.5 Hz, 1H) 1.90-1.82 (m, 
1H), 1.64 – 1.48 (m, 2H), 1.44-1.31 (m, 3H).; 13C NMR (75 MHz, MeOD) 
δ 174.57, 168.13, 158.45, 145.15, 142.59, 132.04, 128.79, 128.16, 
126.60, 126.19, 120.92, 80.44, 72.27, 67.87, 56.28, 40.12, 32.84, 
29.90, 29.48, 24.22. 
 
 
Synthesis of compound STS-A1 The solution of compound 3-15 was 
stirred in 20 % piperidine-DCM solution (5 mL) at rt for 2 h. After the 
reaction was complete, it was concentrated to remove valotiles to give 
the residue which was purified by column chromatography to give 
product. (52 mg, 67 %) 
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To a solution of STS acid (5.0 mg, 8.8 μmol), EDCI (15 mg, 90 μmol) 
and DMAP (2.4 mg, 19.7 μmol) in DMSO (1 mL) at 0 oC was added 
amine (4.2 mg, 17.7 μmol) above, then the reaction was allowed to 
warm to rt and stirred at r.t overnight. Product STS-A1 was purified by 
HPLC as a white solid. (1.3 mg, 19%)) 1H NMR (300 MHz, DMSO-d6) δ 
9.27 (d, J = 7.8 Hz, 1H), 8.58 (s, 1H), 8.34-8.30 (m, 1H), 8.14-8.04 (m, 
3H), 7.99-7.95 (d, J = 8.3 Hz, 1H), 7.66 (d, J = 7.9 Hz, 1H), 7.49 (t, J = 
7.4 Hz, 2H), 7.36 (d, J = 7.4, 1H), 7.29 (d, J = 7.4, 1H), 7.03-6.98 (m, 
1H), 6.21 (dd, J = 17.0, 10.0 Hz, 1H), 6.06 (dd, J = 17.0, 2.2 Hz, 1H), 
5.57 (dd, J = 9.7, 2.4 Hz, 1H), 4.99 (s, 3H), 4.21 (s, 2H), 3.92 – 3.90 (m, 
2H), 3.33 (s, 4H), 3.25 (s, 1H), 3.16 (s, 7H), 2.81 (s, 3H), 2.75 (s, 3H), 
2.67 – 2.61(m, 3H), 2.41 (s, 1H), 2.34 (s, 2H), 2.24 (s, 1H), 2.07 (d, J = 
5.1 Hz, 1H), 1.78 – 1.67 (m, 1H), 1.62 – 1.20 (m, 4H). LCMS m/z calcd 
for C44H48N7O7 [M+H]
+ 786.3615, found 786.340. 
 
7.3.2. Anti-proliferation 
Cell viability was determined using the XTT colorimetric cell 
proliferation kit (Roche) following manufacturer’s guidelines. Briefly, 
cells were grown to 20-30% confluence (since they will reach ∼90% 
confluence within 48 to 72 h in the absence of drugs) in 96-well plates 
under the conditions described above. The medium was aspirated, and 
then washed with PBS, and treated in duplicate, with 0.1 mL of the 
medium containing different concentrations of probes (0-1 μM) or drug 
(0-1 μM, as a positive control). Probes were applied from DMSO stocks 
whereby DMSO never exceeded 1% in the final solution. The same 
volume of DMSO was used as a negative control. Fresh medium, along 
with two probes and one corresponding drug, were added every 24 h. 
After a total treatment time of 72 h, proliferations were assayed using 
the XTT colorimetric cell proliferation kit (Roche) following 
manufacturer’s guidelines (read at 450 nm). Data represent the 




7.3.3. Pure enzyme labeling 
To investigate the labeling specificity of our probes, pure enzyme 
labeling experiments were performed. Briefly, different proteins (a final 
concentration of 100 nM) were incubated with STS-C1 and STS-2 (a 
final concentration of 200 nM), respectively, in above reaction buffer for 
2 h at rt and UV (365 nm, 20 min) for STS-2, followed by click-
chemistry with Rhodamine azide (Rh-PEG-N3). After 2 h of click 
reaction, 6×SDS loading dye was added and the mixture was heated to 
95 ºC for 10 min. The resulting proteins were resolved by SDS-PAGE. 
In-gel fluorescence scanning was used to visualize the labelled protein 
bands. Both in-gel fluorescence scanning (FL) and silver staining was 
always carried out on the gels upon SDS-PAGE separation of labeled 
samples. 
7.3.4. Pure enzyme activity assay 
Concentration-dependent experiments were performed to 
determine the inhibition potency and the binding affinity of the probes 
towards the catalytic domain of the kinases. The inhibition assay was 
performed with Kinase-Glo® Plus Luminescent Kinase assay kit from 
Promega following the manufactures instructions. Recombinant kinase, 
ATP and the probe were mixed in the HEPES buffer (25 mM HEPES, 
pH 7.5, 150 mM NaCl, 2 mM MgCl2) at a volume of 27.5 μL in a flat-
bottom solid white 384-well plate. The incubation was allowed to 
continue for 20 min at 37 °C and the reaction was subsequently 
quenched by the addition of an equal volume of the Kinase-Glo reagent. 
After 5 min of incubation, the luminescence readouts from the wells 
were measured using Tecan microplate reader with i-control software. 
The ATP and substrate peptide concentrations used in the assay were 
10 μM and 50 μM, respectively. Dose-dependent inhibition assays 
were performed by varying the concentration of the probes under 
optimized enzyme concentration of ~50 nM. The IC50 values of the 
142 
 
probes were calculated from the percentage activity vs. log 
[concentration of probe] curves generated using GraphPad Prism 
software. 
 
7.3.5. Bacterial lysate labeling 
 Bacterial lysates were prepared using modified procedures based 
on previous reports. The cultures of LB (100 mL) with a single colony 
containing c-Src were grown at 37 ºC with shaking to reach OD600 = 1.2. 
Subsequently, IPTG (0.2 mM) was added to induce protein expression 
and incubated for further 18 h at 18 ºC with shaking (230 rpm). 5 mL 
LB was taken out before and after inducing, respectively, and 
harvested by centrifugation at 4000 rpm for 10 min at 4 ºC. The 
resulting pellets were resuspended in the lysis buffer (25 mM HEPES, 
pH 7.5, 150 mM NaCl, 2 mM MgCl2, 50 µM PMSF) and sonicated (to 
complete lysis, 10 rounds of 3 s on and 3 s off, at 28 % amplitude) 
followed by centrifugation for 15 min (13,000 rpm at 4 oC). The total 
protein concentrations of these lysates were then quantified by Bio-Rad 
protein assay (Bio-Rad USA), and stored in -20 oC, and used for all 
subsequent labeling experiments.  
For concentration-dependent in vitro labeling, to 20 µg of above 
bacterial lysates, the probe in different concentration were added and 
the reactions were incubated for 2h at r. t., followed by click-chemistry 
with Rhodamine azide (TER-N3). After 2 h of click reaction, 6 X SDS 
loading dye (4 µL) was added and the mixture was heated to 95 oC for 
10 min. The resulting proteins were resolved by SDS-PAGE. In-gel 
fluorescence scanning was used to visualize the labelled protein bands. 
Both in-gel fluorescence scanning (FL) and coomassie Brilliant Blue 
staining (CBB) were always carried out on the gels upon SDS-PAGE 
separation of labeled samples. 
For dose-dependent in vitro labeling, to different amount of above 
bacterial lysates, the probe was added and the reactions were 
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incubated for 2h at r. t., followed by the same procedure as the 
previous labeling experiment. 
For competing in vitro labeling, to 20 µg of above bacterial lysates, 
after different concentration of staurosporine was incubated at rt for 30 
min, the probe were added and the reactions were incubated for 2 h at 
rt, followed by the same procedure as the previous labeling experiment. 
 
7.3.6. in vitro and in situ labeling over cancer cell lines 
For in vitro proteome labeling, the probes was added to 100 µg 
fresh HepG2 cell lysates (prepared as previously described) in 100 µL 
of HEPES buffer at a desired concentration. Samples incubated with 
probe were incubated for 2 h at room temperature. Four microliters of a 
freshly premixed click chemistry reaction cocktail (100 µM Rh-PEG-N3 
from 10 mM stock solution in DMSO, 100 µM TBTA from 10 mM freshly 
prepared stock solution in deionized water, 1 mM TCEP from 100 mM 
freshly prepared stock solution in deionized water, and 1 mM CuSO4 
from 100 mM freshly prepared stock solution in deionized water) was 
added. The reaction was further incubated for 2 h with gentle mixing, 
before being terminated by addition of pre-chilled acetone (0.4 mL; 30 
min incubation at -20 oC). Precipitated proteins were subsequently 
collected by centrifugation (13000 rpm X 10 min at 4 oC). The 
supernatant was discarded and the pellet was washed with 200 µL of 
pre-chilled methanol. The air-dried pellet was added 2 X loading buffer 
and heated for 10 min at 95 oC. Around 20 µg (per gel lane) of proteins 
were separated by SDS-PAGE (10% gel) and then visualized by in-gel 
fluorescence scanning.  
For in situ labeling, HepG2 cells were grown to 80~90% confluency 
in 24-well plates under conditions described above. The medium was 
removed, and cells were washed twice with cold PBS and then treated 
with 0.5 mL of the DMEM-containing probe (diluted from DMSO stocks 
whereby DMSO never exceeded 1% in the final solution). After 2 h of 
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incubation at 37 oC/5% CO2, the medium was aspirated. The cells were 
trypsinized and pelleted by centrifugation. Eventually, the cell pellets 
were re-suspended in HEPES buffer (0.5% NP-40, 100 µL), 
homogenized by sonication, and diluted to 1 mg/mL with HEPES buffer. 
All subsequent procedures were similar to those from in vitro 
experiments. The protein pellets were then re-suspended in 20 µL of 1 
X SDS- loading buffer and heated for 10 min at 95 oC. Around 20 µg 
(per gel lane) of proteins were separated by SDS-PAGE (10% gel) and 
then visualized by in-gel fluorescence scanning. 
 
7.3.7. Pull-down experiment and validation 
To identify potential cellular targets of the probes, pull-down (PD) 
experiments were carried out, and followed by Western blotting (WB) 
and LC-MS/MS, where applicable. The general pull-down procedure 
was based on previously reported procedures with the following 
optimizations. Fresh cell lysates were prepared and their protein 
concentrations determined, as described earlier. For in vitro pull-down 
experiment, cellular lysates (5 mg) were supplemented with 200 μL 5× 
HEPES buffer (125 mM HEPES, pH 7.5; 750 mM NaCl; 10 mM MgCl2), 
the reaction volume was adjusted to 1 mL with milli-Q water. 
Subsequently, a solution of probe STS-C1 (final 1µM) was added, and 
equilibration was carried out for 2 h at rt. Subsequently, the reaction 
was reacted by click chemistry with Rh-biotin-N3 under the conditions 
described before, acetone precipitated, and resolubilized in 1% SDS in 
PBS with brief sonication. This re-suspended sample was then 
incubated with avidin-agarose beads (100 μL/mg protein) at rt 
overnight. After centrifugation, supernatant was removed and the 
beads were washed with 0.1% SDS once and PBS for 1 times, then 
washed with buffer A (8M Urea 200 mM NaCl 2% SDS 100 mM Tris pH 
8), buffer B (8 M Urea 1.2 M NaCl 0.2% SDS 100 mM Tris 10% 
Ethanol 10% Isopropanol pH 8), buffer C (8 M Urea 100 mM Tris pH 8) 
and PBS. After washing, the beads were boiled in 1× SDS loading 
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buffer (200 mM Tris pH 6.8, 400 mM DTT, 8% SDS) for 15 min. Control 
PD using DMSO was carried out concurrently.  
For in situ PD, the probe STS-C1 (1 μM) was directly added to live 
cells, followed by incubation for 2 h. DMSO should never exceed 1% in 
the final solution. After 2 h of incubation at 37 ºC/5% CO2, the medium 
was aspirated, and cells were washed twice gently with PBS to remove 
the excessive probe. The cells were then trypsined and pelleted by 
centrifugation. Eventually, the cell pellets were resuspended in PBS 
(50 μL), homogenized by sonication, and diluted to 1 mg/mL with PBS. 
The labeled lysates were then subjected to click reaction with Rh-
biotin-N3, and all subsequent experiments were carried out as above 
described. Control PD using DMSO were carried out concurrently with 
live cells. WB experiments were carried out as previously described 
using the corresponding antibodies.  
After SDS-PAGE, digestion process was introduced as following: 
the collected gel cut into small particles was washed twice with ~400 µl 
of 25 mM ammonium bicarbonate/50% acetonitrile and vortex for 10 
min; Gel pieces was then washed with 400 µl of 100 mM ammonium 
bicarbonate at pH= 8 for 10 min while vortexing, and dehydrated with 
~400 µl of 100% acetonitrile. After repeating rehydration and 
dehydration and Removing the solution, gel particles was incubated 
with 300 µL of 0.05 mg/mL trypsin solution for 16 h at 37 ºC; the 
solution was combined with two additional extractions using 2 vol of 5% 
FA/50% acetonitrile and concentrated in vacuo. The peptides were 
separated and analyzed on a Shimadzu UFLC system (Shimadzu, 
Japan) coupled to an LTQ-FT Ultra (Thermo Electron, Germany). 
Mobile phase A (0.1% formic acid in H2O) and mobile phase B (0.1% 
formic acid in acetonitrile) were used to establish the 60 min gradient 
comprising 45 min of 5−35% B, 8 min of 35−50% B, and 2 min of 80% 
B, followed by re-equilibrating at 5% B for 5 min. Peptides were then 
analyzed on LTQ-FT with an Advance Captive Spray Source (Michrom 
Bio Resources) at an electrospray potential of 1.5 kV. A gas flow of 2 
L/min, ion transfer tube temperature of 180 °C, and collision gas 
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pressure of 0.85 mTorr were used. The LTQ-FT was set to perform 
data acquisition in the positive-ion mode as previously described, 
except that the m/z range of 350−1600 was used in the full MS scan. 
The raw data were converted to mgf format. The database search was 
performed with an in-house Mascot server (version 2.2.07, Matrix 
Science) with MS tolerance of 10 ppm and MS/MS tolerance of 0.8 Da. 
Two missed cleavage sites of trypsin were allowed. Carbamidome-
thylation(C) was set as a fixed modification, and oxidation (M) and 
phosphorylation (S, T, and Y) were set as variable modifications. 
“False” hits that appeared in negative control pull-down/LCMS 
experiments were further eliminated. All proteins were identified by a 
minimum score of 40 and at least one unique peptides. Based on these 
criteria, a list of the hits, which was potential targets of STS-C1, was 
generated. Some “sticky” or contaminated proteins such as keratin, 
actin, and tubulin have been deleted. “False” hits that appeared in 
negative control pull-down/LCMS experiments have been further 
eliminated. The kinases were extracted into Table S2. 
For Western blotting analysis, the PVDF membrane was blocked 
with 3% BSA-TBST (Tween-20, 0.1%) at 4 ºC overnight after the 
proteins on gel was transferred. Then PVDF membrane was incubated 
with primary antibody in 3% BSA-TBST (Tween-20, 0.1%) at rt for 1 h 
followed by washing with TBST (Tween-20, 0.1%) for 10 min × 4. The 
PVDF membrane was further incubated with corresponding secondary 
antibody at rt for 1 h followed by washing with TBST (tween-20, 0.1%) 
for 10 min × 4. SuperSignal West Dura Kit (Thermo Scientific) was 
used to develop the blot. 
7.3.8. Imaging experiment with STS probes 
a) Colocalization of STS-T1 over MCF-7 
MCF-7 cells were seeded in glass bottom dishes (CELLviewTM, Cat. 
No. 627861) and grown till ~ 60% confluence. The cells were incubated 
with 1, 5, 10 µM of STS-T1 in fresh growth medium (200 µL). The cells 
147 
 
were further incubated for 1 h at 37°C/CO2. Then the cells were 
washed with PBS three times. Subsequently, cells were fixed with 3.7% 
formaldehyde in PBS for 20 min at 37°C/CO2, washed twice again and 
permeabilized with 0.1% Triton X-100 in PBS for 15 min at 37°C/CO2, 
washed twice again. Cell were then blocked with 2% BSA, 0.05% 
Tween-20 in PBS for 30 min at room temperature, washed twice with 
PBS and then subsequently treated with a freshly premixed click 
chemistry reaction in a 200 µL (10 µM Rh-PEG-N3, 200 µM TBTA 2 
mM TCEP, 2 mM CuSO4 ) for 1 h at room temperature with gentle 
shaking. Cells were washed with 2x PBS, several times PBS 
containing 1% Tween-20 and 0.5 mM EDTA (until there was no small 
crystal under microscopy), 2x PBS, 2x methanol, 2x PBS. For ER-
localization experiments, cells were further incubated with ER trackerTM 
Green (glibenclamide BODIPY® FL, Invitrogen, 0.3 µM in final 
concentration) for 2 h, washed with PBS twice. For immunofluorescent 
experiments, cells were further incubated with PDI primary antibody (1 : 
200 in 2% BSA, Santa Cruz, sc-166474) for 1 h at room temperature, 
washed once with 2% BSA and twice with PBS, and then incubated 
with FITC-conjugated anti-mouse IgG secondary antibody (1 : 100 in 2% 
BSA, Santa Cruz, sc-2010), washed once with 2% BSA and twice with 
PBS. For both experiments the cells were incubated with nucleus stain 
(Hoechst, 0.2 µg/mL as final concentration) for 20 min and washed 
twice with PBS. Finally, the cells were washed imaged.  
b) Colocalization of STS-C1 over HepG2 
HepG2 cells were seeded in glass bottom dishes (CELLviewTM, 
Cat. No. 627861) and grown till ~ 60% confluence. The cells were 
incubated with 0, 200 nM, 500 nM, 1 µM of STS-C1 in fresh growth 
medium (200 µL). The cells were further incubated for 2 h at 37°C/CO2. 
Then the cells were washed with PBS three times. Subsequently, cells 
were fixed with 3.7% formaldehyde in PBS for 20 min at 37°C/CO2, 
washed twice again and permeabilized with 0.1% Triton X-100 in PBS 
for 15 min at 37°C/CO2, washed twice again. Cell were then blocked 
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with 2% BSA, 0.05% Tween-20 in PBS for 30 min at room temperature, 
washed twice with PBS and then subsequently treated with a freshly 
premixed click chemistry reaction in a 200 µL (10 µM Rh-PEG-N3, 200 
µM TBTA 2 mM TCEP, 2 mM CuSO4) for 1 h at room temperature with 
gentle shaking. Cells were washed with 2 x PBS, several times PBS 
containing 1% Tween-20 and 0.5 mM EDTA (until there was no small 
crystal under microscopy), 2 x PBS, 2 x methanol, 2 x PBS. The cells 
were incubated with nucleus stain (Hoechst, 0.2 µg/mL as the final 
concentration) for 10 min and washed twice with PBS. Finally, the cells 




7.4. Chapter 4 
7.4.1. The procedure for synthesis of intermediates and 
probes 
 
Dimethyl 2-oxopentanedioate (4-2) To a solution of 2-oxoglutaric 
Acid 4-1 (10 g, 68 mmol) in dry MeOH (100 mL) was added thionyl 
chloride (10 mL) dropwise at 0 oC. After addition was complete, the 
reaction was stirred at rt overnight. The reaction mixture was 
concentratined to give the product as colorless oil, which was used in 
next step without further purification. (11 g, 93%) 1H NMR (300 MHz, 
CDCl3) δ 3.81 (s, 3H), 3.61 (s, 3H), 3.09 (t, J = 6.5 Hz, 2H), 2.60 (t, J = 
6.5 Hz, 2H). 
 
 
(E)-Dimethyl 4-oxopent-2-enedioate (4-3) To a solution of compound 
4-2 (8.0 g, 46 mmol) in DCM (120 mL) was added bromine (4.0 mL) at 
refluxing and the reaction was refluxed for 3 h. Then the mixture was 
concentrated to give an orange oil. The resulted residue was dissolved 
in diethyl ether (200 mL) and TEA (7.2 mL) was added dropwise at rt 
with large of precipitated formed. The mixture was filtered through a 
pad of siliga gel and the filtrate was concentrated to give residue which 
was further purified by column chromatography to give the desired 
product 4-3 as a bright yellow solid. (2.7 g, 34%) 1H NMR (300 MHz, 
CDCl3) δ 7.62 (d, J = 16.0 Hz, 1H), 6.97 (d, J = 16.0 Hz, 1H), 3.93 (s, 





1,5-Dichloro-2,4-dinitrobenzene (4-5) To a clear solution of potassium 
nitrate (14 g, 140 mmol) and sulfuric acid (50 mL) at 60 oC, was added 
1,3-dichlorobenzene 4-4 (10 g, 68 mmol). The the reaction was heated 
at 125 oC for 1 h. After cooled to 90 oC, the reaction mixture was 
poured into ice-water. The solid was collected by filtration and 
recrystallized in ethanol (60.0 mL) to give the product 4-5 as a yellow 




4,6-Dinitrobenzene-1,3-diamine (4-6) 143 A solution of compound 4-5 
(4.0 g, 17 mmol) in ethylene glycol (30 mL) was heated to 140 oC 
under ammomium atmosphere with large of precipitate formed. After no 
more precipitated formed, the reaction was cooled down. Solid was 
collected by filtration followed by washing with boiling water and boiling 
ethanol to give product 4-6 as a yellow powder. (2.1g, 63%) 1H NMR 




carbamate) (4-7) To a solution of compound 4-6 (1.0 g, 5 mmol) and 
DMAP (0.30 g, 2.5 mmol), was added dropwise Boc2O (5.7 g, 26 
mmol) at 0 oC. After addition was complete, the reaction was allowed to 
warm to r.t .and stirred at rt overnight. The reaction was proportioned 
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with water (10 mL) and diethyl ether (10 mL). Aq layer was extracted 
with ether (10 mL X 3). The combined organic layers were dried over 
anhyd sodium sulfate and concentrated to give residue which was 
purified by column chromatography to give the product 4-7 as a white 
solid. (2.5 g, 83%) 1H NMR (300 MHz, CDCl3) δ 8.73 (s, 1H), 7.21 (s, 
1H), 1.36 (s, 36H); 13C NMR (75 MHz, CDCl3) δ 148.99, 143.91, 
137.49, 134.70, 122.04, 84.99, 27.71. 
 
 
Di-tert-butyl (4,6-dinitro-1,3-phenylene)dicarbamate (4-8) To a 
solution of compound 4-7 in DCM (10 mL) at 0 oC, was added TFA (1.9 
mL) dropwise and the reaction was stirred at 0 oC for 2 h. Then the 
reaction was quenched with sat. sodium bicabornate and extracted 
with DCM (20 mL X 3). The combined organic layers were dried over 
anhyd sodium sulfate and concentrated to give the residue which was 
purified by column chromatography to afford the product 4-8 as a white 
solid. (1.4 g, 84%) 1H NMR (300 MHz, CDCl3) δ 10.07 (s, 2H), 9.81 (s, 
1H), 9.22 (s, 1H), 1.57 (s, 18H). 
 
 
Di-tert-butyl (4,6-diamino-1,3-phenylene)dicarbamate (4-9) Dinitro 
compound 4-8 (3.0 g, 7.5 mmol) was subjected to catalytic 
hydrogenation over 10% Pd/C (0.50 g) at 30 psi in EtOAc (40 mL) for 
12 h. The reaction mixture was filtrated through celite and the filtrate 
was concentrated to yield compound 4-9 as a light brown solid. (2.15 g, 
84%) 1H NMR (500 MHz, CDCl3) δ 7.03 (s, 1H), 6.17 (s, 1H), 5.98 (br s, 






rrolo[4,3,2-de]quinoline-4-carboxylate (4-10) To a stirring solution of 
compound 4-9 (100 mg, 0.3 mmol) in chloroform (5 mL) was added 
comound 4-3 (65 mg, 0.38 mmol) at rt After 30 min, TsOH (5.3 mg) and 
Cu(OAc)2 (5.6 mg) was added and the reaction was refluxed for 8 h. 
Then the reaction was quenched with sat. sodium bicarbonate solution. 
The mixture was extracted with chloroform (10 mL X 3). The combined 
extracts were dried over anhyd sodium sulfate and concentrated in 
vacuo to give the residue which was purified by column 
chromatography to afford the desired product 4-10 as a red solid. (50 
mg, 36%) 1H NMR (500 MHz, CDCl3) δ 9.48 (s, 1H), 8.69 (s, 1H), 8.37 






Pyrroloquinoline 4-10 (200 mg, 0.44 mmol) was subjected to 
chlorination with NCS (68 mg, 0.51 mmol) in anhyd DMF (2 mL) at 
60 °C for 30 min. The reaction mixture poured into water. Solid was 
collected with filtration and purified by silica gel column 
chromatography to provide the product 4-11 as a yellow solid. (145.0 
mg, 68%) 1H NMR (300 MHz, CDCl3) δ 9.47 (s, 1H), 8.61 (s, 1H), 7.49 
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(s, 1H), 7.29 (s, 1H), 4.06 (s, 4H), 1.55 (s, 9H), 1.49 (s, 9H); 13C NMR 
(75 MHz, CDCl3) δ 165.75, 164.97, 152.82, 152.27, 149.29, 138.55, 
135.05, 129.12, 127.62, 122.02, 121.85, 119.21, 117.98, 83.51, 81.54, 




carboxylate (4-14) A mixture of 1,3-diamin-6-dinitrobenzene 4-6 (100 
mg, 0.51 mmol) and dimethyl 2-oxoglutaconate 4-3 (44 mg,0.25 mmol) 
in 20 mL of TFA was refluxed for 8 h, after which TFA was chilled 
out.The residue was purified by flash chromatography to yield the 
product 4-14 as a yellow solid (30 mg, 38%) 1H NMR (300 MHz, 




nolone-4-carboxylate (4-15) To a stirring mixture of compound 4-14 
(0.50 g, 1.5 mmol), potassium carbonate (0.45 g, 3 mmol) and 
molecular sieve (4Å, 0.20 g), was added methiodide (0.37 mL, 6 mmol) 
at rt. After overnight of stirring, the reaction mixture was concentrated 
in vacuo to give residue which was purified by column chromatography 
to give the desired product 4-15 as a dark solid. (0.31 g, 60%) 1H NMR 







noline-4-carboxylate (4-16) A solution of compound 4-15 (0.31 g, 0.93 
mmol) in DMF (5.0 mL) was stirred with Pd/C (10%, 0.10 mg) under 
hydrogen atmosphere (5 bar) at rt overnight. Catalyst was filtrated off 
and washed with DMF. The filtrate was concentrated in vacuo to give 
the product 4-16 as a purple solid. (0.22 g, 88%) 1H NMR (300 MHz, 
DMSO-d6) δ 8.33 (s, 1H), 6.35 (s, 2H), 6.24 (s, 1H), 6.03 (s, 2H), 3.93 





carboxylate (4-17) A solution of 3-(3-(but-3-yn-1-yl)-3H-diazirin-3-
yl)propanoic acid (3.0 mg, 0.018 mmol), DMAP (2.2 mg, 0.018 mmol) 
and EDCI (13.8 mg, 0.072 mmol) in DMF (0.60 mL) was stirred at 0 oC 
for 10 min in dark. To above solution was added a solution of 
compound 4-16 (5.0 mg, 0.018 mmol) in DMF (0.50 mL) at 0 oC. Then 
the reaction was allowed to warm to rt and stirred at rt overnight. After 
1 equiv. of the photo-labile linker and 4 equiv. of EDCI were added at 0 
oC, the reaction was stirred at rt overnight until LC-MS analysis showed 
the product peak (m/z: 421.1) stopped increasing. The reaction mixture 
was concentrated to give residue which was purified by column 
chromatography to give the product 4-17 as purple solid. (1.1 mg, 14%) 
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1H NMR (300 MHz, CDCl3) δ 9.61 (s, 1H), 8.66 (s, 2H), 8.31 (s, 1H), 
4.50 (s, 1H), 4.08 (s, 3H), 3.69 (s, 3H), 2.45 (t, J = 7.5 Hz, 2H), 2.12 – 




4-carboxamide (4-18) A mixture of compound 4-16105 (89 mg, 0.32 
mmol) in ammonium solution (10.0 mL) was stirred at rt overnight. 
Sovent was removed in vacuo to give desired product as a purple solid. 
(73 mg, 87%) 1H NMR (300 MHz, DMSO-d6) δ 8.70 (s, 1H), 8.29 (s, 
1H), 7.69 (d, J = 3.8 Hz, 1H), 7.55 (s, 1H), 6.40 (s, 2H), 6.16 (s, 2H), 





yl)propanamide (4-19) A solution of 3-(3-(but-3-yn-1-yl)-3H-diazirin-3-
yl) propanoic acid (6.5 mg, 0.039 mmol), DMAP (4.8 mg, 0.039 mmol) 
and EDCI (30 mg, 0.16 mmol) in DMF (1.3 mL) was stirred at 0 oC for 
10 min in dark. To above solution was added a solution of compound 4-
18 (100 mg, 0.039 mmol) in DMF (1.0 mL) at 0 oC. Then the reaction 
was allowed to warm to rt and stirred at rt overnight until LC-MS 
analysis showed the product peak ([M+H]+, m/z: 421.1) stopped 
increasing. The reaction mixture was concentrated to give residue 
156 
 
which was purified by column chromatography to give the product as 
purple solid. (7.8 mg, 48%) 1H NMR (300 MHz, MeOD) δ 8.59 (s, 1H), 
8.31 (s, 1H), 5.49 (s, 2H), 3.66 (s, 3H), 2.52 – 2.47 (m, 2H), 2.08 (td, J 





carboxylate (4-24) To a solution of the mixture of compound 4-12 and 
4-17 (10 mg) and 3-(3-(but-3-yn-1-yl)-3H-diazirin-3-yl) propanoic acid 
(6.0 mg, 0.036 mmol) in DMF (1 mL), was added EDCI (42 mg, 0.22 
mmol) and DMAP (7.2 mg, 0.059 mmol) at 0 oC. Then the reaction was 
allowed to warm to rt and stirred at rt overnight until LC-MS analysis 
showed the product peak ([M+H]+, m/z: 440.9) stopped increasing.  
The mixture was loaded to column chromatography to give product. 
(3.4 mg) 1H NMR (300 MHz, DMSO-d6) δ 8.39 (s, 1H), 7.16 (s, 2H), 
6.41 (s, 2H), 3.96 (s, 3H), 3.04 – 2.99 (s, 2H), 2.84 (s, 1H), 2.18 – 2.03 




fonyl)oxy)pyrrolo[4,3,2-de]quinoline-4-carboxylate (4-31) To a 
stirred solution of compound 4-10 (33 mg, 0.072 mmol) and pyridine 
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(29 mg, 0.36 mmol) in DCM (1 mL) was added Tf2O (28.5 mg, 0.36 
mmol) at 0 °C. After stirring at rt for 1 h, the solution was treated with 
water. Then the mixture was extracted with DCM (5 mL x 3). The 
organic layer was washed with brine, dried over anhyd sodium sulfate, 
and concentrated to give the residue which was purified by preparative 
TLC (eluent: Hexanes/EA = 4/1) to afford as reddish solid. (34 mg, 
80%) 1H NMR (300 MHz, CDCl3) δ 9.35 (s, 1H), 8.74 (s, 1H), 8.74 (s, 
1H), 8.65 (s, 1H), 8.04 (s, 1H), 4.15 (s, 3H), 1.65 (s, 9H), 1.63 (s, 9H). 
 
 
a) Reduced by Schwartz’s reagent 
Methyl 6,8-bis((tert-butoxycarbonyl)amino)pyrrolo[4,3,2-de]quino 
line -4-carboxylate (4-32) To a stirred solution of compound 4-10 (25 
mg, 0.054 mmol) in dry THF (1 mL) was added Schwartz’s reagent (28 
mg, 0.11 mmol) at -30 oC under argon atmosphere. The solution was 
stirred at that temperature for 2 h before sat. brine was added into the 
solution. The mixture was extracted with ethyl acetate (5 mL x 3). Then 
the combined extracts were dried over anhyd sodium sulfate and 
concentrated to give the residue which was purified by column 
chromatography (Hexanes:EA = 4:1) to get the desired product as 
orange solid. (14 mg, 60%) 
b) Reduced by DIBAL-H 
Methyl 6,8-bis((tert-butoxycarbonyl)amino)pyrrolo[4,3,2-de]quino 
line-4-carboxylate (4-32) To a stirred solution of compound 4-10 (20 
mg, 0.044 mmol) in dry THF was added DIBAL-H (1.0 M, 87 µL) at -78 
oC under argon atmosphere, the reaction was slowly warmed up until 
the starting material was all consumed monitored by TLC analysis. 
158 
 
Then 1 mL of sat. sodium bicarbonate solution was added and the 
mixture was extracted with EA (5 mL x 3). After the extracts were dried 
over anhyd sodium sulfate and concentrated under reduced pressure, 
the residue was purified by column chromatography (Hexane:EA=4:1) 
to give the desired product as orange solid. (7.7 mg, 40%) 1H NMR 
(300 MHz, CDCl3) δ 9.46 (s, 1H), 8.70 (s, 1H), 8.42 (s, 1H), 7.92 (s, 




rrolo[4,3,2-de]quinoline-6,8-diyl)dicarbamate (4-34) To a stirred 
mixture of THF (2 mL) and H2O (1 mL) was added LiOH (7.2 mg, 0.30 
mmol), and the solution was stirred for 10 min., before compound 4-10 
(69 mg, 0.15 mmol) was added. After 1 h of stirring, 3 mL of sat. citric 
acid solution was added. The organic layer was separated and the aq 
layer was extracted with EA (5 mL x 3). The combined organic layer 
was dried over anhyd sodium sulfate and concentrated under the 
reduced pressure. The residue as crude product was used directly in 
next step without further purification as an organic solid. (59 mg, 89%) 
To a solution of the resulted acid (57 mg, 0.13 mmol) above and N,O-
dimethylhydroxylamine hydrochloride(25 mg, 0.26 mmol) in THF (1 mL) 
was added EDCI (49 mg 0.26 mmol) and DMAP (52 mg, 0.51 mmol). 
The reaction was allowed to be stirred for 2 h before 1 mL sat. sodium 
bicarbonate solution was added.  The organic layer was separated and 
the aq layer was extracted with EA (5 mL x 3), dried with anhyd sodium 
sulfate and concentrated under reduced pressure. The residue was 
purified with flash chromatography (Hexanes:EA = 2:1) to afford the 
desired product as orange solid (90%). 1H NMR (300 MHz, CDCl3) δ 
9.50 (s, 1H), 8.22 (s, 1H), 8.17 (s, 1H), 7.89 (s, 1H), 7.05 (s, 1H), 3.65 
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(s, 3H), 3.47 (s, 3H), 3.25 (s, 3H), 1.55 (s, 9H), 1.53 (s, 9H); 13C NMR 
(75 MHz, CDCl3) δ 166.03, 152.65, 152.53, 151.98, 134.50, 132.34, 





pyrrolo[4,3,2-de]quinoline-4-carboxylate (4-36) The compound 4-10 
(0.20 g, 0.44 mmol) was dissoloved in DMF (5.0 mL) and the reaction 
was stirred under microwave at 150 oC for 1 h. Then the reaction was 
cooled to rt and concentrated in vacuo to give product 4-36 as a purple 
solid. (0.14 g, 90%) 1H NMR (300 MHz, DMSO-d6) δ 10.32 (s, 1H), 
8.42 (s, 1H), 8.35 (s, 1H), 7.79 (s, 1H), 7.70 (s, 1H), 6.45 (s, 2H), 3.96 
(s, 4H), 1.54 (s, 9H). 
 
7.4.2. Pure enzyme labeling 
To investigate the labeling specificity of our probes, pure enzyme 
labeling experiments were performed. Briefly, different proteins (a final 
concentration of 100 nM) were incubated with probes respectively, in 
above reaction buffer for 30 min at rt followed by UV irradiation (365 
nm, 20 min). After 2 h of click reaction, 6×SDS loading dye was added 
and the mixture was heated to 95 ºC for 10 min. The resulting proteins 
were resolved by SDS-PAGE. In-gel fluorescence scanning was used 
to visualize the labelled protein bands. Both in-gel fluorescence 
scanning (FL) and silver staining was always carried out on the gels 
upon SDS-PAGE separation of labeled samples. 
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7.4.3. Bacterial lysate labeling 
Bacterial lysates were prepared using modified procedures based on 
previous reports. To 20 µg of above bacterial lysates, the probes were 
added and the reactions were incubated for 30 min at rt followed by UV 
irradiation (365 nm, 20 min). After 2 h of click reaction, 6 X SDS loading 
dye (4 µL) was added and the mixture was heated to 95 oC for 10 min. 
The resulting proteins were resolved by SDS-PAGE. In-gel 
fluorescence scanning was used to visualize the labelled protein 
bands. Both in-gel fluorescence scanning (FL) and coomassie Brilliant 
Blue staining (CBB) were always carried out on the gels upon SDS-
PAGE separation of labeled samples. 
7.4.4. In vitro labeling over cancer cell lysate 
The probes was added to 100 µg fresh cancer cell lysates 
(prepared as previously described) in 100 µL of HEPES buffer at a 
desired concentration. Samples incubated with probes were incubated 
for 30 min at rt followed by UV irradiation (365 nm, 20 min). After 2 h of 
click reaction, 4 μL of a freshly premixed click chemistry reaction 
cocktail (100 µM Rh-PEG-N3 from 10 mM stock solution in DMSO, 100 
µM TBTA from 10 mM freshly prepared stock solution in deionized 
water, 1 mM TCEP from 100 mM freshly prepared stock solution in 
deionized water, and 1 mM CuSO4 from 100 mM freshly prepared stock 
solution in deionized water) was added. The reaction was further 
incubated for 2 h with gentle mixing, before being terminated by 
addition of pre-chilled acetone (0.4 mL; 30 min incubation at -20 oC). 
Precipitated proteins were subsequently collected by centrifugation 
(13000 rpm X 10 min at 4 oC). The supernatant was discarded and the 
pellet was washed with 200 µL of pre-chilled methanol. The air-dried 
pellet was added 2 X loading buffer and heated for 10 min at 95 oC. 
Around 20 µg (per gel lane) of proteins were separated by SDS-PAGE 
(10% gel) and then visualized by in-gel fluorescence scanning.  
7.4.5. Pull-down experiment  
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To identify potential cellular targets of the probes, pull-down (PD) 
experiments were carried out, and followed by and LC-MS/MS. The 
general pull-down procedure was based on previously reported 
procedures with the following optimizations.26 Fresh cell lysates were 
prepared and their protein concentrations determined, as described 
earlier. For in vitro pull-down experiment, cellular lysates (5 mg) were 
supplemented with 200 μL 5× HEPES buffer (125 mM HEPES, pH 7.5; 
750 mM NaCl; 10 mM MgCl2), the reaction volume was adjusted to 1 
mL with milli-Q water. Subsequently, Am-2 were added, and 
equilibration was carried out for 1 h at rt followed by UV irradiation (365 
nm, 30 min). Subsequently, the reaction was reacted by click chemistry 
with Rh-biotin-N3 under the conditions described before, acetone 
precipitated, and re-solubilized in 1% SDS in PBS with brief sonication. 
This re-suspended sample was then incubated with avidin-agarose 
beads (100 μL/mg protein) at rt for 2 h. After centrifugation, supernatant 
was removed and the beads were washed with 0.1% SDS once and 
PBS for 1 time, then washed with buffer A (8 M Urea 200 mM NaCl 2% 
SDS 100 mM Tris pH 8), buffer B (8 M Urea 1.2 M NaCl 0.2% SDS 100 
mM Tris 10% Ethanol 10% Isopropanol pH 8), buffer C (8M Urea 100 
mM Tris pH 8) and PBS. After washing, the beads were boiled in 1× 
SDS loading buffer (200 mM Tris pH 6.8, 400 mM DTT, 8% SDS) for 15 
min. Control PD using NP was carried out concurrently.  
After SDS-PAGE, digestion process was introduced as following: 
the collected gel cut into small particles was washed twice with ~400 µl 
of 25 mM ammonium bicarbonate/50% acetonitrile and vortex for 10 
min; Gel pieces was then washed with 400 µl of 100 mM ammonium 
bicarbonate at pH= 8 for 10 min while vortexing, and dehydrated with 
~400 µl of 100% acetonitrile. After repeating rehydration and 
dehydration and Removing the solution, gel particles was incubated 
with 300 µL of 0.05 mg/mL trypsin solution for 16 h at 37 ºC; the 
solution was combined with two additional extractions using 2 vol of 5% 
FA/50% acetonitrile and concentrated in vacuo. The peptides were 
separated and analyzed on a Shimadzu UFLC system (Shimadzu, 
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Japan) coupled to an LTQ-FT Ultra (Thermo Electron, Germany). 
Mobile phase A (0.1% formic acid in H2O) and mobile phase B (0.1% 
formic acid in acetonitrile) were used to establish the 60 min gradient 
comprising 45 min of 5−35% B, 8 min of 35−50% B, and 2 min of 80% 
B, followed by re-equilibrating at 5% B for 5 min. Peptides were then 
analyzed on LTQ-FT with an Advance Captive Spray Source (Michrom 
Bio Resources) at an electrospray potential of 1.5 kV. A gas flow of 2 
L/min, ion transfer tube temperature of 180 °C, and collision gas 
pressure of 0.85 mTorr were used. The LTQ-FT was set to perform 
data acquisition in the positive-ion mode as previously described, 
except that the m/z range of 350−1600 was used in the full MS scan. 
The raw data were converted to mgf format. The database search was 
performed with an in-house Mascot server (version 2.2.07, Matrix 
Science) with MS tolerance of 10 ppm and MS/MS tolerance of 0.8 Da. 
Two missed cleavage sites of trypsin were allowed. Carbamidome-
thylation(C) was set as a fixed modification, and oxidation (M) and 
phosphorylation (S, T, and Y) were set as variable modifications. 
“False” hits that appeared in negative control pull-down/LCMS 
experiments were further eliminated. Some “sticky” or contaminated 
proteins such as keratin, actin, and tubulin have been deleted. “False” 
hits that appeared in negative control pull-down/LCMS experiments 
have been further eliminated. The list of potential targets was listed in 




7.5. Chapter 5 
Procedure for the synthesis of linkers 
 
4-azidobutanoic acid (5-6) To a solution of compound 5-5 (5.0 g, 30 
mmol) in dry MeOH (50 mL) was added thionyl chloride (4.4 mL, 60 
mmol) dropwise at 0 oC. After the addition was complete, the reaction 
was allowed to warm to rt and stirred at r.t overnight. The reaction 
mixture was concentrated to give residue. To the residue was added 
sat. NaHCO3, then the mixture was extracted with ethyl acetate (EA, 50 
mL X 3). The combined extracts were dried over anhyd Sodium sulfate 
and concentrated to give liquid which was used in next step without 
further purification. 1H NMR (300 MHz, CDCl3) δ 3.63 (s, 1H), 3.30 (t, J 
= 6.6 Hz, 1H), 2.37 (t, J = 7.2 Hz, 1H), 1.85 (p, J = 6.9 Hz, 1H); 13C 
NMR (75 MHz, CDCl3) δ 172.95, 51.52, 50.44, 30.72, 24.06. 
To a solution of the above product methyl 4-bromobutanoate in DMF 
(10 mL) was added NaN3. The mixture was heated at 80 
oC for 40 min 
by microwave. Then the reaction mixture was proportioned with water 
and EA. The organic layer was washed with aq NaHCO3, brine and 
dried over anhyd sodium sulfate. The organic layer was concentrated 
to give the residue used in next step without purification. (4.1 g) 1H 
NMR (500 MHz, CDCl3) δ 4.31 (t, J = 7.1 Hz, 1H), 2.42 (dt, J = 14.0, 
7.5 Hz, 1H), 2.28 – 2.12 (m, 1H). 
To a solution of above product methyl 4-azidobutanoate in MeOH (40 
mL) was added the solution of LiOH (1.4 g, 58 mmol) in H2O (10 mL). 
After the stirring of overnight at rt, the mixture was concentrated to 
residue which was dissolved in EA (20 mL) and acidified to pH = 1 by 1 
N HCl. After extraction with EA (20 mL X 30, the combined extracts 
were dried over anhyd sodium sulfate and concentrated to give product 
5-6 as a colourless liquid without purification. (3.3 g, 89%) 1H NMR 
(500 MHz, CDCl3) δ 4.31 (t, J = 7.1 Hz, 2H), 2.53 – 2.33 (m, 2H), 2.30 





1-(4-Hydroxy-3-methoxyphenyl)ethanone (5-8) To the mixture of 
apocynin (15 g, 90 mmol), KI (0.6 g, 0.36 mmol) and K2CO3 (24 g, 174 
mmol) in acetonitrile (100 mL) was added benzyl bromide (BnBr, 12 mL) 
and the reaction was refluxed overnight. After filtration, the filtrate was 
concentrated to give residue which was purified by column 
chromatography to give product 5-8 as a white solid. (22.1 g, 96%) 1H 
NMR (500 MHz, CDCl3) δ 7.55 (d, J = 1.9 Hz, 1H), 7.50 (dd, J = 8.3, 
2.0 Hz, 1H), 7.44 (dd, J = 4.4, 3.8 Hz, 2H), 7.41 – 7.35 (m, 2H), 7.32 (d, 




1-(4-(Benzyloxy)-5-methoxy-2-nitrophenyl)ethanone (5-9) To a 
solution of compound 5-8 (22 g, 86 mmol) was added nitric acid (HNO3, 
30 mL) dropwise  at 0 oC and the reaction was stirred overnight at rt. 
The reaction mixture was poured into ice and the precipitate was 
collected by filtration. The solid was dissolved in DCM and precipitated 
by addition of MeOH. The product 5-9 was dried in vacuo. (20 g, 77%) 
1H NMR (300 MHz, CDCl3) δ 7.67 (s, 1H), 7.41 (ddd, J = 15.0, 10.0, 





1-(4-Hydroxy-5-methoxy-2-nitrophenyl)ethanone (5-10) After 
compound 5-9 (6.0 g, 20 mmol) was dissolved in TFA (10 mL), the 
reaction was refluxed for 40 min. The reaction mixture was poured into 
ice-water. The product as yellow solid was collected by filtration. After 
filtration, the filtrate was basified by 1 N NaOH to pH = 10 and 
extracted with EA (50 mL X 3).Then the aq layer was acidified to pH = 
2~3 by 1 N HCl and extracted with EA (50 mL X 3). The combined 
extracts were dried over anhyd sodium sulfate and concentrated to 
product 5-10 as a  white solid. (3.4 g, 80%) 1H NMR (300 MHz, CDCl3) 
δ 7.67 (s, 1H), 7.40 (s, 1H), 6.80 (s, 1H), 4.02 (s, 1H), 2.49 (s, 1H). 
 
 
Methyl 4-(4-acetyl-2-methoxy-5-nitrophenoxy)butanoate (5-11) The 
mixture of 5-10 (2.5 g, 12 mmol), methyl 4-bromobutanoate (3.0 g, 17 
mmol) and K2CO3 (3.3 g, 24 mmol) in DMF (40 mL) was heated at 80 
oC overnight. After DMF was removed in vacuo, the desired residue 
was proportioned with DCM (20 mL) and water (20 mL). The aq layer 
was extracted with DCM (10 X 3). The combined organic layer was 
dried over anhyd sodium sulfate and concentrated to give the residue 
which was purified by column chromatography to give product 5-11 as 
a white solid. (1.5 g, 41%) 1H NMR (300 MHz, CDCl3) δ 7.58 (s, 1H), 
6.73 (s, 1H), 4.13 (t, J = 6.2 Hz, 2H), 3.93 (s, 3H), 3.67 (s, 3H), 2.54 (t, 
J = 7.2 Hz, 2H), 2.47 (s, 3H), 2.22 - 2.13 (m, 2H); 13C NMR (75 MHz, 
CDCl3) δ 200.04, 173.18, 154.21, 148.74, 138.22, 132.76, 108.65, 






(5-12) To the mixture of 5-11 (1.5 g, 4.8 mmol) in MeOH (100 mL) was 
added NaBH4 in portions at 0 
oC and stirred for 3 h at 0 oC. After the 
reaction was complete, the reaction was quenched with water and 
concentrated to give residue which was purified by column 
chromatography to yield product 5-12 a yellowish solid. (1.3 g, 87%) 1H 
NMR (300 MHz, CDCl3) δ 7.44 (s, 1H), 7.23 (s, 1H), 5.44 (q, J = 6.1 Hz, 
1H), 4.01 (t, J = 6.1 Hz, 2H), 3.88 (s, 3H), 3.62 (s, 3H), 3.06 (broad, 
1H), 2.48 (t, J = 7.2 Hz, 2H), 2.16 – 2.01 (m, 2H), 1.43 (d, J = 6.2 Hz, 
3H); 13C NMR (75 MHz, CDCl3) δ 173.32, 153.87, 146.53, 139.06, 





imidazole-1-carboxylate (5-13) The solution of 5-12 (1.0 g, 32 mmol), 
1,1'-Carbonyldiimidazole (CDI) (0.53 g, 35 mmo) and 4-
Dimethylaminopyridine (DMAP) (1.2 mg, 0.3 mol%) was stirred at rt for 
4 h under protection from light. After the reaction was complete, the 
reaction mixture was concentrated and purified by column 
chromatography to give the desired product 5-13. (0.85 g, 65%) 1H 
NMR (500 MHz, CDCl3) δ 8.04 (s, 1H), 7.48 (s, 1H), 7.33 (s, 1H), 6.94 
(s, 1H), 6.57 (q, J = 6.4 Hz, 1H), 4.02 (t, J = 6.2 Hz, 2H), 3.83 (s, 3H), 
3.56 (s, 3H), 2.43 (t, J = 7.2 Hz, 2H), 2.05 (dd, J = 13.4, 6.7 Hz, 2H), 
1.70 (d, J = 6.4 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 172.85, 153.79, 
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147.47, 147.21, 139.59, 136.56, 130.42, 130.41, 116.69, 108.61, 




nitrophenoxy)butanoate (5-14) The reaction mixture of 5-14 (0.80 g, 
2 mmol), 5-azidopentan-1-amine (0.64 g, 5 mmol), triethylamine (TEA, 
0.83 g) and DMAP (12 mg, 5 mol%) in DMC (10 mL) was refluxed for 3 
d. The mixture was concentrated to give residue which was purified by 
column chromatography to give the product 5-14. (0.81 g, 85%) 1H 
NMR (300 MHz, CDCl3) δ 7.43 (s, 1H), 6.93 (s, 1H), 6.19 (q, J = 6.1 Hz, 
1H), 5.34 (t, J = 5.7 Hz, 1H), 3.80 (s, 3H), 3.55 (s, 3H), 3.10 (t, J = 6.7 
Hz, 2H), 2.98 (dd, J = 12.5, 6.2 Hz, 2H), 2.41 (t, J = 7.1 Hz, 2H), 2.11 – 
1.98 (m, 2H), 1.52 – 1.14 (m, 9H); 13C NMR (75 MHz, CDCl3) δ 172.88, 
155.03, 153.66, 146.54, 138.96, 133.99, 108.45, 107.67, 68.05, 67.69, 




phenoxy)butanoic acid (5-15) To a solution of 5-14 (0.80 g, 1.7 mmol) 
in THF-H2O (4:1, 40 mL) was added LiOH (0.50 g) and the reaction 
was then stirred at rt overnight. The reaction was quenched with aq 
NH4Cl and concentrated to remove THF. The aq phase was acidified 
by 1 N HCl to pH 3~4 and extracted with EA (10 mL X 3). The 
combined extracts were dried over anhyd sodium sulfate and 
concentrated to give residue which was purified by column 
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chromatography to give product 5-15 as a white solid. (0.71 g, 91%) 1H 
NMR (300 MHz, CDCl3) δ 7.53 (s, 1H), 6.97 (s, 1H), 6.29 (dd, J = 12.5, 
6.1 Hz, 1H), 5.09 (t, J = 5.7 Hz, 1H), 4.06 (t, J = 6.1 Hz, 2H), 3.89 (s, 
3H), 3.20 (t, J = 6.7 Hz, 2H), 3.09 (d, J = 6.3 Hz, 1H), 2.53 (t, J = 7.1 
Hz, 1H), 2.12 (p, J = 6.6 Hz, 1H), 1.66 – 1.26 (m, 9H); 13C NMR (75 
MHz, CDCl3) δ 177.64, 155.35, 153.83, 146.82, 139.33, 134.00, 108.82, 









romene-3,6,9(6bH,9aH,11bH)-trione (6-2) Wortmannin (20 mg, 47 
µmol) was suspended in 0.50 mL of methanol, and diethylamine (12 µL, 
112 µmol) was added. The solution turned orange immediately, and the 
wortmannin dissolved completely within a few minutes. The reaction 
was allowed to stir at r.t overnight. The solution was concentrated to 
remove the methanol. The residue was dissolved in 1.5 mL of distilled 
dioxane. Aq 1 M HCl (1.3 mL) was added and the solution was allowed 
to stir overnight. The solution was concentrated, and the resultant 
residue was purified by column chromatography to give the desired 
desacetyl wortmannin (9.0 mg, 50%) 1H NMR (300 MHz, CDCl3) δ 8.24 
(s, 1H), 5.59 (dd, J = 9.1, 3.9 Hz, 1H), 4.95 – 4.5 (m, 1H), 3.55 – 3.42 
(m, 3H), 3.15 (s, 3H), 2.91-2.85 (m, 1H), 2.84 – 2.80 (m, 1H), 2.58 (dd, 
J = 19.3, 8.2 Hz, 1H), 2.44 (dd, J = 12.7, 6.5 Hz, 1H), 2.30 – 2.14 (m, 
1H), 2.12 – 1.96 (m, 1H), 1.79 (s, 3H), 1.54 (dd, J = 12.6, 10.1 Hz, 2H), 




[4,5-h]isochromen-11-yl pent-4-ynoate (6-4) A solution of 11-deacetyl 
wortmannin (6-2) and pent-4-ynoic acid (6-3) (5.0 mg, 13 µmol), EDCI 
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(22 mg, 12 μmol ) and DMAP (3.6 mg, 30 μmol) in DCM (1 mL) and 
DMF (1 mL) was stirred at rt overnight. The reaction mixture was 
concentrated in vacuo to give the residue which was purified by column 
chromatography to give the product as white solid. (4.0 mg, 67%) 1H 
NMR (500 MHz, CDCl3) δ 8.24 (s, 1H), 6.33 – 6.13 (m, 1H), 4.85 (dd, J 
= 6.7, 1.9 Hz, 1H), 3.45 (dd, J = 11.3, 1.9 Hz, 1H), 3.18 (s, 3H), 3.02 
(dd, J = 11.2, 6.7 Hz, 1H), 2.90 (ddd, J = 12.6, 5.9, 2.7 Hz, 1H), 2.73 – 
2.45 (m, 6H), 2.33 – 2.20 (m, 1H), 2.17 (s, 1H), 1.74 (s, 3H), 1.68 – 
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The list of proteins identified from LCMS experiments Table S1 
 




1 IPI00007188     Tax_Id=9606 Gene_Symbol=SLC25A5 ADP/ATP translocase 2 33102   691 48    0.95 
2 IPI00798387     Tax_Id=9606 Gene_Symbol=- Putative uncharacterized protein ENSP00000319235 48393 672 25   0.39 
3 IPI00022462     Tax_Id=9606 Gene_Symbol=TFRC Transferrin receptor protein 1 85274 547 33    0.63 
4 IPI00141318    Tax_Id=9606 Gene_Symbol=CKAP4 Isoform 1 of Cytoskeleton-associated protein 4 66097  489 23    1.07 
5 IPI00024145     Tax_Id=9606 Gene_Symbol=VDAC2 Isoform 2 of Voltage-dependent anion-selective channel protein 2 30849     442 26    0.85 
6 IPI00013871    Tax_Id=9606 Gene_Symbol=RRM1 Ribonucleoside-diphosphate reductase large subunit 90925     430 31    0.48 
7 IPI00177817     Tax_Id=9606 Gene_Symbol=ATP2A2 Isoform SERCA2A of Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 111103    427 36    0.46 
8 IPI00294779     Tax_Id=9606 Gene_Symbol=VDAC3 Isoform 2 of Voltage-dependent anion-selective channel protein 3 31112     423 32    1.04 
9 IPI00011062     Tax_Id=9606 Gene_Symbol=CPS1 Isoform 1 of Carbamoyl-phosphate synthase [ammonia], mitochondrial 165975    396 25    0.24 
10 IPI00016610     Tax_Id=9606 Gene_Symbol=PCBP1 Poly(rC)-binding protein 1 37987    389 21   0.65 
11 IPI00215965 Tax_Id=9606 Gene_Symbol=HNRNPA1 Isoform A1-B of Heterogeneous nuclear ribonucleoprotein A1 38822 382 10 0.77 
12 IPI00303954    Tax_Id=9606 Gene_Symbol=CYB5B cytochrome b5 outer mitochondrial membrane precursor 16798     347 19    0.74 
13 IPI00302925     Tax_Id=9606 Gene_Symbol=CCT8 59 kDa protein 60011    340 24    0.31 
14 IPI00027497 Tax_Id=9606 Gene_Symbol=GPI Glucose-6-phosphate isomerase 63107 338 13 0.43 
15 IPI00479186     Tax_Id=9606 Gene_Symbol=PKM2 Isoform M2 of Pyruvate kinase isozymes M1/M2 58470     336 14    0.39 
16 IPI00219018     Tax_Id=9606 Gene_Symbol=GAPDH Glyceraldehyde-3-phosphate dehydrogenase 36201     335 16   0.69 
17 IPI00024580     Tax_Id=9606 Gene_Symbol=MCCC1 Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrial 80935     323 19    0.32 
18 IPI00291467     Tax_Id=9606 Gene_Symbol=SLC25A6 ADP/ATP translocase 3 33073     307 31    0.78 
19 IPI00016768 Tax_Id=9606 Gene_Symbol=LDHAL6B L-lactate dehydrogenase A-like 6B 41916 301 7 0.26 
20 IPI00162563 Tax_Id=9606 Gene_Symbol=RNF40 Isoform 1 of E3 ubiquitin-protein ligase BRE1B 113609 271 8 0.19 
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21 IPI00396485 Tax_Id=9606 Gene_Symbol=EEF1A1 Elongation factor 1-alpha 1 50109 240 15 1.02 
22 IPI00022891     Tax_Id=9606 Gene_Symbol=SLC25A4 ADP/ATP translocase 1 33271     235 24    0.46 
23 IPI00011253     Tax_Id=9606 Gene_Symbol=RPS3 40S ribosomal protein S3 26842     225 16    1.02 
24 IPI00028031     Tax_Id=9606 Gene_Symbol=ACADVL cDNA FLJ56425, highly similar to Very-long-chain specific acyl-
CoAdehydrogenase, mitochondrial 
75618    201 15   0.24 
25 IPI00299571     Tax_Id=9606 Gene_Symbol=PDIA6 Isoform 2 of Protein disulfide-isomerase A6 54380     194 8    0.19 
26 IPI00003881     Tax_Id=9606 Gene_Symbol=HNRNPF Heterogeneous nuclear ribonucleoprotein F 45985     189 7    0.15 
27 IPI00554777     Tax_Id=9606 Gene_Symbol=ASNS Asparagine synthetase [glutamine-hydrolyzing] 64899     181 10    0.16 
28 IPI00299402     Tax_Id=9606 Gene_Symbol=PC Pyruvate carboxylase, mitochondrial 130293    178 18    0.1 
29 IPI00010420     Tax_Id=9606 Gene_Symbol=SLC25A31 ADP/ATP translocase 4 35285     178 10   0.09 
30 IPI00027970     Tax_Id=9606 Gene_Symbol=PCBP3 poly(rC) binding protein 3 isoform 1 39725     175 5    0.27 
31 IPI00479191     Tax_Id=9606 Gene_Symbol=HNRNPH1 51 kDa protein 51482     175 11    0.2 
32 IPI00026781     Tax_Id=9606 Gene_Symbol=FASN Fatty acid synthase 275850    168 12    0.05 
33 IPI00298289     Tax_Id=9606 Gene_Symbol=RTN4 Isoform 2 of Reticulon-4 40350     167 13    0.48 
34 IPI00009542     Tax_Id=9606 Gene_Symbol=MAGED2 Isoform 1 of Melanoma-associated antigen D2 65085     161 8    0.1 
35 IPI00303954     Tax_Id=9606 Gene_Symbol=CYB5B cytochrome b5 outer mitochondrial membrane precursor 16798     157 9    0.74 
36 IPI00884896     Tax_Id=9606 Gene_Symbol=TXNRD1 Isoform 1 of Thioredoxin reductase 1, cytoplasmic 72077     156 12    0.25 
37 IPI00384051     Tax_Id=9606 Gene_Symbol=PSME2 Putative uncharacterized protein PSME2 28755     154 10    0.55 
38 IPI00479217 Tax_Id=9606 Gene_Symbol=HNRNPU Isoform Short of Heterogeneous nuclear ribonucleoprotein U 88924 154 7 0.16 
39 IPI00550363  Tax_Id=9606 Gene_Symbol=TAGLN2 Transgelin-2 22377 153 5 0.75 
40 IPI00220740 Tax_Id=9606 Gene_Symbol=NPM1 Isoform 2 of Nucleophosmin 29446 153 5 0.38 
41 IPI00026824     Tax_Id=9606 Gene_Symbol=HMOX2 Heme oxygenase 2 41928     151 28    0.98 
42 IPI00003833     Tax_Id=9606 Gene_Symbol=MTCH2 Mitochondrial carrier homolog 2 33936     150 13    0.75 
43 IPI00215637     Tax_Id=9606 Gene_Symbol=DDX3X ATP-dependent RNA helicase DDX3X 73597     148 11    0.09 
44 IPI00216592  Tax_Id=9606 Gene_Symbol=HNRNPC Isoform C1 of Heterogeneous nuclear ribonucleoproteins C1/C2 32318 145 8 0.48 
45 IPI00216298 Tax_Id=9606 Gene_Symbol=TXN Thioredoxin 11730 144 5 1.16 
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46 IPI00017334  Tax_Id=9606 Gene_Symbol=PHB Prohibitin 29843     141 10    0.53 
47 IPI00008986  Tax_Id=9606 Gene_Symbol=SLC7A5 Large neutral amino acids transporter small subunit 1 54974 141 3 0.06 
48 IPI00024804     Tax_Id=9606 Gene_Symbol=ATP2A1 Isoform SERCA1B of Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 111550   137 22   0.12 
49 IPI00479185     Tax_Id=9606 Gene_Symbol=TPM3 tropomyosin 3 isoform 4 29024     136 14    0.92 
50 IPI00216171   Tax_Id=9606 Gene_Symbol=ENO2 Gamma-enolase 47239 135 5 0.22 
51 IPI00873380     Tax_Id=9606 Gene_Symbol=RTN4 Nogo-C 22295     133 10  0.75 
52 IPI00409635     Tax_Id=9606 Gene_Symbol=ESYT2 Isoform 2 of Extended synaptotagmin-2 99353    130 12    0.18 
53 IPI00006196 Tax_Id=9606 Gene_Symbol=NUMA1 Isoform 2 of Nuclear mitotic apparatus protein 1 236372 130 4 0.04 
54 IPI00879148     Tax_Id=9606 Gene_Symbol=- 18 kDa protein 18534    129 5    0.18 
55 IPI00010896     Tax_Id=9606 Gene_Symbol=CLIC1 Chloride intracellular channel protein 1 27248     128 5    0.26 
56 IPI00216049 Tax_Id=9606 Gene_Symbol=HNRNPK Isoform 1 of Heterogeneous nuclear ribonucleoprotein K 50944 125 6 0.46 
57 IPI00000874 Tax_Id=9606 Gene_Symbol=PRDX1 Peroxiredoxin-1 22096 125 8 1.03 
58 IPI00419585 Tax_Id=9606 Gene_Symbol=PPIA Peptidyl-prolyl cis-trans isomerase A 18001 124 8 1.36 
59 IPI00027350 Tax_Id=9606 Gene_Symbol=PRDX2 Peroxiredoxin-2 21878 122 7 0.33 
60 IPI00183968     Tax_Id=9606 Gene_Symbol=TPM3 tropomyosin 3 isoform 1 32987     121 12    0.47 
61 IPI00021405     Tax_Id=9606 Gene_Symbol=LMNA Isoform A of Lamin-A/C 74380     121 23    0.24 
62 IPI00011200    Tax_Id=9606 Gene_Symbol=PHGDH D-3-phosphoglycerate dehydrogenase 57356     118 8    0.18 
63 IPI00024266    Tax_Id=9606 Gene_Symbol=MGST3 Microsomal glutathione S-transferase 3 16734     118 2    0.44 
64 IPI00646304 Tax_Id=9606 Gene_Symbol=PPIB Peptidyl-prolyl cis-trans isomerase B 23728 118 5 0.48 
65 IPI00011569     Tax_Id=9606 Gene_Symbol=ACACA Isoform 1 of Acetyl-CoA carboxylase 1 267095  117 20    0.09 
66 IPI00022314 Tax_Id=9606 Gene_Symbol=SOD2 Superoxide dismutase [Mn], mitochondrial 24707 117 4 0.46 
67 IPI00000875 Tax_Id=9606 Gene_Symbol=EEF1G;TUT1 cDNA FLJ56389, highly similar to Elongation factor 1-gamma 56114 113 5 0.19 
68 IPI00030255 Tax_Id=9606 Gene_Symbol=PLOD3 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3 84731 113 7 0.12 
69 IPI00922693     Tax_Id=9606 Gene_Symbol=- cDNA FLJ53662, highly similar to Actin, alpha skeletal muscle 38896     112 10    0.09 
70 IPI00219217     Tax_Id=9606 Gene_Symbol=LDHB L-lactate dehydrogenase B chain 36900     111 10    0.29 
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71 IPI00021766     Tax_Id=9606 Gene_Symbol=RTN4 Isoform 1 of Reticulon-4 130250   111 12    0.08 
72 IPI00026230     Tax_Id=9606 Gene_Symbol=HNRNPH2;RPL36AP37 Heterogeneous nuclear ribonucleoprotein H2 49517     111 3   0.07 
73 IPI00027493     Tax_Id=9606 Gene_Symbol=SLC3A2;LOC442497 Isoform 2 of 4F2 cell-surface antigen heavy chain 58023     111 10   0.18 
74 IPI00880053     Tax_Id=9606 Gene_Symbol=- 60 kDa chaperonin 48877     110 9    0.22 
75 IPI00171903     Tax_Id=9606 Gene_Symbol=HNRNPM Isoform 1 of Heterogeneous nuclear ribonucleoprotein M 77749     110 13    0.13 
76 IPI00337495 Tax_Id=9606 Gene_Symbol=PLOD2 Isoform 2 of Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 87043 109 4 0.12 
77 IPI00376798 Tax_Id=9606 Gene_Symbol=RPL11 Isoform 1 of 60S ribosomal protein L11 20240 108 2 0.17 
78 IPI00386755 Tax_Id=9606 Gene_Symbol=ERO1L ERO1-like protein alpha 54358 107 2 0.06 
79 IPI00479786     Tax_Id=9606 Gene_Symbol=KHSRP KH-type splicing regulatory protein 73355     106 13    0.04 
80 IPI00216691 Tax_Id=9606 Gene_Symbol=PFN1 Profilin-1 15045 106 5 0.84 
81 IPI00879148     Tax_Id=9606 Gene_Symbol=- 18 kDa protein 18534     105 6    0.18 
82 IPI00163187 Tax_Id=9606 Gene_Symbol=FSCN1 Fascin 54496 105 2 0.06 
83 IPI00217966     Tax_Id=9606 Gene_Symbol=LDHA Isoform 1 of L-lactate dehydrogenase A chain 36950     99 11    0.41 
84 IPI00008511     Tax_Id=9606 Gene_Symbol=MT-ND5 NADH-ubiquinone oxidoreductase chain 5 67697     98 5    0.05 
85 IPI00745125     Tax_Id=9606 Gene_Symbol=SOAT1 Sterol O-acyltransferase 1 65205     98 10    0.16 
86 IPI00398795    Tax_Id=9606 Gene_Symbol=RTN3 Isoform 2 of Reticulon-3 111211   97 13    0.09 
87 IPI00014053     Tax_Id=9606 Gene_Symbol=TOMM40 Isoform 1 of Mitochondrial import receptor subunit TOM40 homolog 38211     96 13    0.39 
88 IPI00000230    Tax_Id=9606 Gene_Symbol=TPM1 tropomyosin 1 alpha chain isoform 2 32715     96 7    0.21 
89 IPI00218820     Tax_Id=9606 Gene_Symbol=TPM2 Isoform 3 of Tropomyosin beta chain 28666     96 5    0.25 
90 IPI00013991    Tax_Id=9606 Gene_Symbol=TPM2 Isoform 1 of Tropomyosin beta chain 32945     96 5    0.21 
91 IPI00005737 Tax_Id=9606 Gene_Symbol=SURF4 Isoform 1 of Surfeit locus protein 4 30374 96 4 0.11 
92 IPI00221092 Tax_Id=9606 Gene_Symbol=RPS16 40S ribosomal protein S16 16435 94 2 0.21 
93 IPI00396435     Tax_Id=9606 Gene_Symbol=DHX15 Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15 91673     93 6    0.07 
94 IPI00015614 Tax_Id=9606 Gene_Symbol=PRSS3 Isoform A of Trypsin-3 32508 93 3 0.1 
95 IPI00217966    Tax_Id=9606 Gene_Symbol=LDHA Isoform 1 of L-lactate dehydrogenase A chain 36950     92 12    0.19 
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96 IPI00297160 Tax_Id=9606 Gene_Symbol=CD44 Isoform 12 of CD44 antigen 39391 92 2 0.17 
97 IPI00021326 Tax_Id=9606 Gene_Symbol=SHC1 SHC-transforming protein 1 isoform 3 62854 92 86 0.05 
98 IPI00170692     Tax_Id=9606 Gene_Symbol=VAPA Vesicle-associated membrane protein-associated protein A 28103    91 10    0.4 
99 IPI00169383     Tax_Id=9606 Gene_Symbol=PGK1 Phosphoglycerate kinase 1 44985    91 14    0.33 
100 IPI00550021 Tax_Id=9606 Gene_Symbol=RPL3 60S ribosomal protein L3 46080 89 3 0.15 
101 IPI00014424     Tax_Id=9606 Gene_Symbol=EEF1A2 Elongation factor 1-alpha 2 50780     88 14    0.29 
102 IPI00329801     Tax_Id=9606 Gene_Symbol=ANXA5 Annexin A5 35971     87 6   0.3 
103 IPI00218606  Tax_Id=9606 Gene_Symbol=RPS23 40S ribosomal protein S23 15798 87 3 0.22 
104 IPI00006211     Tax_Id=9606 Gene_Symbol=VAPB Isoform 1 of Vesicle-associated membrane protein-associated protein B/C 27439    86 5   0.26 
105 IPI00396378     Tax_Id=9606 Gene_Symbol=HNRNPA2B1 Isoform B1 of Heterogeneous nuclear ribonucleoproteins A2/B1 37464     86 2    0.09 
106 IPI00394665     Tax_Id=9606 Gene_Symbol=ADAR Isoform 1 of Double-stranded RNA-specific adenosine deaminase 137079    86 10    0.05 
107 IPI00014053    Tax_Id=9606 Gene_Symbol=TOMM40 Isoform 1 of Mitochondrial import receptor subunit TOM40 homolog 38211     83 3    0.28 
108 IPI00929577     Tax_Id=9606 Gene_Symbol=ABHD2 Similar to Vesicle-associated membrane protein-associated protein A 34492     83 8    0.1 
109 IPI00218918     Tax_Id=9606 Gene_Symbol=ANXA1 Annexin A1 38918     82  7    0.39 
110 IPI00028888 Tax_Id=9606 Gene_Symbol=HNRNPD Isoform 1 of Heterogeneous nuclear ribonucleoprotein D0 38410 81 3 0.18 
111 IPI00289334     Tax_Id=9606 Gene_Symbol=FLNB Isoform 1 of Filamin-B 280188    80 15    0.02 
112 IPI00848226     Tax_Id=9606 Gene_Symbol=GNB2L1 Guanine nucleotide-binding protein subunit beta-2-like 1 35511     80 13    0.2 
113 IPI00220301     Tax_Id=9606 Gene_Symbol=PRDX6 Peroxiredoxin-6 25133    80 9    0.13 
114 IPI00021263     Tax_Id=9606 Gene_Symbol=YWHAZ 14-3-3 protein zeta/delta 27899     79 5   0.4 
115 IPI00328354    Tax_Id=9606 Gene_Symbol=MAGED1 Isoform 1 of Melanoma-associated antigen D1 86221     79 6   0.04 
116 IPI00013003     Tax_Id=9606 Gene_Symbol=ACACB Isoform Long of Acetyl-CoA carboxylase 2 278375    79 11    0.04 
117 IPI00215719 Tax_Id=9606 Gene_Symbol=RPL18 60S ribosomal protein L18 21621 79 4 0.54 
118 IPI00106509 Tax_Id=9606 Gene_Symbol=HNRNPAB Isoform 4 of Heterogeneous nuclear ribonucleoprotein A/B 30682 78 2 0.11 
119 IPI00025329 Tax_Id=9606 Gene_Symbol=RPL19 60S ribosomal protein L19 23451 78 1 0.14 
120 IPI00375339 Tax_Id=9606 Gene_Symbol=ATP1A4 Isoform 1 of Sodium/potassium-transporting ATPase subunit alpha-4 114093 78 67 0.03 
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121 IPI00396378     Tax_Id=9606 Gene_Symbol=HNRNPA2B1 Isoform B1 of Heterogeneous nuclear ribonucleoproteins A2/B1 37464     77 2    0.09 
122 IPI00306369     Tax_Id=9606 Gene_Symbol=NSUN2 tRNA (cytosine-5-)-methyltransferase NSUN2 87214     77 7    0.04 
123 IPI00451401     Tax_Id=9606 Gene_Symbol=RCTPI1;TPI1 Isoform 2 of Triosephosphate isomerase 27451    77 2    0.12 
124 IPI00299573     Tax_Id=9606 Gene_Symbol=RPL7A 60S ribosomal protein L7a 30148     77 9    0.23 
125 IPI00100656     Tax_Id=9606 Gene_Symbol=TECR Isoform 1 of Trans-2,3-enoyl-CoA reductase 36410    76 3    0.19 
126 IPI00296337     Tax_Id=9606 Gene_Symbol=PRKDC Isoform 1 of DNA-dependent protein kinase catalytic subunit 473749    74 18   0.01 
127 IPI00025491     Tax_Id=9606 Gene_Symbol=SNORA67;EIF4A1 Eukaryotic initiation factor 4A-I 46353     74 5    0.15 
128 IPI00794673     Tax_Id=9606 Gene_Symbol=CCT8 Putative uncharacterized protein CCT8 11522    73 4   0.3 
129 IPI00879622    Tax_Id=9606 Gene_Symbol=- 18 kDa protein 18042    73 7    0.41 
130 IPI00792641     Tax_Id=9606 Gene_Symbol=TKT transketolase isoform 2 59571     72 8    0.06 
131 IPI00643920     Tax_Id=9606 Gene_Symbol=TKT cDNA FLJ54957, highly similar to Transketolase 69382     72 8    0.05 
132 IPI00010796     Tax_Id=9606 Gene_Symbol=P4HB Protein disulfide-isomerase 57480     72 14    0.32 
133 IPI00018248 Tax_Id=9606 Gene_Symbol=KDELR2 Isoform 1 of ER lumen protein retaining receptor 2 24406 72 2 0.29 
134 IPI00219153 Tax_Id=9606 Gene_Symbol=RPL22 60S ribosomal protein L22 14778 72 3 0.51 
135 IPI00792352     Tax_Id=9606 Gene_Symbol=RAN;RANP1 26 kDa protein 26678     71 4    0.27 
136 IPI00220642     Tax_Id=9606 Gene_Symbol=YWHAG 14-3-3 protein gamma 28456     71 6    0.25 
137 IPI00000816     Tax_Id=9606 Gene_Symbol=YWHAE 14-3-3 protein epsilon 29326    71 6    0.24 
138 IPI00018146     Tax_Id=9606 Gene_Symbol=YWHAQ 14-3-3 protein theta 28032     71 5   0.25 
139 IPI00013890    Tax_Id=9606 Gene_Symbol=SFN Isoform 1 of 14-3-3 protein sigma 27871    71 6    0.25 
140 IPI00216319    Tax_Id=9606 Gene_Symbol=YWHAH 14-3-3 protein eta 28372     71 5    0.25 
141 IPI00328328     Tax_Id=9606 Gene_Symbol=EIF4A2 Isoform 1 of Eukaryotic initiation factor 4A-II 46601    71 5    0.07 
142 IPI00025874 Tax_Id=9606 Gene_Symbol=RPN1 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 precursor 72733 71 4 0.09 
143 IPI00021129     Tax_Id=9606 Gene_Symbol=AP3B1 Isoform 1 of AP-3 complex subunit beta-1 121815    70 12    0.05 
144 IPI00021290     Tax_Id=9606 Gene_Symbol=ACLY ATP-citrate synthase 121674   69 3   0.03 
145 IPI00015833    Tax_Id=9606 Gene_Symbol=CHCHD3 Coiled-coil-helix-coiled-coil-helix domain-containing protein 3, mitochondrial 26421     68 2    0.13 
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146 IPI00217030     Tax_Id=9606 Gene_Symbol=RPS4X 40S ribosomal protein S4, X isoform 29807     68 4    0.37 
147 IPI00299000 Tax_Id=9606 Gene_Symbol=PA2G4 Proliferation-associated protein 2G4 43759 67 7 0.34 
148 IPI00027626 Tax_Id=9606 Gene_Symbol=CCT6A T-complex protein 1 subunit zeta 57988 66 1 0.06 
149 IPI00008530 Tax_Id=9606 Gene_Symbol=RPLP0 60S acidic ribosomal protein P0 34252 66 2 0.2 
150 IPI00465361 Tax_Id=9606 Gene_Symbol=RPL13 60S ribosomal protein L13 24247 66 3 0.3 
151 IPI00007289 Tax_Id=9606 Gene_Symbol=ALPP Alkaline phosphatase, placental type precursor 59482 65 1 0.06 
152 IPI00005107 Tax_Id=9606 Gene_Symbol=NPC1 Niemann-Pick C1 protein 142074 65 2 0.02 
153 IPI00019755     Tax_Id=9606 Gene_Symbol=GSTO1 Glutathione S-transferase omega-1 27833     64 3  0.12 
154 IPI00028068     Tax_Id=9606 Gene_Symbol=SLC25A19 Mitochondrial thiamine pyrophosphate carrier 35887     63 5    0.19 
155 IPI00290142 Tax_Id=9606 Gene_Symbol=CTPS CTP synthase 1 66648 63 1 0.05 
156 IPI00027107 Tax_Id=9606 Gene_Symbol=TUFM Tu translation elongation factor, mitochondrial precursor 49843  63 2 0.14 
157 IPI00026328 Tax_Id=9606 Gene_Symbol=TXNDC12 Thioredoxin domain-containing protein 12 19194 63 5 0.38 
158 IPI00455599  Tax_Id=9606 Gene_Symbol=HSP90AB2P Similar to Heat shock protein HSP 90-beta 49377 63 5 0.07 
159 IPI00004584     Tax_Id=9606 Gene_Symbol=KIAA0391 Isoform 2 of Mitochondrial ribonuclease P protein 3 66186    62 2    0.05 
160 IPI00553169    Tax_Id=9606 Gene_Symbol=FLNA Putative uncharacterized protein FLNA 248149    61 14    0.01 
161 IPI00178352    Tax_Id=9606 Gene_Symbol=FLNC Isoform 1 of Filamin-C 293407    61 8   0.01 
162 IPI00216587     Tax_Id=9606 Gene_Symbol=RPS8 40S ribosomal protein S8 24475     61 3    0.14 
163 IPI00217975 Tax_Id=9606 Gene_Symbol=LMNB1 Lamin-B1 66368 61 2 0.1 
164 IPI00024919 Tax_Id=9606 Gene_Symbol=PRDX3 Thioredoxin-dependent peroxide reductase, mitochondrial 27675 61 2 0.12 
165 IPI00220835 Tax_Id=9606 Gene_Symbol=SEC61B Protein transport protein Sec61 subunit beta 9968 61 1 0.35 
166 IPI00026241     Tax_Id=9606 Gene_Symbol=BST2 Bone marrow stromal antigen 2 20041     60 6   0.17 
167 IPI00030179     Tax_Id=9606 Gene_Symbol=RPL7;RPL7P32 60S ribosomal protein L7 29264    60 3    0.24 
168 IPI00008998     Tax_Id=9606 Gene_Symbol=PTPLAD1 Protein tyrosine phosphatase-like protein PTPLAD1 43360     59 5    0.08 
169 IPI00549805     Tax_Id=9606 Gene_Symbol=ATP5A1 23 kDa protein 22943     59 3    0.15 
170 IPI00178700     Tax_Id=9606 Gene_Symbol=ALG3 Dolichyl-P-Man:Man(5)GlcNAc(2)-PP-dolichyl mannosyltransferase 50835     59 1    0.06 
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171 IPI00178440     Tax_Id=9606 Gene_Symbol=EEF1B2 Elongation factor 1-beta 24919     59 1    0.13 
172 IPI00394896    Tax_Id=9606 Gene_Symbol=RTN3 Isoform 5 of Reticulon-3 26606    58 1    0.13 
173 IPI00440493     Tax_Id=9606 Gene_Symbol=ATP5A1 ATP synthase subunit alpha, mitochondrial 59828     58 6    0.11 
174 IPI00291006    Tax_Id=9606 Gene_Symbol=MDH2 Malate dehydrogenase, mitochondrial 35937     58 6    0.09 
175 IPI00006666 Tax_Id=9606 Gene_Symbol=SLC16A3 Monocarboxylate transporter 4 49437 58 2 0.14 
176 IPI00026994 Tax_Id=9606 Gene_Symbol=PRAF2 PRA1 family protein 2 19246 58 1 0.18 
177 IPI00418471     Tax_Id=9606 Gene_Symbol=VIM Vimentin 53676     57 8    0.2 
178 IPI00909509     Tax_Id=9606 Gene_Symbol=- cDNA FLJ59138, highly similar to Annexin A2 21827    57 6    0.15 
179 IPI00418169     Tax_Id=9606 Gene_Symbol=ANXA2 Isoform 2 of Annexin A2 40671    57 6    0.08 
180 IPI00025252     Tax_Id=9606 Gene_Symbol=PDIA3 Protein disulfide-isomerase A3 57146     57 8    0.12 
181 IPI00298971     Tax_Id=9606 Gene_Symbol=VTN Vitronectin 55069    57 2    0.06 
182 IPI00024933 Tax_Id=9606 Gene_Symbol=RPL12 Isoform 1 of 60S ribosomal protein L12 17808 57 3 0.42 
183 IPI00290770 Tax_Id=9606 Gene_Symbol=CCT3 chaperonin containing TCP1, subunit 3 isoform b 60424 56 1 0.05 
184 IPI00291802 Tax_Id=9606 Gene_Symbol=LMO7 Isoform 3 of LIM domain only protein 7 153589 56 1 0.02 
185 IPI00180128 Tax_Id=9606 Gene_Symbol=BZW1 Isoform 2 of Basic leucine zipper and W2 domain-containing protein 1 40513 56 2 0.08 
186 IPI00026625     Tax_Id=9606 Gene_Symbol=NUP155 Isoform 1 of Nuclear pore complex protein Nup155 156697    55 8    0.04 
187 IPI00892935     Tax_Id=9606 Gene_Symbol=XPO1 Putative uncharacterized protein XPO1 15381     55 1   0.22 
188 IPI00298961     Tax_Id=9606 Gene_Symbol=XPO1 Exportin-1 124447    55 6    0.05 
189 IPI00654754    Tax_Id=9606 Gene_Symbol=UBC;UBB;RPS27A RPS27A protein 10833     55 2    0.32 
190 IPI00220194 Tax_Id=9606 Gene_Symbol=SLC2A1 Solute carrier family 2, facilitated glucose transporter member 1 54049 55 2 0.06 
191 IPI00794205     Tax_Id=9606 Gene_Symbol=- 26 kDa protein 25894     54 6   0.27 
192 IPI00010810     Tax_Id=9606 Gene_Symbol=ETFA Electron transfer flavoprotein subunit alpha, mitochondrial 35400     54 5   0.31 
193 IPI00418813    Tax_Id=9606 Gene_Symbol=- Pseudogene candidate 25309     54 6    0.28 
194 IPI00335168 Tax_Id=9606 Gene_Symbol=MYL6;MYL6B Isoform Non-muscle of Myosin light polypeptide 6 16919 54 2 0.44 
195 IPI00022624 Tax_Id=9606 Gene_Symbol=GPRC5A Retinoic acid-induced protein 3 40225 54 1 0.08 
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196 IPI00023001 Tax_Id=9606 Gene_Symbol=FAM162A UPF0389 protein FAM162A 17331 54 2 0.2 
197 IPI00306436     Tax_Id=9606 Gene_Symbol=STAT3 Isoform Del-701 of Signal transducer and activator of transcription 3 88723     53 5   0.04 
198 IPI00465439     Tax_Id=9606 Gene_Symbol=ALDOA Fructose-bisphosphate aldolase A 39851     53 5    0.17 
199 IPI00004534 Tax_Id=9606 Gene_Symbol=PFAS Phosphoribosylformylglycinamidine synthase 144633 53 3 0.05 
200 IPI00329389 Tax_Id=9606 Gene_Symbol=RPL6 60S ribosomal protein L6 32708 53 3 0.21 
201 IPI00395565     Tax_Id=9606 Gene_Symbol=PTGES2 Putative uncharacterized protein PTGES2 21324     52 2   0.16 
202 IPI00024266     Tax_Id=9606 Gene_Symbol=MGST3 Microsomal glutathione S-transferase 3 16734     52 2   0.2 
203 IPI00016513     Tax_Id=9606 Gene_Symbol=RAB10 Ras-related protein Rab-10 22755  52 3    0.15 
204 IPI00014230 Tax_Id=9606 Gene_Symbol=C1QBP Complement component 1 Q subcomponent-binding protein, mitochondrial 31343 52 1 0.21 
205 IPI00003966 Tax_Id=9606 Gene_Symbol=CA9 Carbonic anhydrase 9 49667 52 1 0.07 
206 IPI00911004     Tax_Id=9606 Gene_Symbol=P4HB cDNA FLJ59939, highly similar to Protein disulfide-isomerase 25146     51 4    0.28 
207 IPI00607576     Tax_Id=9606 Gene_Symbol=C9orf5 Isoform 1 of Transmembrane protein C9orf5 101508    51 4   0.03 
208 IPI00022078 Tax_Id=9606 Gene_Symbol=NDRG1 Protein NDRG1 42808 51 1 0.08 
209 IPI00031522     Tax_Id=9606 Gene_Symbol=HADHA Trifunctional enzyme subunit alpha, mitochondrial 83688     50 5   0.04 
210 IPI00216694     Tax_Id=9606 Gene_Symbol=PLS3 Plastin-3 71279     50 12    0.14 
211 IPI00027547 Tax_Id=9606 Gene_Symbol=DCD Dermcidin 11277 50 2 0.3 
212 IPI00032304    Tax_Id=9606 Gene_Symbol=PLS1 Plastin-1 70608     49 10    0.1 
213 IPI00879622     Tax_Id=9606 Gene_Symbol=- 18 kDa protein 18042     49 1    0.19 
214 IPI00029997     Tax_Id=9606 Gene_Symbol=PGLS 6-phosphogluconolactonase 27815     49 5    0.25 
215 IPI00017726     Tax_Id=9606 Gene_Symbol=HSD17B10 Isoform 1 of 3-hydroxyacyl-CoA dehydrogenase type-2 27134     49 6    0.12 
216 IPI00031420 Tax_Id=9606 Gene_Symbol=UGDH UDP-glucose 6-dehydrogenase 54989 49 1 0.06 
217 IPI00293276 Tax_Id=9606 Gene_Symbol=MIF Macrophage migration inhibitory factor 12468 49 1 0.28 
218 IPI00179330     Tax_Id=9606 Gene_Symbol=UBC;UBB;RPS27A ubiquitin and ribosomal protein S27a precursor 18296     48 2    0.18 
219 IPI00012074 Tax_Id=9606 Gene_Symbol=HNRNPR Heterogeneous nuclear ribonucleoprotein R 70899 48 3 0.09 
220 IPI00908791     Tax_Id=9606 Gene_Symbol=LDHA L-lactate dehydrogenase 33970    47 9    0.32 
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221 IPI00300567     Tax_Id=9606 Gene_Symbol=DCI Isoform 1 of 3,2-trans-enoyl-CoA isomerase, mitochondrial 33080     47 3    0.21 
222 IPI00032038     Tax_Id=9606 Gene_Symbol=CPT1A Isoform 1 of Carnitine O-palmitoyltransferase 1, liver isoform 88995     47 2    0.04 
223 IPI00185374     Tax_Id=9606 Gene_Symbol=PSMD12 26S proteasome non-ATPase regulatory subunit 12 53270    47 2    0.06 
224 IPI00010471    Tax_Id=9606 Gene_Symbol=LCP1 Plastin-2 70815     47 3    0.05 
225 IPI00177965     Tax_Id=9606 Gene_Symbol=NT5DC1 5'-nucleotidase domain-containing protein 1 52439     47 6    0.06 
226 IPI00643041 Tax_Id=9606 Gene_Symbol=RAN;RANP1 GTP-binding nuclear protein Ran 24408  47 4 0.47 
227 IPI00789893     Tax_Id=9606 Gene_Symbol=- Pseudogene candidate 21912     45 4    0.15 
228 IPI00246975     Tax_Id=9606 Gene_Symbol=GSTM3 Glutathione S-transferase Mu 3 26998     45 2   0.26 
229 IPI00012048 Tax_Id=9606 Gene_Symbol=NME1 Isoform 1 of Nucleoside diphosphate kinase A 17139 45 5 0.43 
230 IPI00218570 Tax_Id=9606 Gene_Symbol=PGAM2 Phosphoglycerate mutase 2 28748 45 4 0.25 
231 IPI00219525 Tax_Id=9606 Gene_Symbol=PGD 6-phosphogluconate dehydrogenase, decarboxylating 53106 45 1 0.06 
232 IPI00739539     Tax_Id=9606 Gene_Symbol=POTEF POTE ankyrin domain family member F 123020    44 8    0.03 
233 IPI00479743     Tax_Id=9606 Gene_Symbol=POTEE Isoform 1 of POTE ankyrin domain family member E 122882    44 8    0.03 
234 IPI00908506     Tax_Id=9606 Gene_Symbol=DDX3Y cDNA FLJ53122, highly similar to ATP-dependent RNA helicase DDX3Y 44985     44 5    0.07 
235 IPI00293616     Tax_Id=9606 Gene_Symbol=DDX3Y ATP-dependent RNA helicase DDX3Y 73564    44 5    0.04 
236 IPI00552772     Tax_Id=9606 Gene_Symbol=HM13 Isoform 5 of Minor histocompatibility antigen H13 37018    44 9    0.19 
237 IPI00186290     Tax_Id=9606 Gene_Symbol=EEF2 Elongation factor 2 96246     44 6   0.11 
238 IPI00026271 Tax_Id=9606 Gene_Symbol=RPS14 40S ribosomal protein S14 16263 44 2 0.46 
239 IPI00007423     Tax_Id=9606 Gene_Symbol=ANP32B Isoform 1 of Acidic leucine-rich nuclear phosphoprotein 32 family member B 28941     43 2   0.24 
240 IPI00005202     Tax_Id=9606 Gene_Symbol=PGRMC2 Membrane-associated progesterone receptor component 2 26211     43 1    0.13 
241 IPI00023779     Tax_Id=9606 Gene_Symbol=NIT1 Isoform 2 of Nitrilase homolog 1 36728    43 2    0.09 
242 IPI00902969     Tax_Id=9606 Gene_Symbol=GFER FAD-linked sulfhydryl oxidase ALR 24004     43 1    0.14 
243 IPI00302927 Tax_Id=9606 Gene_Symbol=ILK-2;CCT4 T-complex protein 1 subunit delta 57888 43 2 0.12 
244 IPI00017297     Tax_Id=9606 Gene_Symbol=MATR3 Matrin-3 95078     42 6    0.03 
245 IPI00026089    Tax_Id=9606 Gene_Symbol=SF3B1 Splicing factor 3B subunit 1 146464    42 14    0.02 
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246 IPI00024067     Tax_Id=9606 Gene_Symbol=CLTC Isoform 1 of Clathrin heavy chain 1 193260    42 11   0.03 
247 IPI00465248     Tax_Id=9606 Gene_Symbol=ENO1 Isoform alpha-enolase of Alpha-enolase 47481    42 4    0.07 
248 IPI00641829 Tax_Id=9606 Gene_Symbol=BAT1 Isoform 2 of Spliceosome RNA helicase BAT1 50647 42 2 0.07 
249 IPI00100858 Tax_Id=9606 Gene_Symbol=SLCO4A1 Isoform 1 of Solute carrier organic anion transporter family member 4A1 77143 42 4 0.04 
250 IPI00246058     Tax_Id=9606 Gene_Symbol=PDCD6IP Programmed cell death 6-interacting protein 96590    41 3    0.03 
251 IPI00215911 Tax_Id=9606 Gene_Symbol=APEX1 DNA-(apurinic or apyrimidinic site) lyase 35532 41 1 0.09 
252 IPI00170436 Tax_Id=9606 Gene_Symbol=MBOAT7 Leukocyte receptor cluster (LRC) member 4 28580 41 1 0.12 
253 IPI00796094     Tax_Id=9606 Gene_Symbol=SLC25A11 34 kDa protein 34576     40 5    0.1 
254 IPI00797802     Tax_Id=9606 Gene_Symbol=SLC25A11 solute carrier family 25 member 11 isoform 3 28647     40 4 0.12 
255 IPI00010720 Tax_Id=9606 Gene_Symbol=CCT5 T-complex protein 1 subunit epsilon 59633 40 1 0.06 





































































































































































The list of some representative proteins identified from LCMS experiments Table S2 
 
 
   
  in vitro     in situ   
ID Description Mass Score emPAI 
Peptides 




PRKDC_HUMAN DNA-dependent protein kinase 
catalytic subunit OS=Homo sapiens GN=PRKDC PE=1 
SV=3 473749 431 0.13  22(9)    52 0.04  1(0)    
H3BTN5 
H3BTN5_HUMAN Pyruvate kinase (Fragment) 
OS=Homo sapiens GN=PKM PE=2 SV=1 53524 388 0.93 19(11) 127 0.27  6(3)    
B2R5T5 
B2R5T5_HUMAN Protein kinase, cAMP-dependent, 
regulatory, type I, alpha (Tissue specific extinguisher 
1), isoform CRA_a OS=Homo sapiens GN=PRKAR1A 
PE=2 SV=1 43183 61 0.08  2(1)    34 0.08  1(0)    
P60891 
PRPS1_HUMAN Ribose-phosphate 
pyrophosphokinase 1 OS=Homo sapiens GN=PRPS1 
PE=1 SV=2 35325 41 0.29  2(0)    46 0.18  1(0)    
G3V5T9 
G3V5T9_HUMAN Cyclin-dependent kinase 2 
OS=Homo sapiens GN=CDK2 PE=2 SV=1 39553 39 0.17  2(0)    29 0.17  2(0)    
Q5R3A8 
Q5R3A8_HUMAN Tyrosine-protein kinase Fyn 
OS=Homo sapiens GN=FYN PE=2 SV=1 55205 25 0.11  4(0)    25 0.05 2(0) 
E5RIU6 
E5RIU6_HUMAN Cyclin-dependent kinase 1 




PGK1_HUMAN Phosphoglycerate kinase 1 OS=Homo 
sapiens GN=PGK1 PE=1 SV=3 44985 264 1.03  11(4)          
P15531 
NDKA_HUMAN Nucleoside diphosphate kinase A 
OS=Homo sapiens GN=NME1 PE=1 SV=1 15422 100 0.82  3(1)          
B7Z7A9 
B7Z7A9_HUMAN Phosphoglycerate kinase OS=Homo 
sapiens GN=PGK1 PE=2 SV=1 41802 59 0.43  4(0)          
P10398 
ARAF_HUMAN Serine/threonine-protein kinase A-Raf 




acetylmannosamine kinase OS=Homo sapiens 
GN=GNE PE=2 SV=2 79555 48 0.04  1(1)          
P13861 
KAP2_HUMAN cAMP-dependent protein kinase type 
II-alpha regulatory subunit OS=Homo sapiens 
GN=PRKAR2A PE=1 SV=2  45832 47 0.07  4(1)          
B5BU16 
B5BU16_HUMAN Mitogen-activated protein kinase 
kinase 6 OS=Homo sapiens GN=MAP2K6 PE=2 SV=1 37782 43 0.18  2(0)          
A4QPA9 
A4QPA9_HUMAN Mitogen-activated protein kinase 
kinase 1 OS=Homo sapiens GN=MAP2K1 PE=2 SV=1 43753 40 0.08  2(1)          
B4DHB3 
B4DHB3_HUMAN Phosphoglycerate kinase 
OS=Homo sapiens PE=2 SV=1 30258 38 0.11  1(0)          
Q5JT09 
Q5JT09_HUMAN Uridine-cytidine kinase 1 OS=Homo 
sapiens GN=UCK1 PE=2 SV=1 32540 38 0.1  1(1)          
Q14DU5 
Q14DU5_HUMAN ROCK2 protein OS=Homo sapiens 
GN=ROCK2 PE=2 SV=1 82724 36 0.04  1(0)          
Q01813 
K6PP_HUMAN 6-phosphofructokinase type C 




G3V461_HUMAN Creatine kinase B-type (Fragment) 
OS=Homo sapiens GN=CKB PE=2 SV=1 14383 32 0.24  1(0)          
P08237 
K6PF_HUMAN 6-phosphofructokinase, muscle type 
OS=Homo sapiens GN=PFKM PE=1 SV=2 85984 31 0.05  1(0)          
P36507 
MP2K2_HUMAN Dual specificity mitogen-activated 
protein kinase kinase 2 OS=Homo sapiens 
GN=MAP2K2 PE=1 SV=1 44681 31 0.07  2(0)          
F8WBH4 
F8WBH4_HUMAN Interferon-induced, double-
stranded RNA-activated protein kinase (Fragment) 
OS=Homo sapiens GN=EIF2AK2 PE=2 SV=1 11298 30 0.3  1(0)          
Q13131 
AAPK1_HUMAN 5~-AMP-activated protein kinase 
catalytic subunit alpha-1 OS=Homo sapiens 
GN=PRKAA1 PE=1 SV=4 64596 30 0.1  2(0)          
P19367 
HXK1_HUMAN Hexokinase-1 OS=Homo sapiens 
GN=HK1 PE=1 SV=3 103561 28 0.05  1(0)          
Q15208 
STK38_HUMAN Serine/threonine-protein kinase 38 
OS=Homo sapiens GN=STK38 PE=1 SV=1 54498 27 0.06  1(0)          
Q7Z7Q6 
Q7Z7Q6_HUMAN Hexokinase II (Fragment) 
OS=Homo sapiens PE=2 SV=1 5875 25 0.61  1(0)          
M0QYH2 
M0QYH2_HUMAN Bifunctional polynucleotide 
phosphatase/kinase OS=Homo sapiens GN=PNKP 
PE=4 SV=1 54120 23 0.06  1(0)          
F8VTV8 
F8VTV8_HUMAN Cyclin-dependent kinase 4 
OS=Homo sapiens GN=CDK4 PE=2 SV=1 22238 22 0.32  3(0)          
Q5JQ10 
Q5JQ10_HUMAN Adenosine kinase, isoform CRA_a 
OS=Homo sapiens GN=ADK PE=2 SV=1 39078 20 0.08  1(0)          
Q9Y6E0 STK24_HUMAN Serine/threonine-protein kinase 24 49562 20 0.09  1(0)          
252 
 
OS=Homo sapiens GN=STK24 PE=1 SV=1 
J3KPD9 
J3KPD9_HUMAN Nucleoside diphosphate kinase B 
OS=Homo sapiens GN=NME2 PE=3 SV=1 22522 19 0.15  1(0)          
P32298 
GRK4_HUMAN G protein-coupled receptor kinase 4 
OS=Homo sapiens GN=GRK4 PE=1 SV=3 67738 18 0.05  1(0)          
C1PHA2 
C1PHA2_HUMAN Tyrosine-protein kinase receptor 
OS=Homo sapiens GN=KIF5B-ALK PE=2 SV=1 169283 16 0.02  3(0)          
H3BNI9 
H3BNI9_HUMAN Casein kinase II subunit alpha~ 
(Fragment) OS=Homo sapiens GN=CSNK2A2 PE=2 
SV=1 15632 16 0.22  2(0)          
Q05655 
KPCD_HUMAN Protein kinase C delta type OS=Homo 
sapiens GN=PRKCD PE=1 SV=2 78652       39 0.05  1(1)    
Q8IWB6 
TEX14_HUMAN Inactive serine/threonine-protein 
kinase TEX14 OS=Homo sapiens GN=TEX14 PE=1 
SV=2 169107       36 0.02 1(1) 
H7C175 
H7C175_HUMAN Serine/threonine-protein kinase 
LMTK1 OS=Homo sapiens GN=AATK PE=2 SV=2 135361       32 0.02  1(0)    
Q4LE51 
Q4LE51_HUMAN PIK3CA variant protein (Fragment) 
OS=Homo sapiens GN=PIK3CA variant protein PE=2 
SV=1 126129       16 0.03  1(0)    
 


























































The list of potential target proteins identified from LCMS experiments Table S3 
 







Isoform 3 of L-lactate dehydrogenase A chain OS=Homo sapiens 




Voltage-dependent anion-selective channel protein 1 OS=Homo sapiens 




Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens 




POTE ankyrin domain family member E OS=Homo sapiens GN=POTEE 




L-lactate dehydrogenase A-like 6B OS=Homo sapiens GN=LDHAL6B PE=1 




Putative elongation factor 1-alpha-like 3 OS=Homo sapiens 




Heterogeneous nuclear ribonucleoprotein A1 OS=Homo sapiens 
GN=HNRNPA1 PE=4 SV=1 129 32774 11 0.34 
8 
sp|P07195|LDHB_




Isoform 2 of Heat shock protein HSP 90-alpha OS=Homo sapiens 




Heat shock protein HSP 90-beta OS=Homo sapiens GN=HSP90AB1 PE=1 
SV=4 108 83554 12 0.04 
11 tr|F5H740|F5H74 Voltage-dependent anion-selective channel protein 3 OS=Homo sapiens 95 31080 8 0.11 
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Isoform A2 of Heterogeneous nuclear ribonucleoproteins A2/B1 
OS=Homo sapiens GN=HNRNPA2B1 91 36041 7 0.3 
13 
sp|P60842|IF4A1




Voltage-dependent anion-selective channel protein 2 OS=Homo sapiens 
GN=VDAC2 PE=2 SV=1 64 27804 15 0.76 
16 
tr|B1AN99|B1AN




60S ribosomal protein L6 (Fragment) OS=Homo sapiens GN=RPL6 PE=3 




60 kDa heat shock protein, mitochondrial OS=Homo sapiens GN=HSPD1 




Serine/arginine-rich-splicing factor 2 OS=Homo sapiens GN=SRSF2 PE=4 




60 kDa heat shock protein, mitochondrial OS=Homo sapiens GN=HSPD1 




Eukaryotic initiation factor 4A-II OS=Homo sapiens GN=EIF4A2 PE=3 
SV=1 38 41492 7 0.08 
22 
tr|F5H301|F5H30








Isoform 2 of Cytoplasmic dynein 2 heavy chain 1 OS=Homo sapiens 
GN=DYNC2H1 36 496587 10 0.01 







Isoform 2 of NADH-cytochrome b5 reductase 3 OS=Homo sapiens 
GN=CYB5R3 36 31836 7 0.1 
27 
sp|P12755|SKI_H




Pyruvate kinase isozymes M1/M2 OS=Homo sapiens GN=PKM2 PE=4 
SV=1 34 30929 7 0.11 
29 
tr|A2RRB2|A2RRB
2_HUMAN ZNF608 protein OS=Homo sapiens GN=ZNF608 PE=2 SV=1 33 46929 10 0.07 
30 
tr|G3XAL0|G3XAL




Transmembrane protein C5orf28 OS=Homo sapiens GN=C5orf28 PE=4 




WD repeat-containing protein 72 OS=Homo sapiens GN=WDR72 PE=4 




Kelch repeat and BTB (POZ) domain containing 3, isoform CRA_a 




Rho guanine nucleotide exchange factor 17 OS=Homo sapiens 




Cell division control protein 6 homolog OS=Homo sapiens GN=CDC6 




Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial OS=Homo 




CKLF-like MARVEL transmembrane domain-containing protein 7 
OS=Homo sapiens GN=CMTM7 PE=4 SV=1 29 16390 24 0.21 
38 
sp|Q6PHW0|IYD1






tRNA-specific adenosine deaminase 1 (Fragment) OS=Homo sapiens 




Putative short-chain dehydrogenase/reductase family 42E member 2 
OS=Homo sapiens GN=SDR42E2 PE=3 SV=3 27 47125 4 0.07 
42 
tr|A8MQ54|A8M




Isoform 2 of Coiled-coil domain-containing protein 33 OS=Homo sapiens 
GN=CCDC33 26 114508 8 0.03 
44 
tr|A6NJU0|A6NJU
0_HUMAN Heat shock 70 kDa protein 14 OS=Homo sapiens GN=HSPA14 PE=2 SV=2 26 29744 15 0.11 
45 
sp|P12004|PCNA_




40S ribosomal protein S2 (Fragment) OS=Homo sapiens GN=RPS2 PE=3 
SV=1 24 21426 4 0.16 
47 
tr|G3V151|G3V15
1_HUMAN HCG1782642, isoform CRA_a OS=Homo sapiens GN=TATDN3 PE=4 SV=1 23 31331 7 0.11 
48 
tr|E7ENS5|E7ENS
5_HUMAN Uncharacterized protein OS=Homo sapiens GN=SEPT5 PE=3 SV=1 22 42835 4 0.08 
49 
sp|P01880-




Unconventionnal myosin-X (Fragment) OS=Homo sapiens GN=MYO10 








NMR Spectra of representative compounds 
279 
 
 
280 
 
 
281 
 
 
282 
 
283 
 
 
284 
 
285 
 
 
286 
 
 
287 
 
 
288 
 
 
289 
 
290 
 
291 
 
 
292 
 
 
293 
 
294 
 
 
 
295 
 
  
296 
 
Chapter 5 
 
 
297 
 
298 
 
299 
 
 
300 
 
301 
 
302 
 
 
303 
 
 
304 
 
305 
 
306 
 
307 
 
308 
 
309 
 
310 
 
311 
 
 
